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1. Abstract 
 
The transcription factor NF-Y is a trimeric complex composed by three subunits NF-YA, NF-YB and 
NF-YC, which specifically recognizes and binds the CCAAT box sequence, present in almost 30% 
of eukaryotic promoters. NF-YB and NF-YC contain a histone fold domain, structurally related to 
H2A and H2B and they dimerize head to tail; NF-YA exists in two different isoforms and it is thought 
to be the regulatory subunit of the trimer. 
NF-Y is a key regulator of cell cycle progression and it regulates different metabolic pathways in 
proliferating cells. In the last years, it also emerged as important component of stemeness circuitry. 
The projects performed during my PhD were focused on the analysis and characterization of different 
biological and functional properties of NF-Y.  
My main project has been inspired by the inspection of NF-YA 3D structure that suggested us the 
presence, in the evolutionary conserved domain of the protein, of Cell Penetrating Peptide (CPP) 
features: the presence of two alpha helices and the abundance of arginines residues. Previous works 
used a functional recombinant GST-TAT-NFYA fusion protein (TAT is a well-known CPP), to 
transfer NF-YA in hematopoietic stem cells (HSCs), demonstrating its ability to repopulate the bone 
marrow of immunocompromized animals and, in mESCs, demonstrating its cruciality to maintain 
cell pluripotency.  
In this study, we demonstrated NF-YA capability to enter cells and translocate into the nuclei in a 
TAT-independent manner. Mutational analyses, in the evolutionary conserved domain of the protein, 
led to the identification of basic aminoacids required for NF-YA cellular uptake. Thanks to the 
stability of recombinant NF-YA, after transduction, in NIH3T3 and mESCs, we provided evidences 
about the functionality of the protein in vivo. In NIH3T3, NF-YA affects the expression of CCAAT 
cell cycle progression genes causing cell growth delay and induces the activation of the apoptotic 
pathway mediated by E2F1; mESCs, instead, after recombinant NF-YA transduction, maintain their 
pluripotency properties when grown without leukemia inhibitory factor (LIF).  
In the two last decades, the use of CPPs has become an important tool for therapeutic applications. In 
this context, the discovered NF-YA properties, to overpass cell membranes, could be exploited to 
make recombinant NF-YA a new reagent to study its biological effects in different cell contexts, 
avoiding limitations of canonical methods of gene delivery, and laying the groundwork for its 
potential application in clinical trials.  
The cruciality of NF-Y in mESCs pluripotency maintenance, and the possibility to use recombinant 
NF-YA in stem cell systems, pushed us to investigate NF-Y also in human stem cells. We 
reprogrammed adult human fibroblasts to induced pluripotent stem cells (iPSCs). Preliminary data 
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suggest that, similarly to mESCs, NF-Y is involved in stemness circuitry regulation of human stem 
cells. Indeed, we observed a down modulation of master stemness genes after NF-Y subunits 
silencing in human iPSCs.  
 
The second project was focused on a detailed analysis on the regulation of NF-Y metabolic target 
genes, altered in cancer cells. 
By integrating different studies on NF-Y genomic binding with data of gene expression profiling, 
coming from different cell types, after NF-Y subunits inactivation, we demonstrated that NF-Y plays 
an important role in the regulation of genes involved in lipid pathways interacting with master 
lipogenic TFs, SREBPs. Moreover, we found that NF-Y directly and positively regulates genes 
involved in glycolysis, and in the biosynthesis of amino acids (serine, glycine and glutamine), purines 
and polyamines. Differently from its activity in yeast metabolic pathways, in mammalian cells NF-Y 
enhances energy production through anaerobic pathways; the analysis performed in this study, 
indeed, highlighted that NF-Y negatively regulates genes involved in TCA cycle.  
Most of metabolic genes regulated by NF-Y, identified in this study, are altered in different tumors. 
This work contributes to unravel the regulatory circuitry of cancer cells and to better understand how 
the alteration of metabolic pathways affects the progression and growth of cancer cells. 
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2. State of art 
 
2.1. Overview on regulation of gene expression 
The regulation of gene expression is a fine mechanism that orchestrates a plethora of biological 
processes involving development, cell proliferation, differentiation, aging and apoptosis. 
The expression of coding-protein genes is controlled by different steps including chromatin 
organization, transcription, mRNA processing, transport, translation and protein stability. 
In eukaryotic cells, genetic information is encoded in DNA that is packaged in chromatin and 
confined into the nucleus. The chromatin is a complex of macromolecules consisting of 146 base-
pairs of duplex DNA wrapped around a histone octamer consisting of two of each histone proteins, 
H2A, H2B, H3, H4, forming the basic unit of the chromatin: the nucleosome.  
Nucleosomes represent the first level of eukaryotic DNA organization and they are connected by 
linker DNA of variable length. The fifth histone protein, H1, with other non-histone proteins, plays 
an important role to wrap nucleosomes into a 30 nm fiber while others fine and not well understood 
mechanisms, contribute to higher order of compaction. 
Although DNA is highly packaged in the nucleus, its accessibility is fundamental for different 
biological processes: transcription, replication, recombination and DNA repair. DNA accessibility is 
favored by two classes of enzymes: nucleosome remodelers and histone modifying enzymes. 
Chromatin remodeling is promoted by enzymes that, in ATP-dependent process, change the state of 
the chromatin disrupting nucleosome structure and making free the access to transcription factors or 
other protein complexes involved in DNA metabolism. (ATP-dependent) The remodeling complexes 
include two main classes of enzymes: one contains the SWI2/SNF2 family proteins (SWI/SNF and 
RSC) and the other is represented by ISWI-containing complex (NURF, ACF and CHRAC) 
(Tsukiyama et al., 1995), (Dirscherl and Krebs, 2004). 
It has been reported that mammalian SWI/SNF complex plays an important role as tumor suppressor 
in many human malignancy (Versteege et al., 1998); the association with coactivators as well with 
corepressors suggests that remodeling complex are involved not only in transcriptional activation, but 
also in transcriptional repression (Eberharter and Becker, 2004). 
On the other hand, we have to consider that the amino acids of the histones undergo a remarkable 
variety of covalent modifications associated to transcriptional activation or repression contributing to 
establish a condensed or decondensed chromatin state that determines gene expression. Among the 
different histone modifications, acetylation, phosphorylation, methylation, ubiquitylation, 
sumoylation, ADP-ribosylation, the first three are the best characterized (Fig. 1).  
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Figure 1. Representation of the main modifications of histone tails. Ac, acetylation; Me, methylation; P, phosphorylation; 
Ub, ubiquitination. (Manuel Rodríguez-Paredes and Manel Esteller, 2011). 
 
The acetylation of lysine is a dynamic process regulated by the action of two different protein 
families: histone acetyl-transferases (HATs) and histone deacetylases (HDACs) (Xhemalce B, et al., 
2011). The HATs use the cofactor Acetyl CoA to transfer the acetyl group to the ε-amino group of 
lysine chain side. In this way the positive charge of lysine is neutralized creating a weaker interaction 
between histone and DNA. Two main classes of HATs have been characterized: type-A and type-B. 
The type-B HATs are mainly cytoplasmic and they acetylate free histones, before they are included 
in nucleosome.  In particular, type-B HATs acetylate H4 at K5 and K12 and also some residues on 
H3, and these modifications are important for the deposition of histones, to be removed after histones 
localization (Parthun MR, 2007).  
Type-A HATs are composed by a class of enzymes that can be classified in three different groups:  
- GNATs ( GCN5- related N-acetyltransferases) 
- MYST ( including MOZ, Ybf2/Sas3,Sas2 and Tip60) 
- P300/CBP (CREB binding protein) (Hodawadekar SC et al., 2007). 
These enzymes own the ability to modify sites different from N-terminal histone tails. Indeed, a part 
from histone tails, other additional sites are present in the globular histone core, whose modification 
contribute to disrupting the electrostatic interaction that stabilize the nucleosome structure, making 
chromatin much more accessible to transcriptional activators. HGCN5, for example, acetylates 
H3K56 (Tjeertes JV et al., 2009) affecting histone/DNA interaction, and similarly the knockdown of 
p300 HAT is associated with the loss of HK56ac, suggesting that also p300 may target this site (Das 
C. et al., 2009). 
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HDACs play the opposite role to HATs: they remove acetyl group from lysine restoring the positive 
charge and stabilizing the local chromatin architecture. In agreement with their activity, HDACs, 
contrary to the HATs, are predominantly classified as transcriptional repressors. 
HDACs are divided in four classes, Class I, Class II, Class III and Class IV, and in general, they have 
a low substrate specificity, so that single enzyme can deacetylate different sites within the histone. 
Moreover, HDACs were found in multiple complex with other enzymes and other HDAC family 
members (i.e. HDAC1 was found in a complex with HADC2 in the NuRD, Sin3a and Co-REST 
complexes) (Yang et al., 2008) making much more difficult to understand which HADC is 
responsible for a specific effect. 
Not only histone acetylation, but also histone phosphorylation reduces the positive charge disrupting 
electrostatic interaction histone/DNA. Phosphorylation occurs, in a highly dynamic way, on serine, 
threonine and tyrosine residues of N-terminal histone tails (Xhemalce B et al., 2011), thanks to the 
action of kinases that transfer a phosphate group from ATP to the hydroxyl group of targeted residues. 
On the other hand, the action of phosphatases contributes to restore the “close” chromatin 
environment.  
Histone methyltransferases are the class of enzymes that transfer a methyl group from S-
adenosylmethionine (SAM) to lysine and arginine of histone proteins. While lysine residues can be 
mono- (me1), di- (me2) or three-(me3) methylated on their amine group, arginine residues are only 
mono- or di- methylated on their guanidinyl group in a symmetric (me2s) or asymmetric (me2a) 
configuration (Ng SS et al., 2009). 
Specific lysine and arginine residues are methylated on histone H3 and H4, in particular: K4, K9, 
K27, K36, K79, R2, R8 and R17 are methylated on H3 while H4 methylation markers occur on K20 
and R3.  
Starting from the first lysine methyltransferase (KMT) discovered, SUV39H1, many others have been 
identified. Most of them contain a SET domain carrying the catalytic activity and they act on 
relatively specific target residues. Set1 is the only specific histone methyltransferase for H3K4 in 
yeast and it works in a complex (COMPASS) containing Bre2, Spp1, Swd1, Swd2, Swd3 and Sdc1 
proteins. In mammals six Set1 family members have been described: KMT2F, KMT2G, KMT2A, 
KMT2B, KMT2C and KMT2D. All of them carry a specific histone methyltransferase activity on 
H3K4 playing  an important role in transcriptional activation (Dou et al., 2005; Steward et al., 2006). 
However, Dot1 is an exception: this enzyme specifically methylates H3K79 in the histone core and 
it doesn’t carry the SET domain. Histone arginine methylation occurs thanks to the protein arginine 
N-methyltransferase (PRMT) containing two classes of enzimes: type-I enzyme and type-II enzyme. 
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While type-I generate the Rme1 and the asymmetric dimethylation of arginine (Rme2as), type-II 
generate Rme1 and Rme2s. 
 
Modifications provide interaction surfaces for protein complexes that control transcription. 
When enzymes remove modifications that negatively regulate transcription, it is induced a chromatin 
remodeling that allow RNA pol II to be recruited and transcription starts. 
 
2.2 Eukaryotic transcriptional machinery and the transcription regulatory 
elements 
Eukaryotic transcription involves a machinery of factors that include: general transcription factors 
(GTFs), activators and coactivators. 
Apart from RNA polymerase II, a series of auxiliary factors including TFIIA, TFIIB, TFIID, TFIIE 
TFIIF and TFIIH play an important role for an accurate and correct transcriptional process (Figure 
2). 
The assembly of GTFs on the core promoter to for a preinitiation complex (PIC), directs RNA 
polymerase II to bind the transcription start site (TSS). 
 
Figure 2. The eukaryotic transcriptional machinery involves: General Transcription Factos (GTFs), activators and 
coactivators (Maston et al., 2013). 
 
Transcription activity is influenced and stimulated by activators typically characterized by a DNA 
binding domain, by which they recognize and bind a sequence-specific upstream of the core promoter, 
and an activation domain required to stimulate transcription (Ptashne M, Gann A., 1997). The 
activators work promoting the formation of PIC formation and the process subsequent such as 
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transcription initiation, elongation and reinitiation and their activity can be modulated by other factors 
important for eukaryotic transcription, the coactivators. 
Unlike the activators, coactivators do not have a DNA binding region but they are recruited by 
protein-protein interactions with one or more activators. 
A peculiar feature of activators regards their ability to stimulate transcription synergistically. This is 
obtained from the cooperation of multiple copies of the same factor or from the cooperation between 
different factors (Carey et al., 1990) (Lin et al., 1990). The mechanism underlying transcription 
synergy is still unclear; it may occur through the simultaneous interaction of activators with recruited 
GTFs or by the different actions of activators involved to modify chromatin structure and in the 
regulation of transcription steps, initiation and elongation. 
Among transcriptional regulatory elements, the core promoter is the region located at the start of a 
gene that provides a docking site for the assembly of PIC, define the position of TSS and the direction 
of transcription. The first described element of core promoter was the TATA box. In addition to 
TATA box, many other elements were identified in metazoan core promoters such as Initiator element 
(Inr), Downstream Promoter Element (DPE), Downstream Core Element (DCE), TFIIB-Recognition 
Element, Motif Ten Element (MTE) and CCAAT box (Lim et al., 2004)  
Statistical analysis on 10000 human promoters highlighted that the above mentioned regulatory 
sequences are not universal (e.g. TATA box in present in only 24% of human promoters) (Yang et 
al., 2007) suggesting that other core promoter elements have to be discovered and described. 
The region upstream from core promoter, defined proximal prompter element, hold multiple binding 
site for activator elements. 
Roughly 60% of human promoters are near to CpG islands, short DNA sequences rich in C-G di-
nucleotides; because of this, the presence of CpG island is used to predict the presence of a gene. 
CpG islands typically occur near to the TSS of housekeeping genes as well as regulated genes (Bird, 
1987) (Gardiner, Frommer, 1987). The CpG islands scattered along the genome are usually 
methylated, while those near to the promoter are normally unmethylated. Indeed, DNA methylation, 
and in particular the methylation of CpG islands in gene promoters, leads to transcription silencing 
by blocking the ability of transcription factors to bind their specific sequences. CpG island 
methylation, therefore, represents an important mechanism of transcriptional regulation (Jones and 
Laird, 1999).  
Transcription factors regulate gene expression in cooperation with other factors not only by binding 
core promoter regions where transcription starts but also by binding enhancers. 
Enhancers are long distance transcriptional control elements that can be located several hundred 
kilobase upstream or downstream of a promoter that positively increase gene transcription (Lettice et 
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al., 2003). The control of distant genes is allowed by physical contact that involve DNA bending 
between enhancers and core promoters (Krivega and Dean, 2012). Enhancers emerged as very important 
regions for transcription regulation and mutations in their sequences change significantly the binding 
of transcription factors and therefore the regulation of gene expression of target genes; genetic 
variations in these regulatory regions are often associated with diseases (Maurano et al., 2012). 
Unlike enhancers, the silencers are negative transcription regulatory elements sharing binding sites 
for negative transcription factors. Transcriptional repression occurs thank to the action of repressors 
that or prevent the access of GTFs to the promoter, establishing a repressive chromatin structure 
(Srinivasan and Atchison, 2004) or by blocking the assembly of PIC (Chen and Widom, 2005). 
In many cases, gene transcriptional state is repressed and becomes active after specific stimuli. 
It has emerged that a class of silencing elements, the Polycomb group Response Elements (PREs), 
are involved in the process that regulate the promoter switching from repressive to active state. PREs 
work as silencer or activator elements depending on the type of proteins that they bind (Schmitt S et 
al., 2005). 
Finally, among the transcriptional regulatory elements, we find insulators and locus control regions. 
While insulators main work is to limit the action of enhances towards a specific set of genes, 
“protecting” other genes from the transcriptional activity of neighboring genes, locus control regions 
are a class of regulatory elements involving enhancers, silencers and insulators that by binding TFs, 
activators, repressors and chromatin modification factors, regulate the transcription of an entire locus 
or gene cluster (Li et al., 2002). 
Therefore, it is the action of different regulatory elements to determine gene expression pattern in a 
finely tuned dynamic process. 
 
2.3 Gene expression programs control  
It is clear that the identity of a cell is defined by genes that are transcribed and they involve 
housekeeping genes (active in most cells) and cell-specific genes (genes expressed in one cell type). 
The gene expression program of a particular cell type is the result of the activity of specific 
transcription factors that in turn regulate transcription of a selective subset of genes. What emerged 
from studies on TFs involved in establishing and maintaining cell identity, is that only few key TFs 
are necessary to determine cell type specific gene expression programs.  
In the figure 3 are reported some examples. 
 
 11 
 
 
 
Figure 3. Transcription factors that control specific cell states that are able to reprogramming cell states when ectopically 
expressed in different cell types (Lee and Young, 2013). 
 
Among the different transcription factors involved in embryonic stem cells (ESCs) circuitry, only few 
of them, SOX2, OCT4, KLF4 and MYC are involved and are necessary in reprogramming cells to 
induced pluripotent stem cells (iPSCs), with the some properties of ESCs (Yamanaka, 2012). 
The ESCs are characterized by the ability to self-renewal and maintain pluripotency ensuring in this 
way enough cells during organogenesis, the homeostasis control of tissue, regeneration and repair. 
Both human and mouse ESCs are able to maintain their pluripotent state thank to the regulatory 
feedback circuitry formed by SOX2, OCT4 and NANOG, activating target genes that encode 
pluripotency and self-renewal mechanisms. Simultaneously, in this regulatory circuitry the three TFs 
regulate themselves and repress signaling pathways that induce differentiation interacting with 
Polycomb-mediated repression complex (Young, 2011). 
From different studies, what emerged is that TFs that control cell state or that are involved in 
reprogramming have a broad effect on gene expression program by regulating the initiation or the 
elongation transcription processes of regulated genes. 
The c-Myc transcription factor can stimulate increased elongation from the entire active gene 
expression program in different cell lines (Lin et al., 2012; Nie et al., 2012). 
OCT4 and NANOG, e.g., interact with p300 and Mediator coactivators to promote the formation of 
open chromatin and recruit transcriptional apparatus; similarly, it happens for other TFs involved in 
cell trans-differentiation such as MYOD, C/EBPβ, HNF1α, HNF4α, BRN2 and GATA4 (Borgrefe 
and Yue, 2011). 
Among TFs involved in elongation transcription control we can mention hematopoietic TIF1γ  
transcription factor that controls erythroid cell fate interacting with P-TEFb and regulating 
transcription elongation at a specific set of target genes (Bai et al., 2010). 
 12 
 
Genetic variations and mutations in the transcription factors contribute to the onset of diseases due to 
the deregulation of gene expression.  Some transcription factors control RNA polymerase II pause, 
release and elongation, therefore, an altered expression or altered function may produce aggressive 
tumor cells or autoimmune diseases (Lin et al., 2012; Malecki, 2005). Similarly, mutations in 
coactivators complexes that integrate information from many transcription factors can cause 
developmental diseases (Ding et al., 2008; Kaufmann et al., 2010). 
Alteration in specific chromatin regulators contribute to development of cancer and many other 
diseases (Tsurusaki et al., 2012). 
New studies have highlighted that mutations in ncRNA species can play important role in 
cardiovascular diseases (Han et al., 2011; Papageorgiou et al., 2012). 
Addition insights into the role of transcription misregulation in human disease, will require improved 
genome annotation, knowledge of DNA sequences whose alteration contribute to disease and further 
understanding of the role of cofactors, chromatin regulators and ncRNAs. 
 
2.4 The CCAAT-box 
Transcription regulation involves a series of events defined by DNA sequences positioned both in 
proximity of the genes, promoter, and at distance sites, enhancers, that together with chromatin 
conformation and modifications define the territories of activity of transcription factors, expressed in 
a particular cell type. 
Promoters and enhancers that activate the transcription of genes by RNA polymerase II are 
characterized by sequences that are specifically recognized and bound by sequence-specific 
transcription factors. The CCAAT box is one of the most widespread cis-acting elements, identified 
in human, yeast and plant promoters, playing a very important role in transcriptional regulation. 
 
         
 
 
Figure 4. Sequence Logo of NF-Y consensus optimized with ChIP on ChIP data (Dolfini et al., 2009). 
 
It is present in almost 30% of eukaryotic promoters and it is found both in forward and reverse 
orientation (Dolfini et al., 2009) between -60 and -100 bps from transcription start sites (TSS). 
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Although the CCAAT box was long considered only a promoter element important for the recruitment 
of Pol II, genomic data revealed that CCAAT box is contained in not only the “classic” core promoters 
but also it correlates with CpG island promoters, intergenic regions and introns (Dolfini et al., 2009). 
Apart from CCAAT box others well defined cis-acting elements common to eukaryotic promoters 
include TATA box and the GC box. A negative correlation between CCAAT box and TATA box was 
recently found by bioinformatics analysis: the numbers of promoters containing both CCAAT box 
and TATA box is significantly lower compared to the promoters containing only one of them.  
In higher eukaryotes, the CCAAT box has been found in promoters of many classes of genes, 
developmentally controlled and tissue specific genes, housekeeping and inducible genes. A class of 
genes particularly enriched in CCAAT box are genes involved in cell cycle progression and 
regulation: CCNA, CCNB1, CCB2, CDC2, CDC25A, PLK1 (Mantovani, 1998) (Lin et al., 2014). 
Figure 5 shows the list of some cell cycle genes regulated by NF-Y 
 
 
 
Figure 5. List of some cell-cycle genes regulated by NF-Y. Representation of their promoter regions and transcription 
factors binding sites are illustrated (Di Agostino, et al., 2006).  
 
These genes lack the TATA box but present multiple CCAAT boxes in their promoters: CCNB2 for 
instance, has three CCAAT boxes in its proximal promoter region. The major transcription factor that 
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specifically recognizes and binds the pentanucleotide is NF-Y, which absolutely require all five 
nucleotides for efficient DNA binding. 
 
2.5 Nuclear Factor-Y (NF-Y) 
NF-Y (Nuclear Factor Y), also known as CBF (CCAAT Binding Factor), CP1 or HAP2/3/5 in yeast, 
is a trimeric transcription factor composed by NF-YA, NF-YB and NF-YC, all indispensable for DNA 
binding. Each NF-Y subunit contains an evolutionary conserved domain, sufficient for CCAAT 
binding and subunit interaction, indicated as HAP for the homology with the yeast proteins. NF-YA 
contains the HAP domain (HAP2) in the C-terminal portion of the protein, NF-YB in its central region 
(HAP3) and NF-YC in the N-terminal domain (HAP5) (Fig.6). 
 
Figure 6. Schematic representation of the NF-Y genes. The yeast homology domains are indicated by brackets. White 
boxes in NF-YB and NF-YC indicate the position of the four α-helices of the histone fold domains. Below the NF-YB 
and NF-YB schemes are shown the sequences of the conserved domains of the human NF-YC, A. thaliana NF-YCb, S. 
cerevisiae HAP5, NC2a and Xenopus H2A (lower panel ) and of the corresponding sequences of NF-YB, A. thaliana 
NF-YBb, HAP3, human NC2b and Xenopus H2B (upper panel ). The + symbol indicates the position of the α-helices in 
the histone folds; the L1 and L2 are the loop regions. (Mantovani, 1999). 
 
The N-terminal domain of NF-YA and the C-terminal domain of NF-YC are characterized by a large 
glutamine rich portion (Q-rich) important for transactivation function (Mantovani, 1999). 
NF-YB and NF-YC subunits have a histone-like domain characterized by three alpha helices 
separated by short strand regions that associate forming a dimer important for the interaction with 
NF-YA that dictates the association to DNA. The resulting functional trimer binds to the CCAAT 
containing double stranded DNA with high affinity and specificity, inducing a global DNA bending 
of 80°. This is a peculiarity of NF-Y that can reflect functional consequences for the spatial 
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organization of its target promoters. Indeed, the transcriptional regulation of NF-Y target genes is not 
only due to NF-Y CCAAT binding. Different studies highlighted functional and physical interaction 
of NF-Y with other transcription factors, both in vitro and in vivo (Zwicker et al., 1995). 
NF-Y was identified as a factor associated to the conserved promoter element Y-box of the major 
histocompatibility complex class II genes (Dorn et al., 1987). Since, many other eukaryotic promoters 
(type I collagen, albumin, globin, thombospondin 1 and human thymidine kinase gene pomoters) 
were discovered to be activated by NF-Y (Chodosh et al., 1988, Delvoye et al., 1993, Framson and 
Bornstein, 1993; Mantovani et al., 1992; Raymondjean et al., 1988).  
Now it is known that the human genome harbors sites for NF-Y, scattered along the whole genome, 
with most of them residing in annotated gene bodies and intergenic region (45%); localization within 
promoters can be attested at nearly 10% of NF-Y sites. Within promoters, the majority of NF-Y sites 
falls nearby the TSS. For the remnant part of the genome, one third of NF-Y sites is associated to 
mRNA expression area, regions of Pol II activity, enhancers and transcriptional units whose RNAs 
have not been annotated yet (Ceribelli et al., 2008). 
 
2.5.1 NF-YB and NF-YC: the histone like dimer 
NF-YB and NF-YC core region sequences present a high degree of homology with the H2A and H2B 
histones, therefore, they belong to the Histone Fold Domain protein family. 
Mutational analysis in the histone-fold domain of NF-YB and NF-YC highlighted that the integrity 
of these motives is fundamental for subunits dimerization and DNA binding (Maity and 
Crombrugghe, 1998). 
As demonstrated by human NF-YB/NF-YC structure, the two proteins interact with each other head 
to tail, forming a dimer that is structurally similar to H2A/H2B (Romier et al., 2003) (Fig.7). 
                       
Figure 7. Comparison of NF-YC/NF-YB and H2A/H2B dimers. The left panel show the ribbon representation of NF-
YC/NF-YB dimer; the right panel represent the superimposition of NF-YC/NF-YB (orange) and H2A/H2B (gray) histone 
pairs (Romier et al., 2003). 
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The conserved histone fold motif of NF-YB and NF-YC is important for the interaction of NF-Y with 
other histone like proteins such as different TAF(II)s subunits of TFIID. In particular, while TAF11, 
TAF12 and TAF13-TAF11 complex interact with the histone fold domain of NF-Y dimer, TAF6 and 
TAF9-TAF6 complex interact only with NF-Y trimer (Frontini et al., 2002). 
Compared to the general histone fold domain (HFD) structure, characterized by three alpha helices 
linked by two loops, NF-YB and NF-YC core regions carry an additional alpha helix (α-C) at the C-
terminal region of their HFDs that is important for the interaction with other transcription factors.  
NF-YC α-C, indeed, is crucial to establish crosstalk and interactions between NF-Y and other 
transcription factors, for instance c-MYC or p53 (Izumi et al., 2001). 
The formation of NF-YB/NF-YC dimer, offer the correct docking site for the association of NF-YA 
subunit. In this way, in addition to HFD, NF-YA DNA contact further stabilizes DNA binding of the 
composed trimer and adds a layer of high specificity to the trimer. 
 
2.5.2 The different isoforms of NF-Y subunits: NF-YB and NF-YC subunits 
As it is well known, most of the mammalian genes undergo alternative splicing so that the same gene 
generates different protein isoforms; NF-Y subunits undergo the same process. 
While NF-YB gene, in mammals, generates a single protein product of 32 KDa (Fig.8), the 
transcriptional regulation of the NF-YC locus is much more complex. NF-YC protein isoforms, 
indeed, originate not only from events of alternative splicing but also by the activity of alternative 
promoters, P1 and P2. The P1 promoter has substantial housekeep activity as demonstrated by 
transient transfection, ChIP experiments and RT-PCR analysis; the promoter P2 is activated 
following DNA damage in a p53 dependent pathway. 
 
                               
Figure 8. The structure of NF-YB and NF-YC genes. Functional domains and differential splicing are reported (Dolfini 
et al., 2012). 
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The Q-rich transactivation domain of NF-YC is the region affected by alternative splicing. The 
splicing involves exon 8 and exon 9, generating three different protein products of 37, 48 and 50 KDa 
(Fig.8). 
RT-PCR analysis performed in 13 different human cell lines highlighted that the three different 
splicing isoforms are transcribed in the cells but the protein expression level is different: the relative 
abundance of each protein isoform is cell dependent and, in particular, the 37 and 50 KDa isoforms 
are mutually exclusive. These data indicate that strong post-transcriptional mechanism affecting 
mRNA stability and translation (Ceribelli et al., 2009). 
Moreovere, these findings strongly correlate NF-YC to NF-YA subunit, described in the following 
section. 
 
2.5.3 NF-YA isoforms 
NF-YA subunit, differently from NF-YB and NF-YC, does not belong to the histone fold domain 
family.  
NF-YA is composed of a Q-rich trans-activation domain in its N-terminal domain of 180 amino acids 
rich in hydrophobic residues and an evolutionary conserved domain in the C-terminal domain. This 
core region is composed of two alpha helices each specifying a function: A1 mediates the interaction 
with NF-YB and NF-YC and A2 is involved in DNA binding and CCAAT recognition. The two alpha 
helices are connected by a linker and they are rich in basic amino acids (lysines and arginines) with 
the C-terminal domain of A2 helix holding two serines –S292 and S298-, target of CDK2 in a cell 
cycle dependent manner (Yun et al., 2003; Chae et al., 2004; Chan et al., 2010).  
NF-YA gene undergoes alternative splicing involving exon 3 in the Q-rich domain. The exon skipping 
event generates two different protein isoforms: the long (NF-YAl) and the short (NF-YAs) lacking 
the 28 amino acids codified by third exon (Fig. 9). 
 
Figure 9. Structure of NF-YA gene with its functional domains, alternative splicing and post-translational modifications. 
(Dolfini et al., 2012) 
 
Different cell lines preferentially express the long or the short isoform of NF-YA, but never the 
expression of one isoform completely abolish the expression of the other. It was found, as above 
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mentioned, a tight correlation between NF-YA and NF-YC subunits expression: cells harboring the 
short isoform of NF-YA preferentially express the 50 kDa NF-YC isoform while the long isoform of 
NF-YA is enriched in cells expressing the 37 kDa NF-YC (Ceribelli et al., 2009). These data suggest 
that different cell contests harbor different NF-Y complexes, but it is not still clear how and whether 
they activate different set of genes. 
 
2.5.4 NF-YA subunit regulation 
NF-YA is the limiting subunit of the trimer. While the amount of NF-YB and NF-YC subunits are 
relatively constant, it was observed that NF-YA expression level fluctuates during cell cycle 
highlighting its role of regulatory subunit of the trimer. NF-YA accumulation control occurs at post 
transcriptional level. Differently from NF-YB and NF-YC subunits, NF-YA protein is regulated by 
the ubiquitin/proteasome pathway. The short half-life of the protein, estimated about two hours in 
proliferating cells, increases after proteasome inhibition and mutational analysis identified four 
lysines (K283, K289, K292 and K296) in the C-terminal domain of the protein as important targets 
of ubiquitylation. Moreover, it was observed that two of the lysines ubiquitylated are also acetylated 
by the p300 histone acetyl-transferase (Manni et al., 2008). Therefore, the competition between 
acetylation and ubiquitylation on the same lysines residues emerges as mechanism to regulate NF-
YA stability.  
The differential expression of NF-YA, that determines the amount of active trimer available for 
CCAAT-binding activity, was observed in different tissues and cell lines. The expression level of 
NF-YA fluctuates during cell cycle and it is high in G1 and S phase while, it decreases in G2/M 
(Bolognese et al., 1999). The amount of NF-YA protein can be modulated by specific stimuli and cell 
treatments: while deprivation of serum induces a reduction of NF-YA subunit expression level in 
human IMR-90 fibroblasts (Chang et al., 1994), MMS treatment increases it (Lee et al., 2004). 
Finally, although both immortalized and not transformed cell lines express all the three NF-Y 
subunits, it was found that post-mitotic normal cells, differentiated myotubes and circulating 
monocytes do not express NF-YA (Farina et al., 1999; Gurtner et al., 2003). All these data show that 
the level of NF-YA governs the function of NF-Y trimer.  
 
2.5.5 Effects of NF-YA inactivation  
The NF-Y complex is a fundamental player in the regulation of cell proliferation, supporting the basal 
transcription of cell cycle genes. 
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The function of NF-Y in gene transcription and cell cycle regulation took advantage by loss of 
function approaches, such as the expression of dominant negative NF-YA mutants or by conditional 
inactivation of NF-YA. 
The stable expression of dominant negative NF-YA in mouse fibroblast cells induces a delay in S 
phase progression (Hu and Maity, 2000); a truncated NF-YA mutant, lacking the C-terminal 
transcription activation domain, leads cells to cycle block in G2/M phase without apoptosis (Hu et 
al., 2006) while conditional inactivation of NF-YA alleles in mouse embryonic fibroblasts (MEFs) 
completely blocks cells in S phase and then induces apoptosis (Bhattacharya et al., 2003). 
The importance of NF-Y is not just limited to the regulation of genes involved in cell cycle 
progression, but it extends to the control of genes involved in different metabolic pathways. It was 
demonstrated that the conditional inactivation of NF-YA in liver of newborn mice caused a severe 
liver injury with progressive degeneration of hepatocytes and induction of an aberrant endoplasmic 
reticulum stress pathway, demonstrating that NF-YA, and therefore NF-Y, is a key transcription 
factor controlling ER function and metabolic processes in mature hepatocytes (Luo et al., 2011).  
NF-Y was also identified as important factor for preadipocytes and as an adipogenic factor that 
regulates leptin gene expression. In vitro, NF-Y is expressed in adipocytes and its levels decrease 
during adipogenesis. NF-Y knockdown reduces adipocyte differentiation suggesting that it plays an 
important role prior to differentiation or that have functions early in the process before the point of 
adipocytes development when it is no longer expressed. 
RNAi mediated knockout of NF-Y in preadipocytes and adipocyte-specific knockout of NF-YA 
results in a decreased expression of leptin gene and of other fat specific genes; it was observed that 
NF-Y knockout mice develop a moderately severe lipodystrophy, remediable with leptin therapy (Yi-
Hsueh Lu et al., 2015). Further studies are in any case required to elucidate the mechanisms by which 
NF-Y controls leptin gene expression, to identify mechanisms that modulate adipocyte function and 
leptin production in response to changes in adipocyte lipid context.   
A recent study demonstrated that, although NF-Y often loses its activity in differentiated 
nonproliferative cells, it is active in adult neurons. The conditional deletion of NF-YA subunit in post 
mitotic neurons induce progressive neurodegeneration accompanied by a failure of incorporation of 
Ubiquitin and p62 in filamentous inclusions that co-accumulated with insoluble membrane around 
endoplasmic reticulum (ER). Neurodegeneration is characterized by an aberrant increase of smooth 
ER in the perinuclear region without the activation of ER stress response. These data, therefore, place 
NF-Y as an important regulator of ER organization in adult neurons and its ablation causes 
neuropathology with abnormal accumulation of ubiquitin/p62 (Yamanaka et al., 2014). 
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2.5.6 NF-YA: cell cycle regulation and apoptosis 
Cell proliferation and apoptosis are two processes finely related, as two sides of the same coin. 
Most of important effectors of apoptosis are expressed in cells and under appropriate stimuli can alter 
the transcriptome and induce the expression of proapoptotic proteins. 
Different genes, such as c-myc, E2F1 and cyclins, were described as genes involved in both cell 
proliferation, cell-cycle arrest and cell death. The choice and the activation of different pathways 
depend on cell type, cellular environment and genetic background (Vermeulen et al., 2003). Although 
NF-Y is known to play a central role in cell proliferation by controlling the expression of important 
genes involved in cell cycle progression such as cyclin A,  cyclin B1, cyclin B2, cdc25A, cdc25C and 
cdk1, different reports described NF-Y as transcription factor having role also in apoptosis. Gurtner 
et al. demonstrated that NF-Y overexpression, in particular NF-YA overexpression in mouse 
embryonic fibroblasts (MEFs) and human cells inhibits cell proliferation and induces apoptosis by 
activating E2F1-dependent p53 apoptotic pathway. Apoptosis is not induced in E2F1-/- or p53 ablated 
cells and an increasing in cell proliferation is observed after NF-Y overexpression in mutant p53 cells 
(Gurtner et al., 2010). 
It is reasonable to assume that it is the amount of NF-YA, that is the limiting subunit of the trimer, to 
be decisive for cell fate, because NF-YA depletion also leads cells to apoptotic response (Benatti et 
al., 2011). 
Gene expression profilings, ChIP-on-ChIP and bioinformatics analysis identified pro-survival, pro-
growth and anti-apoptotic genes (BCl-xl and BCl2) to be under the direct control of NF-Y (Benatti et 
al., 2006) but also apoptotic genes are under NF-Y transcription control: Bim, a strong pro-apoptotic 
genes, for example, is transcriptionally activated by NF-Y in sympathetic neurons (Hughes et al., 
2011). Bim is a critical mediator of apoptosis in different cell types and in sympathetic neurons is 
required for NGF withdrawal- induced death. 
The inverted CCAAT box present in bim promoter is bound by NF-Y and its activity is essential to 
activate the reporter gene bim-Luciferase in absence of NGF. Moreover, it has been shown that NF-
Y and FOXO3a cooperate and interact with coactivators CBP and p300 for bim promoter activation 
after withdrawal of NGF (Hughes et al., 2011). 
On the other hand, it was demonstrated that NF-YA regulates the transcription of Polo Kinase1 
(PLK1), an important kinase of mitotic phase (Hamanaka et al., 1995). In this paper, the authors 
propose a link between NF-Y, CDK2 a p21. In unstressed cells, NF-YA is associated with CDK2 to 
the CCAAT box of PLK1 promoter to regulate cell cycle progression and cell division. When cells 
are treated with DNA damage agents, p53 is activated, the expression levels of p21 increased and p21 
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associates with NF-YA replacing CDK2 on PLK1 promoter, that is repressed, preventing mitotic 
catastrophe and inducing mitotic death (Lin et al., 2014). The molecule model is shown in figure 10. 
 
 
 
Figure 10. Model in which the dynamic interplay among CDK2, p21 and NF-YA in the promoter fine tunes PLK1 
expression. In unstressed cells, CDK2 associates with NF-YA bound on the CCAAT box in the PLK1 promoter to allow 
cell cycle progression. DNA damage activates p53 and induces p21 to replace CDK2 in binding to NF-YA, which causes 
PLK1 repression and prevents mitotic cell death. (Lin et al., 2014). 
 
In agreement with the role of NF-Y to drive cellular growth, NF-YC subunit was recently classified 
as driver oncogene (Tong et al., 2015). However, the role of NF-YA in apoptosis remain ambiguous 
because both overexpression and depletion of NF-YA subunit induce cells to apoptosis and both pro-
apoptotic and anti-apoptotic genes are modulated by NF-Y. A better understanding about the 
implication of NF-Y in apoptotic processes will come from genomic analysis of NF-Y sites, positive 
and negative, and the matching with the regulome of other TFs involved in apoptosis induction. 
 
2.5.7 NF-YA in embryonic stem cells 
Consistent with its role in cell cycle regulation, NF-Y is required for embryonic stem cells (ESCs) 
and hematopoietic stem cells (HSCs) proliferation. 
It was found that while NF-YA heterozygous mice are normal and fertile, NF-YA null mice die prior 
8.5 dpc, suggesting that NF-Y plays a crucial role in early mouse embryonic development 
(Bhattacharya et al., 2003).  
The involvement of NF-Y in early tissue development was initially suggested by Stathopoulos t al. 
in Drosophila, where he demonstrated that the homologous if NF-Y regulates dorsal-ventral 
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patterning (Stathopoulos et al., 2002). Emerson team, later, found that NF-Y acts as master regulator 
of HSCs self-renewal and differentiation (Zhu et al., 2005). 
Of the two NF-YA isoforms, the short one is considered the stemness isoform as demonstrated by 
different experiments concerning both adult and embryonic stem cells (ESCs). 
The overexpression through retroviral infection of NF-YAs in HSCs induces the expression of 
HOXB4 and HOX4 paralogs (HOXC4, HOXD4 and HOXA4) as well as Hes-1, LEF-1, Notch1, p27 
and telomerase and it address HSCs toward self-renewal rather than differentiation. This aspect is 
highlighted by the prominent ability of HSCs, overexpressing NF-YAs, to repopulate the bone 
marrow of immunocompromized animals (Zhu et al., 2005). 
Similar results were confirmed by Domashenko, using TAT-NF-YAs protein as alternative to using 
retroviral expression of NF-YA in HSCs. TAT-mediated transduction of NF-YAs peptide induces the 
ex vivo proliferation and increased engraftment of human hematopoietic progenitor cells 
(Domashenko et al., 2010). 
Human and mouse ESCs transcriptomes analysis identified the CCAAT box enriched in important 
regulatory regions of embryonic stem specific genes (Grskovic et al., 2007).  
Between the two isoforms, NF-YAs predominates in mouse ESCs and plays a global role in 
maintenance of stemness. A switch between the short and the long isoform was observed upon 
differentiation of mESCs to embryo bodies (EBs): NF-YAl isoform is present at very low levels in 
mESCs, while NF-YAs is the major isoform expressed before and decrease to undetectable levels 
after differentiation (Dolfini et al., 2012). Further experiments demonstrate that the use of dominant 
negative of NF-YAs negatively affects the expression of important stemness genes in mESCs: Klf4, 
Klf5, Arid1a, Fgf4, Sall4 and Jarid2. 
Moreover, the transduction of TAT-fusion NF-YAs activates stemness genes containing CCAAT box 
accelerating growth of mESCs when they are cultured in normal conditions and maintaining cells in 
a pluripotent state when they are growing in absence of LIF (Dolfini et al., 2012). 
 A strong correlation between NF-Y and NANOG emerged from bioinformatics analysis highlighting 
30%-50% of NANOG peaks containing NF-Y sites. In mESCs, the Nanog promoter is not a direct 
target of NF-Y, but it is controlled by SOX2 and OCT4, which are instead directly regulated by NF-
Y; in this way, indirectly, NF-Y regulates mRNA and protein expression levels of NANOG (Dolfini 
et al., 2012). 
After NF-Y depletion, the ESCs gene expression profile is similar to that obtained after inactivation 
of pluripotent master genes Oct4, Sox2, Nanog. The silencing of one of NF-Y subunits leads to self-
renewal defects and start of differentiation toward the trophoblast lineage. 
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Even if NF-Y function has been widely studied in relation to its property to bind CCAAT box in 
proximity to transcription starting sites (TSS), genome wide analysis revealed that NF-Y sites are 
particularly enriched not only in promoters but also in active enhancer regions of ES specific genes. 
It has emerged that at least half of NF-Y binding sites are located at 500 bps from TSS in mESCs 
where NF-Y colocalizes with OCT4, Nanog and Prdm14. As pioneer TF, NF-Y promotes, in these 
sites, chromatin accessibility for other master TFs (Oldfield et al., 2014).  
It is very important to underline that genes regulated by NF-Y from distal binding site are enriched 
in pathways involved in embryonic development. In agreement with the role of NF-Y in ESCs 
maintenance, NF-Y binding to distal sites is lost when cells leave pluripotent state and are committed 
to differentiation (Oldfield et al., 2014). 
All these findings define NF-Y as an essential factor for ESCs pluripotent state regulation. 
 
2.5.8 NF-Y in human diseases and metabolism 
From different studies, NF-Y emerged as a transcription factor involved in the regulation of many 
genes involved in different types of cancers (Li et al., 1992) and its activity plays an important role 
both in the regulation of genes involved in human diseases and in the regulation of cell metabolism.  
NF-Y was not found to be muted or altered in cancers but, different expression profiling experiments 
show that the activation of some CCAAT genes is important to change the normal transcriptome 
profile of the cells, inducing them to transformation. 
Data on gene expression profiles coming from thyroid (Salvatore et al., 2007), breast (Scafoglio et 
al., 2006), colon (Jürchott et al., 2010), prostate carcinoma (Blum et al., 2009; Calvo et al., 2010) 
and leukemias (Forsberg et al., 2010), all indicate that promoters of cancer genes, particularly those 
of most aggressive tumors, are enriched in NF-Y sites (Thomassen et al., 2008). The treatment of 
cells with antitumor drugs, led to repression of NF-Y driver cancer genes (Blum et al., 2007; 
Yamanaka et al., 2009). Analyses extended to more than 6000 expression profiles of tumors found 
NF-Y and E2F sites as the only enriched motifs in genes overexpressed in human cancers (Rhodes 
et al., 2005; Sinha et al., 2008; Goodarzi et al., 2009). 
 Therefore, a link between NF-Y and E2F emerged as an important point in the regulation of cancer 
genes and, a detailed analysis, has to be undertaken in order to better understand mechanisms 
governing these processes.  
The correlation between NF-Y and human disorders emerged from different studies. Several reports 
demonstrated the involvement of NF-Y in polyglutamine diseases, among these: Huntington 
disease-HD- (Yamanaka et al., 2008) and Spincerebellar Ataxia Type 17 -SCA17- (Landsberger 
and Wolffe, 1995). 
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HD is a neurodegenerative disorder due to the accumulation of a mutated Huntingtin protein (HTT), 
with an extended polyglutamine tract, with other TFs containing Gln-rich domain, in post mitotic 
neurons of cortex and striatum. The accumulation of HTT with NF-YA and NF-YC subunits subtract 
NF-Y from its activity of transcription factor. Heat shock genes –HSP40 and HSP70- coding for 
important chaperonins that provide the correct folding of other proteins preventing aggregation, and 
are controlled by NF-Y. Thus, a negative loop is trigged, enhancing cell toxicity and neurological 
disorders (Yamanka et al., 2008). 
SCA17, instead, is due to the expansion of Gln-rich domain of TBP gene a TF binding the TATA 
box. Although TATA boxes are mainly present in CCAAT less promoters, NF-Y and TBP interact 
for the transcription of chaperonins (Bellorini et al., 1997), therefore, similar to HD, poly-Gln TBP 
causes NF-YA aggregation and thus neuron degeneration (Huang et al., 2011). 
Lagor et al. study, links NF-Y to diabetes disease. Insulin induces the production of hepatic 3-
hydroxy-3-methylglutaryl-CoA reductase – HMGR – CCAAT gene that is normally bound by NF-Y 
but not in diabetic animals (Lagor et al., 2005). However, it is not still clear whether the loss of 
binding of NF-Y to the CCAAT box is the cause of the illness or whether it is a secondary effect. 
Different studies report that SNPs in the NF-Y target sequence can affect the expression of genes 
involved in different pathways and related to human disorders. Among genes owning SNPs in 
CCAAT box, were identified genes coding for enzymes involved in the control of telomeres length, 
detoxification (von Richter et al., 2004) and in genes related to Hereditary persistence 
of fetal hemoglobin – HPFH – and β-thalassemia. In HPFH, CCAAT genes coding for fetal globin 
continue to be expressed after the birth, in adult life. The proposed model about this regulation is that 
mutations around CCAAT box prevent the binding of a repressor TF for fetal globin genes, 
maintaining gene expression (Chassanidis et al., 2009; Liberati et al., 2001). 
Finally, a mutation in the CCAAT box of β-globin gene promoter was found to be associated to β-
thalassemia intermedia, characterized by a reduced transcription of this mRNA (Chen et al., 2007).  
NF-Y was also identified as an important regulator of genes involved in different metabolic pathways. 
Two important cholesterogenic genes are regulated by NF-Y: farnesyl diphosphate (FPP) synthase 
and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). An inverted CCAAT box was identified 
in the promoter of FPP synthase, and its mutation leads to a complete transcriptional inhibition while 
the transfection of the NF-YA dominant negative, affects both FPP and HMG-CoA synthase 
transcription (Jackson et al., 1995). In addition, the 7-dehydrocholesterol reductase (Dhcr7), the 
terminal enzyme in the pathway of cholesterol biosynthesis, contains, on its promoter, binding sites 
for NF-Y and Sp1 and mutational analysis highlighted that they play a cooperative role in the 
transcription activation sterol-mediated (Jai-Hyun Kim et al., 2001). Moreover, NF-Y interacts with 
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a potent lipogenic transcription factor, SREBP-1, in particular with the hepatic SREBP-1c, positively 
enhancing the transcription of fatty acid synthase (FAS) (Teran-Garcia et al., 2002). 
In agreement with its ability to work as transcription activator and repressor, NF-Y negatively 
regulates the transcription of pyruvate carboxylase (PC), an enzyme involved in different metabolic 
pathways such as that involved in the secretion of insulin by pancreatic β-cells under glucose 
stimulation. Indeed, it was demonstrated that, the mutation of CCAAT box located in the promoter 
of PC, increased the transcription of a reporter gene transfected in insulin secreting cells 
(Sunyakumthorn et al., 2005). 
In the last years, a tight correlation emerged between cancer and metabolism: different metabolic 
pathways are usually altered tumors.      
A detailed analysis about the link between NF-Y, metabolism and cancer, is reported in the paper 
attached in the second part of this thesis. 
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2.6 Cell Penetrating Peptides 
The integrity of cell membrane is fundamental to protect cells, to favorite their communication and 
to maintain tissue homeostasis. Cell membrane organization, indeed, prevents the exit and the uptake 
of small molecules, proteins and genetic material in unspecific way. However, the presence of cells 
and tissues barriers, such as the blood-brain barrier (in the case of neurodegenerative diseases), 
represent an important obstacle for drug delivery to pelt their targets. 
An efficient and relatively new strategy to deliver pharmaceutical molecules into the cells and to 
increase their tissue distribution emerged in the last years and it is based on the use of cell penetrating 
peptides (CPPs). 
CPPs are relatively short peptide (less of 30 amino acids) able to ubiquitously over cross the plasma 
membrane in a receptor free manner. In this way, therapeutic molecules, antibodies, peptides, 
nanoparticles, nucleic acids, conjugated to a cell penetrating peptide, can be efficiently distributed, 
increasing their concentration, in difficult to access target tissues. Therefore, CPPs represent a 
revolutionary tool, to treat different human diseases, in a relatively low toxic and non-invasive way. 
 
2.6.1 Discovery and properties of cell penetrating peptides  
The first cell-penetrating peptides discovered, Tat-peptide and Penetratin, are still today among the 
most studied (Frankel  and Pabo, 1988). 
After the characterization and the description of HIV to infect cells, TAT protein was identified as 
protein able to over cross cell membranes. TAT is an RNA-binding protein of 14 KDa, that recognizes 
the TAR sequence (transactivator response element) of HIV genome (Feng et al., 1988) 
, 
Figure 10. Tat peptide derived from TAT protein codified by HIV-1 genome (Rizzuti et al., 2014). 
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it stimulates HIV-1 gene expression enhancing the processivity of RNA pol II (Ott et al., 2004). TAT 
protein is composed of a transcriptional activation domain containing a cysteine rich region and of a 
hydrophobic motif rich in arginines that specifies the binding of the protein to RNA (Fig. 10).  
Generating deleted mutants in the N-terminal and C-terminal domain of TAT protein, Park et al. 
arrived to define the minimum Tat peptide sequence (TAT 49-57) needed to translocate cells without 
losing efficiency (Park et al., 2002). This region, required for translocation, is rich in basic amino 
acids, lysines and arginines, and it is important for DNA binding. 
Contemporary to the discovery of Tat peptide, Drosophila Antennapedia homeobox protein (pAntp) 
was identified as CPP able to penetrate differentiated neurons and to accumulate into the nuclei after 
cell translocation (Joliot et al., 1991). Generally speaking, homeoproteins are transcription factors 
that bind  specific DNA sequences through a 60 amino acid sequence composed by three α-helices 
and a β-turn between helix 2 and 3 (Qian et al., 1989). The analyses aimed to the identification of the 
region important for cellular uptake, reveled a sequence of 16 amino acids, named Penetratin, in the 
third α-helix of the protein Antennapedia, sufficient for the uptake of the whole protein (Fig. 11).  
 
 
 
 
 
Figure 11. Sequence corresponding to the Antennapedia homeodomain third helix (Derossi et al., 1994). 
 
The field of CPPs evolved rapidly and new peptides able to cross the cell membranes are emerging 
daily marking hard to have a definition embedding all the cell-penetrating peptides discovered. In 
general, we can define a CPP as a short peptide rich in basic amino acids, with the ability to over 
cross plasma membranes without the necessity to recognize a receptor. The uptake occurs in an ATP 
dependent or independent manner, with very low toxic effects for the cells. A secondary α-helix 
structure is important for protein cellular uptake but not required. 
Many other homeo-box domains were characterized for their ability to internalize the whole protein 
such as Hoxa5, Hoxc8 and PDX-1 (Kong et al., 2008) (Chatelin et al., 1996) (Han et al., 2000). 
Pax4, instead, even if has a homeodomain region, holds the property of CPP in its paired domain (Lu  
et al., 2007). 
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The transcription factor Oct4, diffusely described for its cruciality to maintain the pluripotent state of 
embryonic stem cells (Schöler et al., 1990) and for its involvement in somatic cells reprogramming 
(Nichols et al., 1998), owns a protein transduction domain (PTD) in the third helix of its 
homeodomain. It is represented by a sequence of 16 amino acids sharing a high level of homology 
with Penetratin sequence of Antennapedia (Fig. 12). 
 
Figure 12. (A): The protein transduction domain (PTD) of Oct4 within its homeodomain is highlighted in orange. 
(B): Sequence alignment between Oct4-PTD and Penetratin; identic amino acid (*); same amino acid charge (* or :) 
(Harreither et al., 2014). 
 
Differently from Penetratin that accumulates mainly into the cytoplasm, Oct4-PTD diffuses from 
cytoplasm to the nucleus. Moreover, the peptide maintains the ability to translocate the full-length 
Oct4 protein both in human and mouse cell lines (Harreither et al, 2014). This data lays the basis for 
the use of recombinant Oct4 protein in reprogramming process in order to produce iPSCs in a gene 
integration free-manner. 
 
2.6.2 Classification of cell penetrating peptides. 
CPPs can be classified, according to their origin, in three different classes: peptide derived from 
natural proteins, including viral proteins, DNA/RNA binding protein, antimicrobial peptides and 
homeoproteins; chimeric peptides derived from the fusion of natural proteins or sequences and 
synthetic peptides that are artificially designed peptides based on the sequence of natural proteins. 
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 Table 1. Origin and sequences of same CPPs (Bechara and Sagan, 2013). 
 
Another classification method is based on the physic-chemical properties of the sequences. Sequences 
are classified in cationic, amphipathic and hydrophobic (Milletti, 2012).  
The class of cationic peptides are particularly rich in arginine residues and they can easily penetrate 
cell membranes at physiological pH thanks to the arginine guanidine group. The lysines, instead, 
because lack the guanidine group, show a reduced capability to penetrate cells, even if, similarly to 
arginines, they present a net positive charge. 
Belong to the class of amphipathic CPPs different peptides such as the murine sequence of vascular 
endothelium cadherin, pVEC, peptides characterized by a secondary α-helix structure owing both 
hydrophobic and hydrophilic amino acids distributed on different faces of the helix, like the chimeric 
MAP and peptides rich in prolines such as Bac7 and SAP (Milletti 2012). Hydrophobic CPPs include 
both natural and chemical designed peptides containing prenyl groups that facilitate the attachment 
to cell membranes. 
The relevance of cationic peptides able to over cross the cell membranes push to the search of other 
classes of peptides owing this property. Transcription factors and nuclear proteins are characterized 
by sequences, typically of 12 residues, rich in basic amino acids important for the transport of the 
proteins from cytoplasm into the nucleus. These sequences, known as nuclear localization signals 
(NLSs), coming from transcription factors NF-kB, OCT-6, TFIIE-β, TCF1-α, SV40, HATF3 and C. 
elegans SDC3, were tested for the ability of cellular uptake and subcellular localization. What 
emerged was that all the NLS peptides analyzed, showed a rapid accumulation inside to the cells 
when added to culture media expanding the list of cationic peptides available for delivery of 
therapeutic agents in a noninvasive way (Ragin et al., 202). 
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2.6.3 Cell penetrating peptides applications 
Thanks to the capability to over cross cell membranes, CPPs represent a very important tool to 
transport inside to the cells different covalently or non-covalently linked cargoes ranging from small 
molecules (drugs and imaging molecules) to nucleic acids, proteins and liposomes. 
 
2.6.3.1 Peptides, proteins and enzymes 
As it known, many proteins are unable to passively penetrate cell membrane so, CPPs represent an 
effective method to delivery inside to the cells proteins with a pharmacological/therapeutic activity. 
The transport of small and large 120 KDa proteins through CPPs was achieved both in vivo and in 
vitro, and it was employed to treat different diseases. CPPs, for instance, were used to hit cancer cells 
in different studies. The herpes virus E2 protein was fused to TAT peptide to induce apoptosis in 
cervical cancer cells (Roeder et al., 2004); the tumor suppressor p53 associated to a synthetic 
polyarginines peptide was used to block the growth of bladder cancer cells (Araki et al., 2010). 
Moreover, CPPs were used to release inside to the cells endonucleases able to remove genes causing 
diseases (Liu et al., 2014) and in the treatment of inflammatory diseases combining inhibitors of NF-
kB to different cell penetrating peptides (Orange et al., 2008). Enzymes able to prevent oxidative 
damage, such as glyoxalase and superoxide dismutase, were coupled to TAT peptide in order to 
prevent ischemic injury and protect cells from oxidative damages (Shin et al., 2014). TAT peptide 
was successfully used to transport NF-YA (the regulatory subunits of the trimeric transcription factor 
NF-Y) inside to human hematopoietic cells inducing the activation of HOXB4 gene and the 
proliferation of primitive hematopoietic progenitor cells (Domashenko et al., 2010) providing an 
alternative approach to retroviral stem cells therapy. 
Applications of CPPs for protein delivery were used not only to target human cells but also bacteria 
and fungi. This represents a new approach to inhibit the growth of pathogenic agents bringing benefits 
to human well-being. Considering the growing antibiotic resistance of bacteria, the possibility to use 
CPPs as antimicrobial agents or as tool to transport antimicrobial molecules in non-mammalian cells 
is of great interest and represent a new developing research field. 
 
2.6.3.2 Nucleic acids and liposomes 
Cell penetrating peptides are widely used to transport into the cells nucleic acids. Nucleic acids, for 
their hydrophilic nature, are very inefficient to over-cross plasma membranes. The conjugation of 
CPPs to nucleic acids improves the delivery of genetic material into the cells exceeding problems 
related to classic methods of gene delivery: toxicity, low transfection efficiency and low safety profile 
of viral infection. CPPs were associated also to other molecules to further improve the delivery of 
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genes after cell entry. As it was recently demonstrated, the association of TAT peptide with the fusion 
protein dynein light chain Rp3, improved DNA delivery in the nucleus rather than seven fold 
compared to the transport protein alone (Favaro et al., 2014). 
Although cell penetrating peptides have the ability to reach cells also bypassing physical barriers, the 
main limitation of their application is due to their low cell specificity. For this reason, to better control 
and direct molecules toward specific cells, CPPs have been incorporated to targeting ligands. Fang 
demonstrated in his study how the association of TAT peptide with the vascular endothelial growth 
factor receptor 1, selectively delivered siRNAs against specific targets, in tumor cells (Fang et al., 
2013). 
Thanks to CPPs, therapeutic gene delivery became possible and much easier to target tissues difficult 
to access like skin and brain.  
Cell penetrating peptides modified micelles, were used to transport siRNA and camptothecin in the 
brain of rats with malignant glioma through intranasal cavity, prolonging their life (Kanazawa et al., 
2014) while SPACE peptide was used to topically transport into the skin siRNAs encapsulated in 
liposomes (Chen et al., 2014). 
The combination of cell penetrating peptides with liposomes represents indeed a very promising 
system for gene delivery. New liposomes, with a good pharmacokinetic profile, have been designed 
and their association with CPPs, significantly improve their poor intracellular delivery.  
 
2.6.4 Mechanism of internalization 
The mechanism used by CPPs to enter cells is still not well understood.  However, several uptake 
mechanisms have been identified. The origin and the properties of peptides provide information about 
their way to over-cross cell membranes. 
Positively charged arginine-rich peptides, generally take advantages from the basic residues to 
penetrate cells. In fact, the electrostatic interactions with the negatively charged plasma membrane, 
allow to the peptide to find their way to be internalized. 
The cruciality of positively charged residues for cell uptake, was demonstrated by different 
experiments. The truncation or the substitution of positively charged amino acids with alanine, 
dramatically reduced the efficiency of TAT peptide to enter cells (Wender et al., 2000). A similar 
effect was observed for Penetratin after the mutation of basic residues to alanines.  
More detailed studies demonstrate that arginine residues are much more effective to favor cell uptake 
rather than lysines, indeed, the replacement of lysine residues with arginines, is associated to a more 
efficient uptake. Therefore, the efficiency with which peptides enter cells is associated to the 
guanidine group of arginine side chain rather than to the only positive charge (Rothbard et al., 2004). 
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Moreover, it was also demonstrated that the number of arginine residues is fundamental in order that 
the peptide maintains the best uptake level. 
In addition, the secondary structure of CPPs was studied in order to explain the effects of cell 
membrane perturbation when the peptide contacts the cell surface. However, the relationship between 
secondary structure and ability to penetrate cells remain an open question. In fact, it was observed 
that, although a secondary α-helix structure characterizes many cell penetrating peptides, they adopt 
different structures following the interaction with phospholipids. This variability may be associated, 
to the experimental conditions such as buffer composition, pH and temperature. Penetratin, for 
instance, has an α-helix structure but it can also adopt β strand conformation. The orientation of 
secondary structure elements, have been determined using oriented circular dichroism spectroscopy. 
These experiments revealed that the helical structures are predominantly perpendicular to the 
membrane surface, while that of the β-type carbonyls is parallel to the membrane surface (Clayton et 
al., 2006). What it seems to be relevant for internalization is the structural flexibility and CPPs 
malleability. 
Starting from electrostatic interactions and cell membrane destabilizations, following the contact of 
the CPPs with the cell surface, two mechanisms have been described to explain the uptake of CPPs 
into the cells: the endocytosis and the direct translocation (Fig. 13).  
 
 
 
 
 
 
 
Figure 13. Two different mechanisms for CPPS of internalization: direct translocation and endocytosis.  
 
Endocytosis represents an energy dependent mechanism of internalization that involves different 
pathways such as macropinocytosis, clathrin-mediated endocytosis, caveolae or lipid-raft-mediated 
endocytosis, and clathrin- or caveolae-independent endocytosis (Conner et al., 2003). 
The choice of endocytotic pathway employed for internalization depends on the nature, on the 
properties of the peptide and of its connected cargo as well as of the targeted cell type. 
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It is clear that peptide stability is fundamental to allow its conjugate to reach the intracellular target; 
proteolytic cleavages and degradation are avoided by the endosomal escape. 
It is not so easy determine exactly the specific way that CPPs chose for cell uptake. Different studies 
aimed to determine the endocytotic pathways are performed using chemical inhibitors and by 
detecting the colocalization of the peptide with protein markers. The issue is that sometimes, the 
outcomes of these studies depend on the cell line used and have low specificity, so results have be 
considered with caution (Ivanov, 2008). 
The alternative method used by CPPs to over-cross cell membrane refers to the energy and 
temperature independent direct translocation pathway. This internalization method is merely based 
on the direct interaction between peptide and cell membrane and can involve four different pathways: 
inverted micelle formation, pore formation model, carpet-like model and membrane thinning model. 
Although these processes are temperature independent, direct translocation is however decreased at 
4°C because membrane fluidity is affected at low temperatures (Zaro et al., 2005). 
Generally speaking, direct translocation and endocytosis can occur at the same time. Different 
endocytotic pathways can be used by the same peptide as demonstrated for Penetratin and TAT 
peptides. Because the internalization of CPPs is not completely understood, many studied pointed the 
attention on the importance of the interaction between the peptide and the negatively charged cell 
membranes. Therefore, peptide internalization remains an open challenge for next studies. 
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3. Aim of the projects and main results 
NF-Y is a pioneer transcription factor that, by binding the CCAAT sequence, governs complex genes 
regulatory networks such as those involved in cell cycle progression and proliferation, cell signaling, 
DNA repair, metabolism and stem pluripotency pathways. 
The increased knowledge about gene regulation, derived from the identification of new cis-acting 
sequences in promoters and enhancers, together with the characterization of their corresponding 
transcription factors, have represented a valid tool to better understand the activity of NF-Y as 
transcription regulator and chromatin organizer. My PhD thesis contributed to illustrate new 
biological properties of NF-Y, through studies ranging from biochemical to functional aspects, in 
different cell contexts, including non-transformed, cancer and pluripotent stem cells. 
 
3.1 Characterization of NF-YA as Cell Penetrating Peptide 
In the last years, many studies have been centered on the identification of new cell penetrating 
peptides (CPPs) in order to solve problems of drugs delivery through cell membrane to treat and 
manage several diseases. 
As mentioned in the previous paragraphs, CPPs are a class of short peptides that retain the ability to 
overpass cell plasma membranes and gain access to the cell interior. Their main properties reside in 
owning amino acid sequences rich in basic residues and in the organization of their secondary 
structure in alpha helices. CPPs are used as carrier to uptake inside to the cells, proteins, nucleic acids, 
drugs and molecules. A well-known and characterized CPP, HIV TAT peptide (Park et al., 2002), 
was demonstrated to efficiently transduce into primary hematopoietic stem cells (HSCs) a functional 
GST-TAT- NF-YA fusion protein (Domashenko et al., 2010). 
NF-YA is the limiting subunit of NF-Y, composed by NF-YA, NF-YB and NF-YC subunits, each of 
which possess an evolutionary conserved domain important for subunit interactions and DNA 
binding. The analysis of NF-Y/CCAAT tridimensional structure highlighted, in NF-YA subunit, the 
rich presence of exposed basic aminoacids in the conserved 56- aminoacids residues, organized in 
two alpha helices (A1 and A2) connected by a linker (Nardini et al., 2013). 
These observations have laid the foundations for the rationale of my work. The main project of my 
PhD was dedicated to i) verify the hypothesis that NF-YA could own the properties of CPP, ii) 
identify the aminoacidic stretches that confer CPP features, iii) analyze the functionality of the 
recombinant protein into the cells. 
In order to verify the ability of NF-YA to penetrate cells, the two isoforms of NF-YA, NF-YAs and 
NF-YAl, were produced as recombinant proteins and transfected in HCT116 WT cells. Interestingly, 
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we noticed a rapid uptake of NF-YA into the nuclei at very low concentrations, suggesting that NF-
YA is able to penetrate cells in a TAT independent way. 
We reasoned that, the stretches of basic aminoacids, contained in the evolutionary conserved domain 
of NF-YA, could confer to the protein the property to overpass plasma membrane. Mutational 
analysis identified two aminoacidic stretches that, when mutagenized to alanines, completely abolish 
NF-YA ability to penetrate cells: the first stretch is in α helix 1- KRR- and the other in alpha helix 2 
–RRK and RKR-. 
NF-YA, as part of a transcription complex, has a typically nuclear localization. As demonstrated in 
previous work, basic aminoacids in A1 and A2 helices are important nuclear localization signals 
(Kahle et al., 2005) and they are the same identified in this study as cell penetrating peptides.  
The aminoacidic sequences identified as CPPs, in the evolutionary conserved domain of the protein, 
are also involved in NF-YB/NF-YC subunit interactions and in CCAAT binding. The overlapping of 
sequence motifs necessary for cellular uptake with the conserved domain of the protein may suggests 
that the ability of NF-YA to penetrate cells is related to functional purposes. Although, at day, there 
are not studies about the release of NF-YA from cells, data obtained from this study leave us to 
assume that NF-YA might be part of a possible mechanism of protein export, alternative to paracrine 
signaling pathway, where released proteins are received by surrounding cells that, consequently, 
change their behavior. Concept that can be extended to other transcription factors described as CPPs. 
Moreover, we wanted to verify that the ability of recombinant NF-YA to penetrate cells was not cell 
type or specie specific. For this reason, experiments of protein transduction were performed in 
different human and mouse cell lines. We observed that NF-YA penetrates efficiently in the nuclei 
of all tested cell types. 
Whether, from one side, we noticed that the half-life of the recombinant protein was brief for many 
transformed cell lines such as HeLa, HCT116, HT1080 and U2OS cells, on the other, we observed 
that for non-transformed NIH3T3 and HaCaT cells, the trend was different, as they retain NF-YA 
protein in the nuclei for at least 24 hours from transfection. This was a very exciting data because 
allowed us to assess recombinant NF-YA functionality. We monitored NIH3T3 cell growth, after 
recombinant NF-YAs and NF-YAl transduction, for 24 and 48 hours. We observed that recombinant 
NF-YA protein, in NIH3T3 cells, led a cell proliferation delay and this effect was more pronounced 
with the long isoform. 
Although the activity of NF-Y transcription factor is mainly associated to cell growth and cell 
proliferation, it is likewise a regulator of both anti and pro-apoptotic genes (Benatti et al., 2006).  
In this work, we demonstrated that recombinant NF-YA is active after cell translocation. Its 
overexpression induces cell growth inhibition, characterized by the down modulation of cell cycle 
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progression genes -Pcna and Ccnb1/2-, and the activation of apoptosis pathway as demonstrated by 
the increased transcription levels of E2f1 (target of NF-Y) and its apoptotic target genes -Apaf1 and 
Bax- such as by the reduced expression of the anti-apoptotic Bcl2.   
We know that NF-YA is the limiting subunit of NF-Y and its expression is cell cycle regulated. 
Therefore, a deregulated expression of the protein, in this case the overexpression, could be perceived 
by the cells as a “threat” for their normal healthy state and the activation of apoptotic response may 
represent a defense response to this stimulus. However, these data are in line with the effects obtained 
by DNA-mediated NF-YA overexpression in murine fibroblasts where the activation of apoptotic 
genes, with a mechanism dependent on the up-regulation of E2F1, was described in Gurtner work 
(Gurtner et al., 2010). 
 
3.2 NF-Y modulates stemness circuitry both in mouse and in human stem cells 
Results obtained in the first part of the work, and the well-known properties of NF-YA to stimulate 
growth and to maintain the pluripotency of stem cells (Zhu et al., 2005; Dolfini et al., 2012), prompted 
us to investigate recombinant NF-YA also in mouse embryonic stem cells (mESCs) (reported in the 
last part of the thesis). We observed that after transduction, recombinant NF-YA had a relatively long 
half-life in mESCs. This result pushed us to verify whether, similarly to GST-TAT-NF-YA, 
recombinant NF-YA, could counteract leukemia inhibitory factor (LIF) withdrawal. LIF is a cytokine 
that plays a very important role in the maintenance of mESCs pluripotency. When LIF levels drop, 
the cells differentiate (He et al., 2006). Our preliminary data demonstrated that, mESCs, daily treated 
with recombinant NF-YA, and in particular with the short isoform, grow faster and maintain their 
pluripotency features, compared to control cells, when grown in absence of LIF. In these conditions, 
after NF-YA transduction, the expression of cell cycle genes and master stemness transcription 
factors are maintained near to the normal levels, while a drastic reduction in the expression levels of 
Nanog, Klf4, Klf5 and Ccnb2 is observed in control cells. These data are well in line with what was 
observed in previous studies where GST-TAT-NF-YAs was described as able to promote stem cell 
growth and compensate withdrawal of LIF (Dolfini et al., 2012). Data obtained from these 
experiments, further confirm the functionality of recombinant NF-YA and suggest that a potential 
future application of recombinant NF-YA, in other stem cell systems, can be considered. 
Considering the involvement of NF-Y in the regulation of mESCs stemness circuitry, an additional 
goal of my work was to investigate NF-Y in human stem cells. Starting from human dermal 
fibroblasts, we generated induced pluripotent stem cells using Yamanaka factors. Colonies obtained 
from reprogramming process were characterized for stemness properties and used as model to start 
this study. Preliminary data obtained from hiPSCs, from their differentiation to embryo bodies and 
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from NF-Y single subunits inactivation, highlighted similes between human and mouse ESCs about 
NF-Y activity; in particular, we observed that like mESCs, hiPSCs mainly express the short isoform 
of NF-YA while the relative abundance of NF-YAl isoform increases upon differentiation. Moreover, 
the inactivation of NF-Y subunits, and in particular NF-YA silencing, dramatically affects the 
expression of important stemness genes: SOX2, OCT4, KLF4, NANOG and KLF5 expression levels 
are indeed greatly reduced. All these evidences suggest that NF-Y influences the stemness circuitry 
in human stem cells as well as in mESCs. 
 
3.3 NF-Y regulates different metabolic pathways 
The manuscript reported in the second part of this thesis, (accepted paper for publication in 
Oncotarget), to which I took part, was dedicated to a study of NF-Y in the regulation of metabolic 
genes in cancer cells.  
The rationale of this work was dictated by: i) analysis of NF-Y regulome that highlight the term 
“metabolism” as particularly enriched among the class of genes regulated by NF-Y in Gene Ontology 
categorization; ii) bioinformatic analysis highlighting the CCAAT box regulatory sequence enriched 
in promoters of genes overexpressed in cancer cells; iii) computational analysis showing different 
metabolic pathways altered in cancer cells. 
These observations pushed us to analyze available Affymetrix gene expression profiles of HeLa S3 
cells depleted for NF-YA subunit as well as those of mESCs after the inactivation of NF-Y single 
subunits. Moreover, we performed other experiments of gene expression profiles for HCT116 and 
H322 cells after NF-YA silencing and for HeLa cells after inactivation of NF-YB subunit. 
Farther, we analyzed ENCODE ChIP-seq data for NF-YA and NF-YB in HeLa-S3, GM12878, K562 
and mESCs in order to correlate functional data with the effective binding of NF-Y to the CCAAT 
box. Data collected by these analyses highlighted that NF-Y influences, positively or negatively, 
different metabolic pathways; while anabolic genes are down modulated after NF-Y subunits 
depletion, catabolic genes tend to be upregulated. 
Although the expression levels of specific metabolic pathway genes are different between cancer and 
mESCs after NF-Y subunits inactivation, overall what emerged is that NF-Y positively controls genes 
of the biosynthetic pathway of lipids, cholesterol and fatty acids metabolism, most of them are 
overexpressed in many cancers and involved in neoplastic transformation. 
NF-Y regulates also other metabolic pathways usually altered in cancer cells: it targets genes involved 
in amino acids metabolism, in particular, the pathways involved in de novo synthesis of serine and 
glycine (the SOCG -Serine, One Carbon, Glycine-), glutamine pathway as well as genes involved in 
purines and polyamines biosynthesis.  
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NF-Y activates the transcription of genes involved in glycolysis, but it has a negative or neutral role 
in regulating mitochondrial respiratory genes. 
An important point, emerged from this work, is that in mammalian cells, NF-Y promotes the 
expression of genes involved in the production of energy through anaerobic pathways, a typical 
feature of cancer cells. This underlines a change of course during evolution as, in yeast S.cerevisiae, 
NF-Y promotes the expression of genes involved in mitochondrial energy production. Data emerged 
from this study highlighted that NF-Y does not favor anapleroris process but promotes the expression 
of genes involved in pathways out of Krebs cycle. 
These data provide an important starting point to understand how NF-Y metabolic targets are 
involved in cancer growth and development. In the future, the identification of new NF-Y TFs 
partners, involved in metabolic genes expression, such as further information about their DNA 
regulatory elements, today poorly understood, will provide further news about the regulation of these 
processes. 
 
4. Conclusions and future perspectives 
The work performed during my PhD describes, for the first time, NF-YA as new component of the 
class of proteins owning the properties of cell penetrating peptide and contributes to enrich the 
knowledge about the properties and the features of this protein. We demonstrated that specific basic 
aminoacids residues, in the evolutionary conserved domain of NF-YA, are fundamental to allow to 
the protein cell penetration and nucleus translocation. 
In the last two decades, the application of CPPs took hold in biotechnological applications thanks to 
their ability to over-cross physical barriers and transport cargos to pelt their targets. 
The description of NF-YA carrying protein transduction domains, and in particular the proved 
functionality of the protein into the cells after translocation, represent a very important starting point 
for its potential application in clinical therapeutic. Data collected during my PhD suggest that, 
recombinant NF-YA, may represent a valid tool to undertake cell treatments and studies bypassing 
conventional therapy applications. The use of recombinant NF-YA represents indeed an efficient and 
no toxic tool to overexpress NF-YA avoiding classic methods of gene delivery. 
The already tested GST-TAT-NF-YA protein, used to stimulate the growth of HSCs, in treatments of 
bone marrow transplantation, could be replaced by recombinant NF-YA devoid of tags or epitopes. 
Considering the capability of NF-YA protein to maintain the pluripotent state of stem cells and to 
promote their growth, further applications could relate its use to the treatment of degenerative diseases 
characterized by depletion of stem cells pool (e.g. muscular dystrophy). 
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Moreover, it will be interesting to validate whether the identified CPPs, in the evolutionary conserved 
domain of NF-YA, work likewise when fused to other molecules or proteins. 
A question remains to be clarified: which is the biological function of NF-YA cellular uptake and, at 
the same time, which is the mechanism of its cell exit. A possible action of NF-YA in the biological 
process of monocytes maturation to macrophages, during inflammation, is an appealing hypothesis. 
We know that monocytes express NF-YB/YC subunits but not NF-YA. Their maturation needs the 
activation of genes, which are under NF-Y trimer control. Therefore, monocytes could uptake NF-
YA protein released from the nearby damaged tissues during an inflammatory state, hence triggering 
their maturation to adult macrophages.  
Finally, data obtained from hiPSCs, encourage us to further investigate the relationship between NF-
Y and other human master stemness TFs, in order to better collocate the role of NF-Y in human 
stemness maintenance and differentiation. The employment of recombinant NF-YA may be useful to 
shed light on these proposes as well as ChIP experiments and cell differentiation toward a specific 
cell lineage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 40 
 
5.Reference 
 
Araki, D., Takayama, K., Inoue, M., Watanabe, T., Kumon, H., Futaki, S., Matsui, H., and Tomizawa, K. 
(2010). Cell-penetrating D-isomer peptides of p53 C-terminus: long-term inhibitory effect on the growth of 
bladder cancer. Urology 75, 813-819. 
Bai, X., Kim, J., Yang, Z., Jurynec, M.J., Akie, T.E., Lee, J., LeBlanc, J., Sessa, A., Jiang,  
H., DiBiase, A., Zhou, Y., Grunwald, D.J., Lin, S., Cantor, A.B., Orkin, S.H., and Zon, L.I. (2010). 
TIF1gamma controls erythroid cell fate by regulating transcription elongation. Cell. 142, 133-143. 
Bechara, C., and Sagan, S. (2013). Cell-penetrating peptides: 20 years later, where do we stand? 
Letters 587, 1693–1702. 
Bellorini, M., Lee, D.K., Dantonel, J.C., Zemzoumi, K., Roeder, R.G., Tora, L., and Mantovani, R. 
(1997). CCAAT binding NF-Y-TBP interactions: NF-YB and NF-YC require short domains 
adjacent to their histone fold motifs for association with TBP basic residues. Nucleic Acids Res 25, 
2174–2181. 
Benatti P, Basile V, Merico D, Fantoni LI, Tagliafico E, Imbriano C. A balance between NF-Y and 
p53 governs the pro- and anti-apoptotic transcriptional response.  
Berk, A.J. (2012). Yin and yang of mediator function revealed by human mutants. Proc Natl Acad 
Sci USA 109, 19519–19520. 
Bhattacharya, A., Deng, J.M., Zhang, Z., Behringer, R., de Crombrugghe, B. and Maity, S.N. 
(2003). The B subunit of the CCAAT box binding transcription factor complex (CBF/NF-Y) is 
essential for early mouse development and cell proliferation. Cancer Res 63, 8167–8172. 
Bird, A. (1987). CpG islands as gene markers in the vertebrate nucleus. Trends Genet. 3, 342–347. 
Blum, R., Elkon, R., Yaari, S., Zundelevich, A., Jacob-Hirsch, J., Rechavi, G., Shamir, R., and 
Kloog, Y. (2007). Gene expression signature of human cancer cell lines treated with the ras 
inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res 67:3320–3328. 
Blum, R., Gupta, R., Burger, P.E., Ontiveros, C.S., Salm, S.N., Xiong, X., Kamb, A., Wesche, H., 
Marshall, L., Cutler, G., Wang, X., Zavadil, J., Moscatelli, D., and Wilson, E.L. (2009). Molecular 
signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate 
cancer. PLoS ONE 4:e5722. 
Bolognese, F., Wasner, F., Dohna, C. L., Gurtner, A., Ronchi, A., Muller, H., Manni, I., Mossner, 
J., Piaggio, G., Mantovani, R., and Engeland, K. (1999). The cyclin B2 promoter depends on NF-Y, 
a trimer whose CCAAT-binding activity is cell cycle regulated. Oncogene 18, 1845–1853. 
Borggrefe, T., and Yue, X. (2011). Interactions between subunits of the Mediator complex with 
gene-specific transcription factors. Semin. Cell Dev. Biol. 22, 759–768. 
Calvo, A., Perez-Stable, C., Segura, V., Catena, R., Guruceaga, E., Nguewa, P., Blanco, D., Parada, 
L., Reiner, T., and Green, J.E. (2010). Molecular characterization of the Ggamma-globin-Tag 
transgenic mouse model of hormone refractory prostate cancer: Comparison to human prostate 
cancer. Prostate 70, 630–645. 
Carey, M., Lin, Y.S., Green, M.R., and  Ptashne, M. (1990). A mechanism for synergistic activation 
of a mammalian gene by GAL4 derivatives. Nature 345, 361–364. 
 41 
 
Ceribelli, M., Dolfini, D., Merico, D., Gatta, R., Vigano`, A. M., Pavesi, G., and Mantovani, R. 
(2008). The histone-like NF-Y is a bifunctional transcription factor. Molecular and cellular biology 
28, 2047–2058. 
Chae, H.D., Yun, J., Bang, Y.J., and Shin, D.Y. (2004). Cdk2-dependent phosphorylation of the 
NF-Y transcription factor is essential for the expression of the cell cycle-regulatory genes and cell 
cycle G1/S and G2/M transitions. Oncogene 23, 4084–4088. 
Chan, Q.K., Lam, H.M., Ng, C.F., Lee, A.Y., Chan, E.S., Ng, H.K., Ho, S.M., and Lau, K.M. 
(2010). Activation of GPR30 inhibits the growth of prostate cancer cells through sustained 
activation of Erk1/2, c-jun/c-fosdependent upregulation of p21, and induction of G(2) cell-cycle 
arrest. Cell Death Differ 17, 1511–1523. 
Chang, Z. F., and Liu, C. J. (1994). Human thymidine kinase CCAAT-binding protein is NF-Y, 
whose A subunit expression is serum-dependent in human IMR-90 diploid fibroblasts. J. Biol. 
Chem. 26, 17893–17898. 
Chassanidis, C., Kalamaras, A., Phylactides, M., Pourfarzad, F., Likousi, S., Maroulis, V., 
Papadakis, M.N., Vamvakopoulos, N.K., Aleporou-Marinou, V., Patrinos, G.P., and Kollia, P. 
(2009). The Hellenic type of nondeletional hereditary persistence of fetal hemoglobin results from a 
novel mutation (g.-109G>T) in the HBG2 gene promoter. Ann Hematol 88, 549–555. 
Chatelin, L., Volovitch, M., Joliot, H., Perez, F., and Prochiantz, A. (1996). Transcription factor 
hoxa-5 is taken up by cells in culture and conveyed to their nuclei. Mech Dev 55, 111–117. 
Chen, X.W., Mo, Q.H., Li, Q., Zeng, R., and Xu, X.M. (2007). A novel mutation of -73(A–>T) in 
the CCAAT box of the beta-globin gene identified in a patient with the mild beta-thalassemia 
intermedia. Ann Hematol 86, 653–657. 
Chen, L., and Widom, J. (2005). Mechanism of transcriptional silencing in yeast. Cell 120, 37–48. 
Chen, M., Zakrewsky, M., Gupta, V., Anselmo, A. C., Slee, D. H., Muraski, J. A. and Mitragotri, S. 
(2014). Topical delivery of siRNA into skin using SPACE-peptide carriers. Journal of 
Controlled Release 179, 33-41. 
 
Baldwin, A.S., Carthew, R.W., and Sharp, P.A. (1988). Human CCAAT-binding proteins have 
heterologous subunits. Cell 8, 11-24. 
Clayton, A.H., Atcliffe, B.W., Howlett, G.J. and Sawyer, W.H. (2006). Conformation and 
orientation of penetratin in phospholipid membranes. J. Pept. Sci. 12, 233–238. 
Conaway, R.C., and Conaway, J.W. (2011). Function and regulation of the Mediator complex. Curr. 
Opin. Genet. Dev. 21, 225–230. 
Conner, S.D. and Schmid, S.L. (2003). Regulated portals of entry into the cell. Nature 422, 37–44 
Das, C., Lucia, M.S., Hansen, K.C.,and Tyler, J.K. (2009). CBP/p300-mediated acetylation of 
histone H3 on lysine 56. Nature 459, 113-117. 
Delvoye, N.L., Destroismaisons, N.M., and Wall, LA. (1993). Activation of the beta-globin 
promoter by the locus control region correlates with binding of a novel factor to the CAAT box in 
murine erythroleukemia cells but not in K562 cells. Mol Cell Biol 13, 6969-83. 
 42 
 
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandinoand, G., 
and Piaggio, G. (2006). Gain of function of mutant p53: The mutant p53/NF-Y protein complex 
reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer cell 10, 191–202. 
 
Ding, N., Zhou, H., Esteve, P.O., Chin, H.G., Kim, S., Xu, X., Joseph, S.M.,Friez, M.J., Schwartz, 
C.E., Pradhan, S., and Boyer, T.G. (2008). Mediator links epigenetic silencing of neuronal gene 
expression with x-linked mental retardation. Mol. Cell 31, 347–359. 
Dolfini, D., Zambelli, F., Pavesi, G., and Mantovani, R. (2009). A perspective of promoter 
architecture from the CCAAT box. Cell Cycle 8, 4127-4137. 
Dolfini, D., Minuzzo, M.,Pavesi, G., Mantovani, R. (2012). The Short Isoform of NF-YA Belongs 
to the Embryonic Stem Cell Transcription Factor Circuitry. STEM CELLS 30, 2450–2459. 
Domashenko, A.D., Danet-Desnoyers, G., Aron, A. et al. (2012). TAT-mediated transduction of 
NF-Ya peptide induces the ex vivo proliferation and engraftment potential of human hematopoietic 
progenitor cells. Blood 116, 2676–2683. 
Dorn, A., Bollekens, J., Staub, A.,  Benoist, C., and Mathis, D. (1987). A multiplicity of CCAAT 
box-binding proteins. Cell 50,  863–872. 
Dou, Y., Milne, T.A., Tackett, A.J., Smith, E.R., Fukuda, A., Wysocka, J., Alli, C.D., Chait, B.T., 
Hess, J.L., and Roeder, R.G. (2005). Physical association and coordinate function of the H3 K4 
methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121, 873-885. 
Eberharter, A., and Becker, P. ATP-dependent nucleosome remodelling: factors and functions.       
Journal of Cell Science 117, 3707-3711. 
Farina, A., Manni, I., Fontemaggi, G., Tiainen, M., Cenciarelli, C., Bellorini, M., Mantovani, R., 
Sacchi, A., and Piaggio, G. (1999). Down-regulation ofcyclin B1 gene transcription in terminally 
differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y 
complex. Oncogene 18, 2818–2827. 
Favaro, M., Toledo, d. M., Alves, R., Santos, C., Beloti, L., Janissen, R., de la Torre, L., Souza, A., 
and Azzoni, A. (2014). Development of a non-viral gene delivery vector based on the dynein 
light chain Rp3 and the TAT peptide. Journal of biotechnology 173, 10-18. 
 
Feng, S. and Holland, E.C. (1988). HIV-1 tat trans-activation requires the loop sequence within tar. 
Nature 334, 165–167. 
Forsberg EC, Passegué E, Prohaska SS, Wagers AJ, Koeva M, Stuart JM, and Weissman IL. 
(2010). Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem 
cells. PLoS ONE 5:e8785. 
Framson, P., and Bornstein P. (1993). A serum response element and a binding site for NF-Y 
mediate the serum response of the human thrombospondin 1 gene. J Biol Chem 5, 4989-96. 
Frankel, A. D. and C. O. Pabo (1988). Cellular uptake of the tat protein from human 
immunodeficiency virus. Cell 55, 1189-1193. 
Frontini, M., Imbriano, C., diSilvio, A., Bell, B., Bogni, A., Romier, C., Moras, D., Tora, L., 
Davidson, I., and Mantovani, R. (2002). NF-Y Recruitment of TFIID, Multiple Interactions with 
Histone Fold TAFIIs. J Biol Chem 277, 5841–5848. 
 43 
 
Gardiner-Garden, M., and Frommer, M. (1987). CpG islands in vertebrate genomes. J. Mol. Biol. 
196, 261–82. 
Goodarzi, H., Elemento, O., and Tavazoie, S. (2009). Revealing global regulatory perturbations 
across human cancers. Mol Cell 36, 900–911. 
Grskovic, M., Chaivorapol, C., Gaspar-Maia,A., Li, H., and Ramalho-Santos, M. (2007). 
Systematic identifi- cation of cis-regulatory sequences active in mouse and human embryonic stem 
cells. PLoS Genet 3, 1524-1540. 
Gurtner, A., Manni, I., Fuschi, P., Mantovani, R., Guadagni, F., Sacchi, A., and Piaggio, G. (2003). 
Requirement for down-regulation of the CCAAT binding activity of the NF-Y transcription factor 
during skeletal muscle differentiation. Mol Biol Cell 14, 2706–2715. 
H. Izumi,  Molander, C.,  Penn, L.Z.,  Ishisaki, A.,  Kohno, K., and  Funa, K. (2001). Mechanism 
for the transcriptional repression by c-Myc on PDGF (β)-receptor. J Cell Sci 114, 1533-1544. 
Hamanaka, R, Smith, M.R., and O'Connor, P.M. (1995). Polo-like kinase is a cell cycle-regulated 
kinase activated during mitosis. J Biol Chem 270, 21086-21091. 
Han, K., Jeon, M.J., Kim, K.A., Park, J., and Choi, S.Y. (2000). Efficient intracellular delivery of 
GFP by homeodomains of Drosophila Fushi-tarazu and Engrailed proteins. Mol Cells 10, 728–732. 
Han, M., Toli, J., and Abdellatif, M. (2011). MicroRNAs in the cardiovascular system. Curr. Opin. 
Cardiol. 26, 181–189. 
Harreither, E., Rydberg, H.A., Åmand, H.L., Jadhav, V., Fliedl, L., Benda, C., Esteban, M.A., Pei, 
D., Borth, N., Grillari-Voglauer, R., Hommerding, O., Edenhofer, F., Nordén, B., and Grillari, J. 
(2014). Characterization of a novel cell penetrating peptide derived from human Oct4. Cell 
Regeneration 3:2. 
He, Z., Li, J.J., Zhen, C.H., Feng, L.Y., Ding, X.Y. (2006). Effect of leukemia inhibitory factor on 
embryonic stem cell differentiation: implications for supporting neuronal differentiation. Acta 
Pharmacol Sin. 27, 80-90. 
Hodawadekar, S.C., and Marmorstein, R. (2007). Chemistry of acetyl transfer by histone modifying 
enzymes: structure, mechanism and implications for effector design. Oncogene 26, 5528-5540. 
Hu, Q. and Maity, S.N. (2000) Stable expression of a dominant negative mutant of CCAAT binding 
factor/NF-Y in mouse fibroblast cells resulting in retardation of cell growth and inhibition of 
transcription of various cellular genes.J. Biol. Chem 275, 4435–4444. 
Hu, Q., Lu, J.F., Luo, R., Sen, S. and Maity, S.N. (2006) Inhibition of CBF/NF-Y mediated 
transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at 
G2/M phase of the cell cycle. Nucleic Acids Res 34, 6272–6285. 
Huang, S., Ling, J.J., Yang, S., Li, X.J., and Li, S. (2011). Neuronal expression of TATA box-
binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein 
response by impairing the function of nuclear factor-Y transcription factor. Brain 134, 1943–1958. 
Huang, W., Zhao, S., Ammanamanchi, S., Brattain, M., Venkatasubbarao, K. and Freeman, J.W. 
(2005). Trichostatin A induces transforming growth factor beta type II receptor promoter activity 
and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex. J Biol Chem 280, 
10047-10054. 
 44 
 
Hughes, R., Kristiansen, M., Lassot, I., Desagher, S., Mantovani, R. and Ham, J. (2011). NF-Y is 
essential for expression of the proapoptotic bim gene in sympathetic neurons. Cell Death and 
Differentiation 18, 937–947. 
Ivanov, A.I. (2008). Pharmacological inhibition of endocytic pathways: is it specific enough to be 
useful? Methods Mol. Biol. 440, 15–33. 
Jackson, S.M., Ericsson, J., Osbornei, T.F., and Edwards, P.A. (1995). NF-Y has a novel role in 
steroldependent transcription of two cholesterogenic genes. J Biol Chem 270, 21445–21448. 
Jones, P.A., Laird, P.W. (1999). Cancer epigenetics comes of age.  Nat. Genet. 21, 163–167. 
Jürchott, K., Kuban, R.J., Krech, T., Blüthgen, N., Stein, U., Walther, W., Friese, C., Kielbasa, 
S.M., Ungethüm, U., Lund, P., Knösel, T., Kemmner, W., Morkel, M., Fritzmann, J., Schlag, P.M., 
Birchmeier, W., Krueger, T., Sperling, S., Sers, C., Royer, H.D., Herzel, H., and Schäfer, R. (2010). 
Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathwaydependent gene 
signatures in colorectal cancer cells. PLoS Genet 6:e1001231. 
Joliot, A., Pernelle, C., Deagostini-Bazin, H., and Prochiantz, A. (1991). Antennapedia homeobox 
peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A 88, 1864-1868. 
 
Kagey, M.H., Newman, J.J., Bilodeau, S., Zhan, Y., Orlando, D.A., van Berkum, N.L., Ebmeier 
C.C., Goossens, J., Rahl, P.B., Levine, S.S., Taatjes, D.J., Dekker, J., and Young, R.A. (2010). 
Mediator and cohesin connect gene expression and chromatin architecture.Nature 467, 430–435. 
Kahle, J., Baake, M., Doenecke, D., and Albig, W. (2005). Subunits of the heterotrimeric 
transcription factor NF-Y are imported into the nucleus by distinct pathways involving importin β 
and importin 13. Molecular and cellular biology 25, 5339–5354. 
Kanazawa, T., Morisaki, K., Suzuki,S., and Takashima, Y. (2014). Prolongation of life in rats with 
malignant glioma by intranasal siRNA/drug codelivery to the brain with Cell-Penetrating Peptide-
modified micelles. Molecular Pharmaceutics 11, 1471-1478. 
Kaufmann, R., Straussberg, R., Mandel, H., Fattal-Valevski, A., Ben-Zeev, B.,Naamati, A., Shaag, 
A., Zenvirt, S., Konen, O., Mimouni-Bloch, A., et al. (2010).Infantile cerebral and cerebellar 
atrophy is associated with a mutation in the MED17 subunit of the transcription preinitiation 
mediator complex. Am. J.Hum. Genet. 87, 667–670. 
Kim, J.H., Lee, J.N., and Paik, Y.K. (2001). Cholesterol Biosynthesis from LanosterolA concerted 
role for sp1 and nf-y-binding sites for sterol-mediated regulation of rat 7-dehydrocholesterol 
reductase gene expression. J Biol Chem 276, 18153–18160. 
Kong, K.A., Gadi, J., Park, H.W., Bok, J., and Kim, M.H. (2008). The third helix of the murine 
Hoxc8 homeodomain facilitates protein transduction in mammalian cells. Biochem Biophys Res 
Commun 377, 161–164. 
Kristiansen, M., and Ham, J. (2014). Programmed cell death during neuronal development: the 
sympathetic neuron model. Cell Death and Differentiation 21, 1025–1035. 
Krivega, I., and Dean, A. (2012). Enhancer and promoter interactions-long distance calls. Curr Opin 
Genet Dev 22, 79–85. 
 
 45 
 
Lagor, W.R., de Groh, E.D., and Ness, G.C. (2005). Diabetes alters the occupancy of the hepatic 3-
hydroxy-3-methylglutaryl-CoA reductase promoter. J Biol Chem 280, 36601–36608. 
Landsberger, N., and Wolffe, A.P. (1995). Role of chromatin and Xenopus laevis heat shock 
transcription factor in regulation of transcription from the X. laevis hsp70 promoter in vivo. Mol 
Cell Biol 15, 6013–6024. 
Larivie` re, L., Seizl, M., and Cramer, P. (2012). A structural perspective on Mediator function. 
Curr. Opin. Cell Biol. 24, 305–313. 
Lee, M.R., Kim, S.H., Cho, H.J., Lee, K.Y., Moon, A.R., Jeong, H.G., Lee, J.S., Hyun, J.W., 
Chung, M.H.,  and You, H.J. (2004). Transcription factors NF-YA regulate the induction of human 
OGG1 following DNA-alkylating agent methylmethane sulfonate (MMS) treatment. J Biol Chem 
279, 9857–9866. 
Lettice, L.A., Heaney, S.J., Purdie, L.A., Li, L., de Beer, P., Oostra, B.A., Goode, D., Elgar, 
G., Hill, R.E., and de Graaff, E. (2003). A long-range Shh enhancer regulates expression in the 
developing limb and fin and is associated with preaxial polydactyly. Hum. Mol. Genet. 12, 
1725,1735. 
Li, Q., Peterson, K.R., Fang, X., and Stamatoyannopoulos, G. (2002). Locus control regions. 
Blood100, 3077–3086. 
Li, X.Y., Mantovani, R., Hooft van Huijsduijnen, R., Andre, I., Benoist, C. and Mathis, D. (1992). 
Evolutionary variation of the CCAAT-binding transcription factor NF-Y. Nucleic Acids Res 20, 
1087-1091. 
Liberati, C., Cera, M.R., Secco, P., Santoro, C., Mantovani, R., Ottolenghi, S., and Ronchi, A. 
(2001). Cooperation and competition between the binding of COUP-TFII and NF-Y on human 
epsilon- and gammaglobin gene promoters. J Biol Chem 276, 41700–41709. 
Lim, C.Y., Santoso, B., Boulay, T., Dong, E., Ohler, U., and Kadonaga, J.T. (2004). The MTE, a 
new core promoter element for transcription by RNA polymerase II. Genes Dev. 18, 1606–1617. 
Lin, C.Y., Love´ n, J., Rahl, P.B., Paranal, R.M., Burge, C.B., Bradner, J.E., Lee,T.I., and Young, 
R.A. (2012). Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56–67. 
Lin, Y.C., Chen, Y.N., Lin, K.F., Wang, F.F., Chou, T.Y. and ChenY-C, M.Y. (2014).  Association 
of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in 
response to DNA damage Cell Death and Disease 5, e987. 
Lin, Y.S., Carey, M., Ptashne, M., and Green, M.R. (1990). How different eukaryotic 
transcriptional activators can cooperate promiscuously. Nature 345, 359–61. 
Lu, J., Li, G., Lan, M.S., Zhang, S., Fan, W., Wang, H., and Lu, D. (2007). Pax4 paired domain 
mediates direct protein transduction into mammalian cells. Endocrinology 148, 5558–5565. 
Lu, Y.H., Dallner, O.S., Birsoy, K., Fayzikhodjaeva, G., and Friedman, J.M. (2015). Nuclear 
Factor-Y is an adipogenic factor that regulates leptin gene expression. Molecular metabolism 4, 
392-405. 
Luo, R., Klumpp, S.A., Finegold, M.J. and Maity, S.N. Inactivation of CBF/NF-Y in postnatal liver 
causes hepatocellular degeneration, lipid deposition, and endoplasmic reticulum stress. Scientific 
reports  1 : 136. 
 46 
 
Maity, S.N., and de Crombrugghe, B. (1998). Role of the CCAAT-binding protein CBF/NF-Y in 
transcription. Trends Biochem Sci.  23, 174-178. 
Malecki, M.T. (2005). Genetics of type 2 diabetes mellitus. Diabetes Res. Clin.Pract. 68, 10–21. 
Malik, S., and Roeder, R.G. (2010). The metazoan Mediator co-activator complex as an integrative 
hub for transcriptional regulation. Nat. Rev. Genet. 11, 761–772. 
Manni, I., Caretti, G., Artuso, S., Gurtner, A., Emiliozzi, V., Sacchi, A., Mantovani, R., and 
Piaggio, G. (2008). Posttranslational regulation of NF-YA modulates NF-Y transcriptional activity. 
Molecular Biology of the Cell 19, 5203–5213.  
Mantovani, R. (1998). A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Research 26, 
1135–1143 
Mantovani, R., Pessara, U., Tronche, F., Li, X.Y., Knapp, A.M., Pasquali, J.L., Benoist, C., 
and  Mathis, D. (1992). Monoclonal antibodies to NF-Y define its function in MHC class II and 
albumin gene transcription. EMBO J 11, 3315–3322. 
Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, H., Reynolds, 
A.P., Sandstrom, R., Qu, H., Brody, J., Shafer, A., Neri, F., Lee, K., Kutyavin, T., Stehling-Sun, 
S., Johnson, A.K., Canfield, T.K., Giste, E., Diegel, M., Bates, D., Hansen, R.S., Neph, S., Sabo, 
P.J., Heimfeld, S., Raubitschek, A., Ziegler, S., Cotsapas, C., Sotoodehnia, N., Glass, I., Sunyaev, 
S.R., Kaul, R., and Stamatoyannopoulos, J.A. (2012). Systematic localization of common disease-
associated variation in regulatory DNA. Science 337, 1190–1195. 
Milletti, F. (2012). Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. 
Today 17, 850–860. 
Nardini, M., Gnesutta, N., Donati, G., Gatta, R., Forni, C., Fossati, A.,Vonrhein, C., Moras, D., 
Romier, C., Bolognesi, M., and Mantovani, R. (2013). Sequence-specific transcription factor NF-Y 
displays histone-like DNA binding and H2B-like ubiquitination. Cell 152, 132–143. 
Ng, S.S., Yue, W.W., Oppermann, U., and Klose, R.J. (2009). Dynamic protein methylation in 
chromatin biology. Cell Mol Life Sci 66, 407-422. 
Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D.R.,Tessarollo, L., 
Casellas, R., et al. (2012). c-Myc is a universal amplifier of expressed genes in lymphocytes and 
embryonic stem cells. Cell 151, 68–79. 
Niimi, T., Hayashi, Y., Futaki, S. and Sekiguchi, K. (2004). SOX7 and SOX17 regulate the parietal 
endoderm-specific enhancer activity of mouse laminin alpha1 gene. J Biol Chem 279, 38055-
38061. 
Orange, J.S. and May, M.J. (2008) Cell penetrating peptide inhibitors of nuclear factor-kappa B. 
Cell. Mol. Life Sci. 65, 3564–3591. 
Ott, M., Dorr, A., Hetzer-Egger, C., Kaehlcke, K., Schnolzer, M., Henklein, P., Cole, P., Zhou, 
M.M., and  Verdin, E. (2004). Tat acetylation: a regulatory switch between early and late phases in 
HIV transcription elongation. Novartis Found Symp 259, 182–193. 
Papageorgiou, N., Tousoulis, D., Androulakis, E., Siasos, G., Briasoulis, A.,Vogiatzi, G., Kampoli, 
A.M., Tsiamis, E., Tentolouris, C., and Stefanadis, C. (2012). The role of microRNAs in 
cardiovascular disease. Curr. Med. Chem.19, 2605–2610. 
 47 
 
Park, J., J. Ryu, K. A. Kim, H. J. Lee, J. H. Bahn, K. Han, E. Y. Choi, K. S. Lee, H. Y. Kwon and 
Choi, S. Y. (2002). Mutational analysis of a human immunodeficiency virus type 1 Tat protein 
transduction domain which is required for delivery of an exogenous protein into mammalian cells. J 
Gen Virol 83, 1173-1181. 
Parthun, M.R. (2007). Hat1: the emerging cellular roles of a type B histone acetyltransferase. 
Oncogene  26, 5319-5328. 
Pooga, M., U. Soomets, M. Hallbrink, A. Valkna, K. Saar, K. Rezaei, U. Kahl, X.J. and Jing- 
Ptashne, M., and Gann, A. (1997). Transcriptional activation by recruitment. Nature 386, 569–577. 
 
Qian, Y. Q., Billeter, M., Otting, G., Muller, M., Gehring, W. J., and Wuthrich, K. (1989) Cell 59, 
573-580. 
Ragin, A. D., Morgan, R.A., and Chmielewski, J. (2002). Cellular Import Mediated by Nuclear 
Localization Signal Peptide Sequences. Chemistry & Biology 8, 943–948. 
Raymondjean, M., Cereghini, S., and Yaniv, M. (1988). Several distinct "CCAAT" box binding 
proteins coexist in eukaryotic cells. Proc Natl Acad Sci USA 85, 757-761. 
Reith, W., Siegrist, C.A., Durand, B., Barras, E. and Mach, B. (1994). Function of major 
histocompatibility complex class II promoters requires cooperative binding between factors RFX 
and NF-Y. Proc Natl Acad Sci U S A  91, 554-558. 
Rhodes, D.R., Kalyana-Sundaram, S., Mahavisno, V., Barrette, T.R., Ghosh, D., and Chinnaiyan, 
A.M. (2005). Mining for regulatory programs in the cancer transcriptome. Nat Genet 37, 579–583. 
Rodríguez-Paredes, M., and Esteller, M. (2011). Cancer epigenetics reaches mainstream oncology.          
Nature Medicine 17, 330–339.  
Roeder, G. E., Parish, J. L., Stern, P. L. and Gaston, K. (2004). Herpes simplex virus VP22–human 
papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells 
and induce apoptotic cell death. Biotechnology and applied biochemistry 40, 157-165. 
Romier, C., Cocchiarella, F., Mantovani, R., and Moras, D. (2003). The NF-YB/NF-YC structure 
gives insight into DNA binding and transcription regulation by CCAAT factor NF-Y. J Biol 
Chem.  10, 1336-1345. 
Rothbard, J.B., Jessop, T.C., Lewis, R.S., Murray, B.A. and Wender, P.A. (2004). Role of 
membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich 
peptides into cells. J. Am. Chem. Soc. 126, 9506–9507. 
Salvatore, G., Nappi, T.C., Salerno, P., Jiang, Y., Garbi, C., Ugolini, C., Miccoli, P., Basolo, F., 
Castellone, M.D., Cirafici, A.M., Melillo, R.M., Fusco, A., Bittner, M.L., and Santoro, M. (2007). 
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer 
Res 67, 10148–10158. 
Scafoglio, C., Ambrosino, C., Cicatiello, L., Altucci, L., Ardovino, M., Bontempo, P., Medici, N., 
Molinari, A.M., Nebbioso, A., Facchiano, A., Calogero, R.A., Elkon, R., Menini, N., Ponzone, R., 
Biglia, N., Sismondi, P., De Bortoli, M., and Weisz, A. (2006). Comparative gene expression 
profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in 
human breast cancer cells. J Cell Biochem 98, 1163–1184. 
 48 
 
Schmitt, S., Prestel, M., and Paro, R. (2005). Intergenic transcription through a polycomb group 
response element counteracts silencing. Genes Dev. 19, 697–708. 
Schöler, H.R., Ruppert, S., Suzuki, N., Chowdhury, K., and Gruss, P. (1990). New type of POU 
domain in germ line-specific protein Oct-4. Nature 344, 435–439. 
Sinha, S., Adler, A.S., Field, Y., Chang, H.Y., and Segal, E. (2008). Systematic functional 
characterization of cis-regulatory motifs in human core promoters. Genome Res 18, 477–488. 
Shin, M. J., Kim, D. W., Lee, Y. P., Ahn, E. H., Jo, H. S., Kim, D.S., Kwon,O.S., Kang, T.C.,  
Cho, Y.J. and Park, J. (2014). Tat-glyoxalase protein inhibits against ischemic neuronal cell damage 
and ameliorates ischemic injury. Free Radical Biology and Medicine 67, 195-210. 
 
Spaeth, J.M., Kim, N.H., and Boyer, T.G. (2011). Mediator and human disease. Semin. Cell Dev. 
Biol. 22, 776–787. 
Srinivasan, L., and Atchison, M.L. (2004). YY1 DNA binding and PcG recruitment requires CtBP. 
Genes Dev. 18, 2596–2601. 
Steward, M.M., Lee, J.S., O'Donovan, A., Wyatt, M., Bernstein, B.E., and Shilatifard, A. (2006). 
Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat 
Struct Mol Biol 13, 852-854. 
Sunyakumthorn, P.,Boonsaen, T.,Boonsaeng, V., Wallace, J.C., and Jitrapakdee, S. (2005). 
Involvement of specific proteins (Sp1/Sp3) and nuclear factor Y in basal transcription of the distal 
promoter of the rat pyruvate carboxylase gene in b-cells. Biochemical and Biophysical Research 
Communications 329, 188–196. 
Taatjes, D.J. (2010). The human Mediator complex: a versatile, genome-wide regulator of 
transcription. Trends Biochem. Sci. 35, 315–322. 
Teran-Garcia, M., Rufo, C., Nakamura, M.T., Osborne, T.F., and Clarke, S.D. (2002). NF-Y 
Involvement in the polyunsaturated fat inhibition of fatty acid synthase gene transcription. 
Biochemical and Biophysical Research Communications 290, 1295–1299.  
Thomassen, M., Tan, Q., and Kruse, T.A. (2008). Gene expression meta-analysis identifies 
metastatic pathways and transcription factors in breast cancer. BMC Cancer 8:394. 
Tjeertes, J.V., Miller, K.M., and Jackson, S.P. (2009). Screen for DNA-damage-responsive histone 
modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J 28, 1878-1889. 
Tsurusaki, Y., Okamoto, N., Ohashi, H., Kosho, T., Imai, Y., Hibi-Ko, Y., Kaname, T., Naritomi, 
K., Kawame, H., Wakui, K., et al. (2012). Mutations affecting components of the SWI/SNF 
complex cause Coffin-Siris syndrome. Nat. Genet. 44, 376–378. 
Vermeulen, K., Berneman, Z.N., and Van Bockstaele, D.R. (2003). Cell cycle and apoptosis. Cell 
Prolif 36, 165–175. 
Versteege, I., Sévenet, N., Lange, J., Rousseau-Merck,M.F., Ambros, P., Handgretinger, R., Aurias, 
A., and Delattre, O. (1998). Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. 
Nature 394, 203–206.  
 49 
 
Von Richter, O., Pitarque, M., Rodríguez-Antona, C., Testa, A., Mantovani, R., Oscarson, M., 
Ingelman-Sundberg, M. (2004). Polymorphic NF-Y dependent regulation of human nicotine C-
oxidase (CYP2A6). Pharmacogenetics 14, 369–379. 
Wender, P.A., Mitchell, D.J., Pattabiraman, K., Pelkey, E.T., Steinman, L. and Rothbard, J.B. 
(2000). The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: 
peptoid molecular transporters. Proc. Natl. Acad. Sci. USA 97, 13003–13008. 
Xhemalce, B., Dawson, M. A. and Bannister, A. J. (2011). Histone Modifications. Reviews in Cell 
Biology and Molecular Medicine. 
Xia Hao, X. (1998). Cell penetrating constructs regulate galanin receptor levels and modify 
Yamanaka, K., Mizuarai, S., Eguchi, T., Itadani, H., Hirai, H., and Kotani, H. (2009). Expression 
levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple 
cancers. Genomics 94,219–227. 
Yamanaka, T., Tosaki, A., Kurosawa, M., Matsumoto, G., Koike, M., Uchiyama, Y., Maity, S.N., 
Shimogori, T., Hattori, N., and Nukina, N. NF-Y inactivation causes atypical neurodegeneration 
characterized by ubiquitin and p62 accumulation and endoplasmic reticulum disorganization. 
Nature communications  5, 3354. 
Yamanaka, T., Miyazaki, H., Oyama, F., Kurosawa, M., Washizu, C., Doi, H., and Nukina, N. 
(2008). Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y 
transcription factor. EMBO J 27, 827–839. 
Yang, C., Bolotin, E., Jiang, T., Sladek, F.M., and Martinez, E. (2007). Prevalence of the initiator 
over the TATA box in human and yeast genes and identification of DNA motifs enriched in human 
TATA-less core promoters. Gene 389, 52–65. 
Yang, X.J., and Seto, E. (2008). The Rpd3/Hda1 family of lysine deacetylases: from bacteria and 
yeast to mice and men. Nat Rev Mol Cell Biol 9, 206-218. 
Yun, J., Chae, H.D., Choi, T.S., Kim, E.H., Bang, Y.J., Chung, J., Choi, K.S., Mantovani, R., and 
Shin, D.Y. (2003). Cdk2-dependent phosphorylation of the NF-Y transcription factor and its 
involvement in the p53-p21 signaling pathway. J Biol Chem 278, 36966–36972. 
Zaro, J.L. and Shen, W.C. (2005). Evidence that membrane transduction of oligoarginine does not 
require vesicle formation. Exp. Cell Res. 307, 164–173. 
Zhu, J., Zhang, Y., Joe, G.J., Pompetti, R., and Emerson, S.G. (2005). NF-Ya activates multiple 
hematopoietic stem cell (HSC) regulatory genes and promotes HSC self-renewal. PNAS 102, 
11728-11733. 
Zhu, X., Wang, Y., Pi, W., Liu, H., Wickrema, A. and Tuan, D. (2012). NF-Y recruits both 
transcription activator and repressor to modulate tissue- and developmental stage-specific 
expression of human gamma-globin gene. PLoS One 7, e47175. 
Zwicker, J., Gross, C., Lucibello, F.C., Truss, M., Ehiert, F., Engeland, K., and Muller, R. (1995). 
Cell cycle regulation of cdc25C transcription is mediated by the periodic repression of the 
glutamine rich activators NF-Y and Spi1. Nucleic Acids Research 23, 3822-3830. 
 
 50 
 
 
 
PART II 
 
 
Accepted paper:  
 
Paolo Benatti1, Maria Luisa Chiaramonte2, Mariangela Lorenzo2, John A Hartley3, Daniel 
Hochhauser3, Nerina Gnesutta2, Roberto Mantovani2, Carol Imbriano1 and Diletta Dolfini2*. 
NF-Y activates genes of metabolic pathways altered in cancer cells. Oncotarget 
 
 
 
 
NF-Y activates genes of metabolic pathways altered in cancer cells. 
 
Paolo Benatti1, Maria Luisa Chiaramonte2, Mariangela Lorenzo2, John A Hartley3, Daniel 
Hochhauser3, Nerina Gnesutta2, Roberto Mantovani2, Carol Imbriano1 and Diletta 
Dolfini2*. 
 
1) Dipartimento di Scienze della Vita, Università di Modena e Reggio Emilia, Via Campi 
213/D, 41125 Modena, Italy; 
2) Dipartimento di Bioscienze, Università degli Studi di Milano, Via Celoria 26, 20133, 
Milano, Italy;  
3) Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, 
Paul O'Gorman Building, University College London, 72 Huntley Street, London WC1E 
6BT, UK. 
 
*To whom correspondence should be addressed. 
e-mail: diletta.dolfini@unimi.it; 
Tel: 39-02-50315004 
Fax: 39-02-50315044 
 
Keywords: transcription, cancer metabolism, NF-Y, Glycolysis, SOCG pathway
 2 
ABSTRACT 
 
The trimeric transcription factor NF-Y binds to the CCAAT box, an element enriched in 
promoters of genes overexpressed in tumors. Previous studies on the NF-Y regulome 
identified the general term metabolism as significantly enriched. We dissect here in detail 
the targeting of metabolic genes by integrating analysis of NF-Y genomic binding and 
profilings after inactivation of NF-Y subunits in different cell types. NF-Y controls de 
novo biosynthetic pathways of lipids, teaming up with the master SREBPs regulators. It 
activates glycolytic genes, but, surprisingly, is neutral or represses mitochondrial 
respiratory genes. NF-Y targets the SOCG (Serine, One Carbon, Glycine) and Glutamine 
pathways, as well as genes involved in the biosynthesis of polyamines and purines. 
Specific cancer-driving nodes are generally under NF-Y control. Altogether, these data 
delineate a coherent strategy to promote expression of metabolic genes fuelling anaerobic 
energy production and other anabolic pathways commonly altered in cancer cells.  
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INTRODUCTION 
 
The CCAAT box is an important element present in promoters and enhancers of 
eukaryotic genes. It is bound by the evolutionarily conserved NF-Y (also named CBF), a 
trimer formed by NF-YA, NF-YB and NF-YC. NF-YB and NF-YC have histone-like 
structures, which, upon hetero-dimerization, present a complex surface for NF-YA 
association, in turn providing sequence-specific CCAAT recognition [1]. The use of 
genome-wide assays has generalized the concept previously derived by in vitro 
experiments that NF-Y is the primary CCAAT binding protein [2]. Yeast S. cerevisiae 
produces energy and ethanol through glycolysis and fermentation when grown in medium 
containing glucose; when challenged with non-fermentable carbon sources, yeast cells 
switch to oxygen-fueled metabolism, by activation of nuclear genes of the mitochondrial 
respiratory complexes. All these genes contain a CCAAT sequence in their regulatory 
UAS (Upstream Activating Sequences) sequences and are dependent upon the NF-Y 
yeast homologue HAP2/3/4/5 [3]. 
In mammals, the NF-Y regulome is apparently more complex, but it is becoming 
intelligible, thanks to converging sets of data: (i) the precise biochemical characterization 
of the target sequence led to the definition of a DNA-binding matrix with high 
information content, characterized in hundreds mammalian promoters, highlighting a 
strong positional bias [4]. (ii) Genome-wide experiments confirmed and further extended 
these observations to enhancers and other genomic regions [5-11]. (iii) Profiling analysis 
of genes whose expression is affected by functional inactivation of one of the subunits 
[11-13] found that in addition to a positive role on transcriptional units, NF-Y is also part 
of repressive mechanisms of transcription.  
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A common theme in the analysis of the NF-Y regulome in mammalian cells is the 
presence of the term metabolism at the top of Gene Ontology categorizations; functional 
dissection of individual promoters of metabolic genes indeed indicated the importance of 
NF-Y for high level of expression. There has been a renewed interest in the 
transcriptional control of such genes, since specific metabolic pathways are found altered 
in cancer cells; a vast array of biochemical, genetic and pharmacological data highlight 
the importance of the expression levels of single genes for “metabolic reprogramming”, 
an hallmark of the development and progression of tumors [14-16]. This is well 
exemplified by the recent computational evaluation of expression levels of genes of the 
SOCG -Serine One Carbon Glycine- pathway across cancer samples, indicating that 
collective overexpression of genes is predictive of the increased flux of metabolites 
observed in tumors [17]. Interestingly, analysis of large sets of expression profilings 
comparing tumors and normal tissues indicate that the NF-Y matrix is enriched in 
promoters of genes overexpressed in cancer cells [18]; however, it was not determined 
whether these genes belong to specific pathways. Finally, compelling genetic experiments 
have recently established that NF-YC, with TAF12 and RAD54L, is a driver oncogene of 
choroid plexus carcinomas [19]. 
For these reasons, we decided to take a closer look at the metabolic pathways influenced 
by the transcriptional activity of NF-Y. We analysed available genomic data and 
performed additional gene expression experiments after inactivation of NF-Y subunits, to 
rationalize its role in the regulation of metabolic genes. The results point to specific 
pathways, and within them specific nodes, which are under tight NF-Y control.
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RESULTS AND DISCUSSION 
 
Experimental strategy. 
Top rank GO terms of NF-Y-regulated genes include metabolic pathways [11-13]. For 
this reason, we focused specifically on metabolic genes with the following strategy. 
(i) We analyzed the results of Affymetrix gene expression profilings of Hela-S3 cells 
inactivated of NF-YA by shRNA interference [11] and performed additional profilings in 
epithelial HCT116 and H322 cells under identical conditions of NF-YA inactivation. Fig. 
S1 shows the levels of NF-YA, as assessed by Western blot analysis; the complete list of 
genes up- and down-regulated in HCT116 and H322, considering a threshold of 1.3 fold 
difference, is in Fig. S2. Moreover, we analyzed the recently reported profilings data of 
mES cells functionally inactivated of individual and of all three subunits of NF-Y [12]. 
(ii) To validate profilings, we analyzed the expression of selected genes of the affected 
pathways by qRT-PCR after inactivation of the NF-YB subunit in Hela cells with two 
different shRNAs. 
(iii) To match function with location, we analyzed ChIP-Seq data of NF-YA and NF-YB 
in Hela-S3, GM12878 and K562 derived from ENCODE [9, 11], as well as the individual 
binding of the three subunits in mouse ES cells [12]. Specifically, we verified binding to 
the bona fide CCAAT matrix in the prototypical promoter position, between -60 and -100 
from the TSS [4], as well as in distal locations classified as enhancers by virtue of the 
presence of appropriate epigenetic marks (H3K27ac, H3K4me1).  
The lack of NF-Y functional dependence in the presence of promoter binding might be 
due to an effective CCAAT-independence of the gene -and activity of compensatory TFs- 
or to the long half-life of the specific mRNA: the latter is a particularly relevant point, as 
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we consider here housekeeping genes involved in basic metabolic functions, whose 
mRNAs tend to be relatively stable. 
 
Overall density of NF-Y regulated genes in metabolic pathways. 
The profilings and ChIP-Seq data of Hela-S3 cells were first analyzed within the KEGG 
global metabolic chart. Genes whose expression is decreased after NF-YA inactivation 
are in red and those increased are in green (Fig. 1A); genes with core promoters bound by 
NF-YA are in blue (Fig. 1B). The charts of gene expression profilings of human H322 
and HCT116 cells after NF-YA, and of mouse ES cells after NF-YA, NF-YB and NF-YC 
inactivation, are shown in Figs. S3 and S4. Genes bound by NF-YB in Hela-S3, showing 
marginal differences with NF-YA, are in Fig. S5. Similarly, NF-YA and NF-YB binding 
in K562 and GM12878, as well as NF-YA, NF-YB and NF-YC in mES cells are shown in 
Figs. S6-8. A bird’s eye view of the results collectively indicates high densities in areas of 
lipids, carbohydrates and nucleotides metabolisms. Other locations -glycan, vitamins, 
terpenoids and xenobiotics- are mostly depleted, with only selected genes positive. 
Aminoacids pathways show density in specific areas. We calculated the statistical 
significance of the regulated pathways in profilings of Hela-S3 and mES cells using 
KOBAS 2.0 [20], a software providing a better definition for the different metabolic sub-
pathways. This led to the identification of globally enriched terms (Fig. S9). As 
previously reported [11], the Hela-S3 pathways at the top of the list are related to cell-
cycle and mitosis, but specific metabolic terms are enriched and they are indeed 
predominant in mES cells. Focusing specifically on metabolic terms (Table 1), we note 
that anabolic genes are less expressed after NF-Y removal, whereas catabolic ones tend to 
be increased; among the formers, aminoacids -notably Ala, Asp, Glu; Ser, Gly; Gln- 
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lipids and nucleic acids are enriched. As for carbohydrate, carbon metabolism -mostly 
glycolysis- is enriched. We hereafter further examine the role of NF-Y in such pathways. 
 
Lipids metabolism. 
NF-Y activates genes of the two main branches of lipids metabolism, cholesterol and fatty 
acids (Fig. 2A): inactivation leads to decreased expression of most cholesterol genes, with 
the exception of HMGCS2, GGPS1, IDI1/2, HSD17B7, SC5D (Fig. 2A). A similar 
situation is observed for the fatty acids branch. With the exception of HMGCS2 and 
PMVK, all promoters are bound in vivo in most cell types, including those negatively 
regulated in mES cells. Rate limiting enzymes of cholesterol -HMGCS1, HMGCR, 
Squalene Synthase (SQLE), DHCR - and fatty acids pathways -Acetyl COA Carboxylase 
(ACACA), Fatty Acids Synthase (FASN), Steatoryl CoA Desaturase (SCD)- were 
previously reported to be under NF-Y positive control [21-36]. Acyl-CoA lyase (ACLY) 
and Acetyl-CoA synthase of the short chains (ACSS2) are also controlled. 
Sustained proliferation rates of cells require a high level of de novo biosynthesis of lipids, 
which are incorporated into newly formed cell membranes. Indeed, these pathways are 
crucial for cancer cells, and many genes are overexpressed [37]. What is particularly 
relevant is that the genes more sensitive to NF-Y-inactivation are also those implicated in 
cancer development. On the cholesterol side, the mevalonate genes are overexpressed in 
many cancers, including HMGCS1, indeed a cancer-driving gene [38], and the target of 
statins, a promising “new” class of anti-cancer drugs [39]. In the fatty acids branch, NF-Y 
targets FASN, SCD1 and GPAM, frequently overexpressed in tumors; FASN is a driver 
of neoplastic transformation [40]. ACSS2 is essential for transformation of acetate to 
Acetyl-CoA, thereafter used for lipids synthesis, as well as for histone acetylations 
[41,42]; expression of ACSS2 is high in many types of tumors and KO mice are protected 
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in mouse models of liver carginogenesis. The parallel strong NF-Y positivity of the less 
studied ACSM3 and ACSL3 invites evaluation of their expression levels across cancer 
samples, and role in tumorigenesis. Finally, ACLY is at the crossroad of lipids and 
glucose metabolism, mediating the production of Acetyl-CoA by transformation of 
cytoplasmic citrate to oxaloacetate. ACLY deregulation is generally observed in cancer, 
often correlating with tumor stage and prognosis [43] and silencing blocks proliferation of 
cancer cells by different mechanisms, impairing lipid biosynthesis, glycolytic enzymes, 
citrate accumulation and histone acetylation. 
SREBP-1 and SREBP-2 are the master TFs of cholesterol and fatty acids biosynthesis 
[44]; the SREBP-1 gene itself is controlled by NF-Y [45,46]. Genome-wide experiments 
reported a significant overlap between NF-YA and SREBP-1 sites [7], and enrichment of 
NF-Y sites in SREBP-1 peaks in mouse liver cells [47]. ChIP-Seq data of SREBP-1/2 in 
HepG2 and GM12878 were recently reported by the ENCODE consortium: inspection of 
binding to lipidogenic genes indicates a perfect correlation with NF-Y in cholesterol 
genes, and near perfect in fatty acids genes (SREBP1/2 positive promoters are marked in 
grey in Fig. 2A). We thus decided to analyze the global genomic overlap of NF-Y and 
SREBP-1/2: to do so, we used the PScan-ChIP software [48], which allows the 
identification of Transcription Factor Binding Site (TFBS) present in the JASPAR or 
TRANSFAC databases, as enriched in close proximity -<75 bps- of genomic peaks of a 
given TF. The statistical enrichment of positively correlating TFBSs is measured as 
“global” or “local“, depending on the robustness of the overlap (Fig. S10). The results of 
such analysis for SREBP-1 and SREBP-2 are shown in Fig. 2B: the NF-Y consensus 
present in JASPAR -termed NFYA or NFYB- is significantly enriched in SREBP-1 and 
SREBP-2 peaks in HepG2 cells treated with pravastatin, but not in untreated GM12878 
(Fig. S10); similarly, SREBP-1 peaks are enriched in CCAAT boxes in HepG2 cells 
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treated with insulin. For SREBPs in pravastatin treated HepG2, the program signals 
“global” enrichments -p values of 10-20- indicating that the CCAAT box is a “primary” 
binding site. By comparison, the SREBF motif has similar p values, indicating that the 
majority of SREBP-1 genomic sites in HepG2 have both a canonical SRE and a CCAAT 
box. No other TFBS is significantly enriched. The data of SREBP-1 peaks of insulin-
treated HepG2 are very similar, except that RFX motifs also emerge, with similar 
frequencies (Fig. 2B). To validate these results, we used the MEME tools for de novo 
motif discovery, to inspect SREBP-1/2 genomic peaks: we indeed retrieved logos 
identical to the NF-Y binding site -the ATTGG reverse of CCAAT- in addition to the 
expected SRE sequence, and, in insulin-treated HepG2, the RFX logo (Fig. 2B). Thus, 
two types of analysis indicate that NF-Y and SREBPs share a vast set of genomic 
locations, extending beyond lipidogenic genes, at least in liver cells. Intriguingly, this is 
not observed in untreated GM12878 B cells, possibly suggesting treatment- or cell-type 
specific regulation. 
Mechanistically, NF-Y and SREBPs are believed to serve different functions in 
transcriptional activation: the former as a “pioneer” TF, which binds to promoters and 
predispose a positive chromatin environment [11,12,49,50]; SREBPs as “activator” TFs 
promoting transcriptional elongation. In fact, nuclear translocation and DNA-binding of 
SREBPs are visible under specific conditions: typically, this requires relocation from the 
ER into the nucleus, following addition of PTMs and proteolysis, according to specific 
stimuli [44,47]. 
 
Respiratory genes, Glycolysis and the TCA cycle.  
The NF-Y homologue HAP2/3/5 is the master transcriptional activator of all genes of the 
respiratory chain in yeast, following the shift from fermentable (glucose) to non-
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fermentable (lactate) carbon sources [3]. The promoters of two human respiratory chain 
genes -ATP Synthase /ATP5B and CYC1- were originally shown to rely on CCAAT 
boxes [51-54], and it could be inferred that NF-Y globally controls mammalian 
respiratory genes as well. The mitochondrial electron transport chain is composed of five 
complexes (I-V), each containing multiple subunits encoded by nuclear and mitochondrial 
genes. Surprisingly, we notice differential densities, both in genomic binding and 
transcriptional activation, in the areas of oxygen-fueled (low) and carbohydrate (high) 
metabolisms (Fig. 1); this is matched by KOBAS analysis, with terms such as aerobic 
respiration and oxidative phosphorylation being up-regulated upon NF-YA inactivation, 
hence normally repressed (Table 1). Further analysis of the genes of the 5 respiratory 
complexes indicates the following: CYC1 (complex III) is -modestly- down-regulated in 
NF-Y-inactivated cells, but not bound by NF-Y; ATP5B (complex V) is bound and 
regulated; in general, however, only a handful genes -NDUFA2, NDUFS8, ATP5E, 
ATP5G1 and SDHB- are directly activated in cancer cells, eight genes in mES cells (Fig. 
3A). A larger set of genes is repressed by NF-Y, either through direct binding, or 
indirectly. We verified the expression analysis by inactivation of NF-YB through shRNA 
interference of Hela cells: of seven representative genes analyzed by qRT-PCR, either 
bound or not by NF-Y in vivo, four showed negligible changes, ATP6AP was modestly 
increased and CYC1 was modestly decreased, in accordance with the profilings data (Fig. 
3B). Experiments using a second shRNA directed against NF-YB yielded similar results 
(Fig. S11). In summary, NF-Y activation of respiratory genes is globally an exception, 
and expression of most genes are either not controlled, or repressed. 
 
On the other hand, glycolytic genes are densely populated of NF-Y-activated units (Figs. 
1 and 4A). The sensitivity of such genes to NF-Y inactivation is very high in mES cells; 
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PKFB2 and SLC16A7 are the only genes showing up-regulation. Critical genes such as 
PFKFB, PGK, GAPDH, PKM, LDH are bound and heavily rely on NF-Y activity. Note 
that Aldolase B, one of the first NF-Y promoters dissected [55,56], is negative, possibly 
because it is mostly expressed in liver cells, not assayed here. Regulation is similar in 
cancer cells, with differences in SLC2A3, SLC16A7, PFKFB2/3 (in HCT116 and H322), 
PKM and HKII. Note that HKII and PKM promoters were shown to be NF-Y-dependent 
[57-59]. We verified the expression of some of these genes in NF-YB-inactivated Hela 
cells by qRT-PCR: most are decreased, with the exception of HKI, HKII and PKM (Fig. 
4B and Fig. S11 ). We also checked the protein levels of several glycolytic enzymes, and 
found HKI, HKII, GAPDH and LDHA to be decreased, whereas PFKP was unchanged 
(Fig. 4C). These data are in agreement with the mRNA analysis, with two exceptions: 
HKII, whose protein is decreased and mRNA is increased after NF-YA inactivation, and 
PKM, showing no change at the protein level. The differential effects could be due to the 
long half-life of the proteins, which would require assessment at longer times after NF-Y 
removal, or to the previously reported differences in sets of genes regulated by NF-YA 
and NF-YB inactivation [13].  
  
Downstream of pyruvate, Acetyl-CoA enters the TCA cycle, which is functionally linked 
to mitochondrial oxidative phosphorylation: at the level of binding, the density of NF-Y 
sites in promoters is high, but the regulation is apparently complex and, intriguingly, 
somewhat dissimilar in cancer and mES cells (Fig. S12A). The Pyruvate Dehydrogenase -
PDH- complex, leading to Acetyl-CoA production by oxidation of pyruvate, illustrates 
such complexity: PDHA1 is affected, but not the DLD and DLAT subunits, which are, if 
anything, repressed by NF-Y; at the same time, the regulatory PD Kinase -PDK1/4- 
which inhibits the activity of the PDH complex, is robustly activated by NF-Y, as shown 
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before [60]. Parallel pathways feed into oxalacetate from (i) Phosphoenol-pyruvate via 
PCK (PEPCK), positively controlled by NF-Y, notably PCK2; (ii) Pyruvate Carboxylase 
(PC), which is bound -promoter and enhancer- and negatively regulated (Fig. S12A). The 
control of PC by NF-Y is also complex [61], including positive effects upon removal of 
single repressive CCAAT boxes [62]. Note the PC route is crucial for anaplerosis, that is, 
replenishment of the pools of the TCA cycle intermediates [63]. Production of citrate 
from Acetyl-CoA and oxaloacetate, and further to isocitrate, is mediated by Citrate 
synthase and Aconitase, whose promoters are bound in vivo, but modestly affected. 
Thereafter, enzymes are not uniformly regulated: Succinate Dehydrogenases (SDH) and 
Malate Dehydrogenase (MDH) are repressed by NF-Y in cancer cells (Fig. S12A). For 
IDH1/2, OGDH and FH, there is less significant regulation in the different cancer cell 
types analyzed, and a positive –indirect- effect on IDH2 in mES cells. We assayed some 
of the TCA genes by qRT-PCR after NF-YB inactivation in Hela cells: consistent with the 
profilings, PDHB, PDK1, ACLY but not PDHA1, are decreased, whereas OGDH, IDH2 
and DLD are unchanged (Fig. S12B). In the second set of experiments using shNF-YB-2, 
the data are similar, except that OGDH is decreased, and PDHB is not, as in the 
profilings,  (Fig. S11). The protein levels of PDHA were evaluated in Western Blots and 
found to be unchanged (Fig. S12C). Note that NF-Y appears to promote expression of 
enzymes converting -ketoglutarate and malate out of the TCA cycle (See below). In 
summary, NF-Y does bind to most promoters of TCA cycle genes, but its role is less 
relevant, and possibly cell-type specific; in general, it does not uniformly favor the 
progression of Acetyl-CoA derived from glucose, lipids and aminoacids catabolism 
through the oxidative production of energy, particularly in cancer cells. Again, this is in 
striking contrast to the results obtained in yeast, where the CIT1, IDH, FH and MH genes 
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are robustly activated by the HAP2/3/4/5 complex during activation of the respiratory 
response [64]. 
 
A major and unexpected finding of our analysis is that the control of energy metabolism 
by NF-Y changed during evolution, from promoting mitochondrial energy production, in 
fungi, to activating genes of anaerobic pathways, in mammals. The preference for 
anaerobic energy production by glycolysis in the presence of oxygen is a hallmark of 
cancer cells, a phenomenon known as the Warburg effect [65]. This requires a high 
activity of glycolytic enzymes; accordingly, the overall levels of many of them are 
elevated in many types of tumors, with respect to normal cells, mainly because of 
increased mRNA expression [66].  
In general, NF-Y appears to have a coherent strategy of promoting glucose, but not 
oxygen utilization. Among glycolytic enzymes, GAPDH produces Glyceraldeyde-3P, 
which enters the biosynthetic pathway of Serine biosynthesis (See below). PKM promotes 
the final, rate-limiting step of glycolysis to generate pyruvate and ATP and is important in 
cancer cells [67]. Lactate Dehydrogenases are key to drive regeneration of NAD+ and 
continuous ATP production from glycolysis. Lactate Dehydrogenase is produced by two 
genes -LDHA and LDHB- whose relative expression varies depending upon the cellular 
status: in cancer cells, it is shifted toward LDHA, generating the LDH5 enzyme, most 
efficient in driving the Pyruvate-to-Lactate conversion required to keep the glycolytic flux 
flowing [68]. It is thus noteworthy that NF-Y is more important for LDHA expression in 
cancer cells, and for LDHB in mESCs. At the end of glycolysis, NF-Y does not appear to 
promote a flux of Acetyl-CoA entering the TCA cycle: this is exemplified by the modest 
impact on PDH, on the associated subunits, and activation of its repressor PDK. At the 
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same time, NF-Y promotes exit of -ketoglutarate and malate from the TCA cycle to 
enter alternate pathways, in cancer cells at least (See below). 
Long time considered as housekeeping genes subject to modest levels of regulation, the 
promoters of these genes recently regained interest, but information about the DNA 
elements and TFs acting on many of them remains scarcely abundant. HIF-1, MYC, 
STAT3 and p53 are TFs associated with the regulation of glycolytic enzymes [69-74]. 
The formers are generally activators, while p53 is inhibitory, at least in the wt 
configuration. HIF-1 is activated by anaerobic stress and constitutively active in many 
cancer cells, targeting essentially all glycolytic genes; MYC was shown to interact with 
NF-Y directly [75] and the peaks of MYC and NF-Y overlap significantly in ENCODE 
data [11]. Interestingly, p53 was shown to promote gluconeogenesis [76], while 
oncogenic Gain-of-Function mutations of p53, reported to impact on expression of NF-Y 
genes [77,78], mediate metabolic reprogramming and increased glycolysis [79]: it will be 
interesting to evaluate the effects of mutp53 on the metabolic genes targeted by NF-Y 
identified here.  
 
The SOCG and Glutamine pathways. 
We noticed high densities of NF-Y targets in specific pathways of Serine/Glycine, 
Glutamine and Methionine, all enriched in KOBAS analysis (Table I). The SOCG 
pathway is central for de novo production of Serine and Glycine, and for additional 
metabolisms -folates, nucleotides- crucially required for growing cells [80]. NF-Y binding 
is present on all promoters of the pathway in at least one cell type with the exception of 
the SLC19A1 transporter, MTHFD2L and AMT (Fig. 5A). Serine synthesis stems from a 
branch of glycolysis, through Glyceraldeyde 3P being sequentially metabolized by three 
enzymes: PHGDH, PSAT and PSHP; the promoters are all bound, and the mRNAs 
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decreased upon NF-YA removal. For the PHGDH promoter, genetic evidence of the 
importance of the CCAAT box was reported [81]. Conversion to Glycine is then obtained 
through the activity of SHMT, present in two isoforms, one located in the cytoplasm -
SHMT1- the other -SHMT2- in mitochondria: NF-YA regulates the former, but 
apparently not the latter. qRT-PCR analysis of Hela cells inactivated with the two 
shRNAs against NF-YB confirmed the control of PHGDH, PSAT1, PSPH, whereas 
SHMT1 was, if anything, positively affected (Fig. 5B and Fig. S11). Interestingly, NF-Y 
also impacts on the mitochondrial branch, by activation of two key enzymes, MTHFDL1 
and MTHFD2. Control of MTHFR and DHFR signals a further role on folates 
metabolism, which is linked to Methionine synthesis and nucleotides production (See 
below). In summary, the data indicate that NF-Y plays a crucial role in the activation of 
SOCG genes. 
Glutamine is another pathway dense with NF-Y targets, at the level of promoter 
recognition and function (Fig. 5A). Binding of NF-Y is absent only in SLC3A2, CAD, 
SLC38A5 and SLC38A3; the latter gene, GLUD1 and GPT are unchanged in expression 
after NF-YA-inactivation in cancer cells. Most genes are activated by NF-Y through 
direct promoter binding [82]. Specifically, GLS and GLS2 are differentially regulated in 
Hela and mES cells: the former is bound and activated in Hela (but repressed in H322), 
but not regulated in mES cells. The reciprocal is true for GLS2. These enzymes are 
crucial for the conversion of Glutamine to Glutamate, which can then be transformed to 
-ketoglutarate by GLUD1, not regulated by NF-Y in cancer cells and modestly repressed 
in mES cells. This branch is a second leg of anaplerotic mechanisms filling the TCA cycle 
with metabolites from the Glutamine pathway: the positivity of GOT1/2, but not GLUD1, 
is yet another indication that NF-Y is not favoring anaplerosis per se. GOT1/2, in fact, 
convert Aspartate from Glutamine into oxaloacetate, then converted into malate [83]: 
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thereafter, the Malic enzymes ME1 ME2, both regulated by NF-Y (Fig. 5A), mediate 
pyruvate production and exit from TCA. In summary, NF-Y appears to promote a shift of 
Glutamine catabolism from the TCA cycle into alternative biosynthetic pathways, 
matching the modest role exerted on PDH (Fig. S12A). The negative regulation of SDH 
(Fig. 3A and S12A) and the activation of genes deviating metabolites from the TCA cycle 
are a further indication that NF-Y is not promoting oxygen-mediated production of 
energy. 
The Glutamine and SOCG pathways are altered in cancer cells. As to the former, tumors 
usually become addicted to high levels of Glutamine. The key GLS2 is activated by p53 
[84,85], and regulation is shared by p63 and p73, with a different outcome depending 
from the isoforms [86,87]. Genes of the SOCG pathways are overexpressed in cancer 
[88], the global alteration directly impinges on an altered flux of metabolites [17]. 
PHGDH and SHMT2 are predictive of survival outcomes in breast cancer, PSPH of 
hepatocellular carcinomas [89,90]. SHMT2 is a cancer driver gene [91,92]; PHGDH 
overexpression, resulting from genomic amplification, is essential for growth of certain 
human breast cancers [93] and melanomas [94]; PSAT1 is overexpressed in colon cancer 
[95]. In general, there are very few data on the mechanisms of transcriptional regulation 
of SOCG pathway genes: p53 is a repressor of PHGDH [96], whereas cMYC 
overexpression leads to increased biosynthesis of serine [90]. The identification of NF-
Y/CCAAT as a pivotal element should facilitate the identification of neighboring 
elements and TFs involved in regulation of these units. 
 
Polyamine and purine metabolism. 
The biosynthetic pathways of purines and polyamines have high density of NF-Y-
controlled genes (Fig. 1 and Table I). In the polyamine pathway, which is extremely 
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important for cancer cells (97), there are two rate-limiting steps, mediated by ODC1, from 
the Urea cycle, and AMD1, from the Methionine salvage pathway. AMD1 is directly 
controlled by NF-Y in cancer and mES cells, but NF-Y inactivation also leads to an 
indirect decrease of ODC1 (Fig. 6A). Additional regulated genes are ADI1, AGMAT, 
GOT1, SMOX, SMS and SRM. ADI1, AMD1, GOT1 and SRM were tested in Hela cells 
inactivated of NF-YB: GOT 1 was unaffected, ADI1 was substantially decreased, AMD1 
and SRM decreased with one of the shRNAs used (Fig. 6B and Figure S11).  
AMD1 and ODC1 are deregulated in a number of cancers, notably prostate 
adenocarcinomas and MYCN-amplified neuroblastomas: in the latter system, ODC1 is 
required for tumor formation and overexpression predicts patient survival [98]. ODC1 
pharmacological inhibition leads to normalization of several pathways -NMYC levels, 
LIN28/Let-7 expression and glycolysis- altered in neuroblastomas, and it is currently 
tested in clinical trials [99]. Interestingly, ODC1 and AMD1 are independently involved 
in mESC self-renewal, in assays of LIF-deprived cells, and can increase reprogramming 
of differentiated fibroblasts by OCT4, SOX2 and KLF4 [100]. NF-Y is also involved in 
mESC self-renewal [12,101,102]: a positive role on expression of the three TFs was 
reported, as an important part of the cohort of NF-Y targets involved in stem cells 
maintenance. 
Many genes of the purine pathway are under NF-Y control (Fig. S13); two targets are 
bona fide tumor suppressors: MTAP, frequently deleted in many types of cancers along 
with the neighboring CDKN2A [103], and Adenylate Kinase 2 AK2 [104]. MTAP shows 
differential regulation by NF-Y, repressed in cancer cells and activated in mES cells. As 
for the synthesis of dNTPs required for the DNA biosynthetic pathways (DNA replication 
and repair), the key step is the reduction from ribonucleotides to desossiribonucleotides, 
performed by the rate-limiting enzyme Ribonucleotide Reductase (RnR), an 
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heterotetramer composed of two large (RRM1) and two small (RRM2) subunits. While 
RRM1 is abundant and constant throughout the cell-cycle, the limiting RRM2 is 
transcribed only in S-phase [105]. RRM1 is regulated by NF-Y in Hela cells, but the 
dependence is higher for RRM2 (Fig. S13), whose promoter contains three functionally 
crucial CCAAT boxes [106], conserved and important also in Zebrafish [107]. Recently, 
RRM2 has attracted considerable therapeutic interest, because its targeting leads cancer 
cells to senesce [108,109]. It is important to note that cells inactivated of NF-YA are 
crippled in S-phase progression, develop signs of DNA-damage, with subsequent 
triggering of an apoptotic response [12,13]: it is possible that a decrease in the dNTPs 
pools, due to a decrease in the conversion from NTPs as a consequence of the RRM2 
drop, might be at least partially responsible for this behavior.  
 
Conclusions and perspectives. 
The detailed analysis of metabolic genes under the control of NF-Y described here and 
summarized in Fig. 7 opens several future avenues of investigations. (i) A thorough 
phylogenetic analysis of the conservation of CCAAT boxes in metabolic genes targeted 
by NF-Y should be performed; specifically, genes involved in energy production should 
be examined, to identify when the switch from aerobic -in yeast- to anaerobic -in 
mammals- energy production has occurred during evolution. (ii) Further studies should be 
undertaken on the many NF-Y metabolic targets whose role in cancer development is 
unknown. Systematic investigation of their expression levels in large cohorts of gene 
expression data of cancer cells could point at additional regulatory nodes to be further 
examined experimentally by genetic and biochemical means. (iii) A few TFs known to 
impact on transcription of metabolic genes emerged, and some have been associated to 
NF-Y activity; in this regard, the SREBP analysis performed here is illustrative of what 
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can be done, given the availability of large datasets of TFs genomic sites; the 
identification of major NF-Y partners in the regulation of metabolic genes will shed light 
on the arrangement of promoter sites and reciprocal interplay. Such catalogue will help 
our understanding of regulatory circuits of cancer cells. 
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MATERIALS AND METHODS 
 
Lentiviral knockdown and gene expression arrays.  
Scrambled control (shSC), NF-YA (shNF-YA) and two NF-YB (shNF-YB-1 -
gctatgtctactttaggcttt-; shNF-YB-2 -ccaaagaatgtgttcaagaatc-) shRNAs were cloned into 
pLKO.1 vector (Sigma Aldrich), and viral production and transduction were carried out as 
previously described [13]. H322 and HCT116 cells were transduced with shSC or shNF-YA 
viral supernatants, in triplicate, and cells collected after 72 hrs of incubation. Hela cells were 
infected with shSC or shNF-YB or shNF-YA and collected at 72 hrs after infection. In the 
experiments shown in Figure S11, transient DNA transfections with shSC and shNF-YB-2 
were performed in triplicate with Lipofectamine 2000 (Invitrogen 11668027). Cells were 
collected after 72 hours. Knockdown efficiency was assayed by PCR on cDNAs and by 
Western Blots on whole cell protein extracts using anti-NF-YA, anti NF-YB and anti-Actin 
antibodies. Total RNA was prepared by Trizol extraction and retrotranscribed with Iscript 
cDNA Synthesis kit (BIORAD 170-8890). For arrays, RNA was prepared according to 
Affymetrix standard protocol and hybridized to Hu-Gene 2.0 expression arrays. 
 
Gene expression analyses.  
For HeLa cells, raw data were retrieved from GSE40215 [11]; for mouse embryonic stem 
cells, raw data were retrieved from GSE56840 [12]. For gene expression analysis of HCT116 
and H322 using the Affymetrix platform, biological triplicates of control and shNF-YA-
treated cells were independently processed: normalization (rma), quality controlled, probe set 
filtered, identification of differentially expressed probe sets and annotation of those probe sets 
to gene symbols were performed using Bioconductor packages (Affy and Limma). We 
defined upregulated and downregulated genes when the fold change is above 1.3 and FDR 
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<0.05. Gene Ontologies and pathways analyses were performed using the KOBAS 2.0 tool 
with default settings [20]. Raw data have been deposited in GEO Repository under the 
accession number GSE70543. 
 
Immunoblots.  
For Western Blot analysis, NF-Y-inactivated and control cells were lysed in lysis buffer 
(50mM Tris–HCl pH 8.0, 120mM NaCl, 1% Triton X100, 20%SDS, 1mM EDTA, 
protease and phosphatase inhibitors). Equivalent amount of extracts were run on SDS-
PAGE, transferred to nitrocellulose membrane (Whatman) and immunoblotted with the 
following antibodies: anti-Actin (sc-1616, Santa Cruz) anti-NF-YA (Mab1a), anti-NF-YB 
(Pab001, GeneSpin), anti-Glycolytic enzymes (Glycolysis 2 kit, Cell Signaling 8337S), 
anti-Vinculin (SAB4200080, Sigma Aldrich). 
 
qRT-PCR.  
The Primer3 0.4.0. program was used for primers design using default parameters. See Fig. 
S14 for primer sequences. qPCR was performed with a Biorad myIQ instrument: values are 
normalized over an internal control ribosomal gene used as normalizator -RPS20- and are 
represented as fold-enrichment over control sample shSC. Data are presented as mean  
standard error of fold change of 3 biological replicates run in qPCR triplicates. Statistical 
significance are assessed with one sample t-test and indicated with asterisk when p<0.05.
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FIGURE LEGENDS 
 
Figure 1. NF-Y targets in metabolic pathways.  
Global map of metabolic pathways targeted by NF-YA. A) Metabolic genes upregulated 
(in green) and downregulated (in red) after silencing of NF-YA in HeLa cells [11]. B) 
Metabolic genes with core promoters bound by NF-YA are indicated in blue according to 
ENCODE ChIP-Seq data. The maps are constructed with the KEGG Mapper v 2.5 tool. 
 
Figure 2. NF-Y activates genes of lipid metabolism.  
A) Genes involved in cholesterol and fatty acids metabolisms are shown. The heatmap 
represents the log2 fold change of relative expression derived from profiling analysis (See 
colour scale) in the indicated cell lines after inactivation of NF-Y subunits: H322 (This 
manuscript, Fig S2), HCT116 (This manuscript, Fig. S2), HeLaS3 [11] and mESC [12]. 
The presence of NF-Y binding in ENCODE datasets is indicated with P (core promoter 
binding), E (external enhancer), Ei (enhancer in gene body) or R (repetitive sequence 
within 5 kb from the TSS). In vivo binding of SREB-1/2 according to ChIP-Seq 
experiments is indicated by a grey background. B) Analyses of over-represented motifs in 
SREBPs peaks in HepG2 ChIP-Seq data analyzed by ENCODE. The matrices were 
derived with Pscan-ChIP (Left panel) and MEME (Right panel), and the relative p-values 
are shown. 
 
Figure 3. NF-Y and expression of respiratory genes.  
A) Genes of oxidative phosphorylation chain complexes are shown with the relative 
expression levels after inactivation of NF-Y in different cell lines, and the relative 
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presence of NF-Y binding in P (promoter), E (external enhancer), Ei (enhancer in gene 
body) or R (repetitive sequence within 5 kb from TSS). B) qRT-PCR evaluation of 
expression levels of respiratory genes after inactivation of NF-YB in Hela cells. The 
average -/+ SD of three biological replicates is represented. (*p<0.05) 
 
Figure 4. Glycolytic enzymes are regulated by NF-Y. 
A) Genes encoding for glycolytic enzymes are shown with their expression levels after 
inactivation of NF-Y in different cell lines, and the presence of NF-Y binding is indicated 
as in Fig. 3. B) qRT-PCR evaluation of expression levels of selected genes after 
inactivation of NF-YB in Hela cells. The average -/+ SD of three biological replicates is 
represented. (*p<0.05). C) Western blot analysis of protein levels of NF-Y targets in Hela 
cells inactivated of NF-YA (Left panel), or NF-YB (Right panel). 
 
Figure 5. Activation of SOCG genes by NF-Y. 
A) Genes of the SOCG (Serine, One Carbon, Glycine) pathway are shown with the 
expression levels after inactivation of NF-Y, and the presence of NF-Y binding as in Fig. 
3. B) qRT-PCR evaluation of expression levels of PHGDH, PSAT1, PSPH, SHMT1 after 
inactivation of NF-YB in Hela cells. The average -/+ SD of three biological replicates is 
represented (*p<0.05). 
 
Figure 6. Activation of genes of the polyamine metabolism by NF-Y. 
Genes of the polyamine pathway are shown with the expression levels after inactivation 
of NF-Y, and the presence of in vivo NF-Y binding as in Figs 3-5. 
 
Figure 7. Schematic representation of metabolic pathways regulated by NF-Y. 
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Table 1. Metabolic terms enriched in genes whose expression is changed upon 
inactivation of NF-YA in Hela-S3 cells (Left panel) and in mouse ES cells (mESC) (Right 
panel). Pathways and Gene Ontology analyses were performed with Kobas 2.0 and 
metabolic terms extracted from the list. The full list of terms enriched in differentially 
expressed genes is shown in Fig. S9. 
HeLa-S3 mESC 
 CATEGORY ID P-Value CATEGORY ID P-Value  
D
O
W
N
R
E
G
U
L
A
T
E
D 
Alpha-amino acid biosynthetic process GO:1901607 3.73E-04 Carboxylic acid metabolic process GO:0019752 7.86E-16 
D
O
W
N
R
E
G
U
L
A
T
E
D 
Cellular amino acid biosynthetic process GO:0008652 7.16E-04 Metabolism REACT_188937 3.20E-13 
Alanine, aspartate and glutamate metabolism hsa00250 7.93E-04 Small molecule metabolic process GO:0044281 2.51E-12 
Serine glycine biosynthesis P02776 1.48E-03 Metabolic pathways mmu01100 5.73E-11 
Glutamine metabolic process GO:0006541 2.86E-03 Cellular amino acid metabolic process GO:0006520 4.98E-10 
Amino acid synthesis and interconversion (transamination) REACT_238 3.39E-03 Small molecule biosynthetic process GO:0044283 6.69E-10 
Metabolism of polyamines REACT_14820 3.39E-03 Carbon metabolism mmu01200 8.45E-08 
Glutamine family amino acid metabolic process GO:0009064 4.02E-03 Oxidation-reduction process GO:0055114 1.65E-07 
Polyamine metabolic process GO:0006595 4.48E-03 Biosynthesis of amino acids mmu01230 2.76E-07 
Glycemic traits (pregnancy) NHGRI GWAS  4.49E-03 Metabolism of amino acids and derivatives REACT_232845 1.63E-06 
L-serine metabolic process GO:0006563 7.32E-03 Amino acid synthesis and interconversion (transamination) REACT_239550 4.43E-06 
Purine nucleobase biosynthetic process GO:0009113 1.01E-02 Glycolysis / Gluconeogenesis mmu00010 6.44E-06 
Nucleotide catabolic process GO:0009166 1.05E-02 Glycine, serine and threonine metabolism mmu00260 1.87E-05 
Fatty acid biosynthesis hsa00061 1.94E-02 Glucose metabolism REACT_261601 3.03E-05 
Purine metabolism hsa00230 2.92E-02 Fatty acid biosynthetic process GO:0006633 3.70E-05 
  Cholesterol metabolic process GO:0008203 6.50E-05 
U
P
R
E
G
U
L
A
T
E
D 
Cellular catabolic process GO:0044248 2.24E-06 Lipid metabolic process GO:0006629 6.74E-05 
Carboxylic acid catabolic process GO:0046395 7.94E-05 Fructose and mannose metabolism mmu00051 8.88E-05 
Fatty acid catabolic process GO:0009062 1.03E-04 Pyruvate metabolic process GO:0006090 9.33E-05 
Lipid oxidation GO:003440 1.14E-04 Valine, leucine and isoleucine degradation mmu00280 1.49E-04 
Autophagy GO:0006914 1.84E-04 Aspartate family amino acid metabolic process GO:0009066 3.12E-04 
Monocarboxylic acid catabolic process GO:0072329 2.42E-04 Glycogen storage diseases REACT_203949 4.37E-04 
Branched-chain amino acid catabolism REACT_197 1.12E-03 Metabolism of carbohydrates REACT_248571 4.37E-04 
Fatty acid beta-oxidation GO:0006635 1.17E-03 Arginine and proline metabolism mmu00330 6.05E-04 
Macroautophagy GO:0016236 1.93E-03 Activation of gene expression by SREBF (SREBP) REACT_198969 8.19E-04 
Protein catabolic process GO:0030163 2.60E-03   
Valine, leucine and isoleucine degradation hsa00280 2.73E-03 Regulation of cellular macromolecule biosynthetic process GO:2000112 1.10E-05 
U
P
R
E
G
U
L
A
T
E
D 
Macromolecule catabolic process GO:0009057 2.84E-03 Regulation of cellular biosynthetic process GO:0010556 3.43E-05 
Cellular response to starvation GO:0009267 3.01E-03 Regulation of macromolecule metabolic process GO:0006355 4.52E-05 
Ribonucleoside bisphosphate metabolic process GO:0033875 7.23E-03 Regulation of biosynthetic process mmu05220 5.70E-05 
Purine nucleoside bisphosphate metabolic process GO:0034032 7.23E-03 modification-dependent macromolecule catabolic process mmu04068 1.59E-04 
Nucleotide metabolic process GO:0009117 7.31E-03 MyD88:Mal cascade initiated on plasma membrane GO:0031326 1.69E-04 
Aerobic respiration GO:0009060 1.64E-02 Toll Like Receptor TLR6:TLR2 Cascade GO:0016070 1.72E-04 
Nucleotide-sugar metabolic process GO:0009225 1.67E-02 Ubiquitin-dependent protein catabolic process GO:0060255 2.14E-04 
Glycosphingolipid metabolism REACT_116105 1.68E-02 Modification-dependent protein catabolic process GO:0009889 2.25E-04 
Metabolism of lipids and lipoproteins REACT_22258 2.15E-02 Clathrin derived vesicle budding GO:1903507 3.17E-04 
Citrate cycle (TCA cycle) hsa00020 5.24E-02 Negative regulation of macromolecule metabolic process REACT_206529 3.33E-04 
Fatty acid, triacylglycerol, and ketone body metabolism REACT_22279 6.20E-02 Regulation of lipid metabolism by PPARalpha REACT_263004 3.58E-04 
Cytochrome c-mediated apoptotic response REACT_831 6.91E-02 Signaling by PDGF GO:0006511 3.78E-04 
Oxidative phosphorylation hsa00190 7.55E-02 Hippo signaling pathway REACT_198602 7.65E-04 
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Fig.S1 Inactivation of NF-YA in HCT116 and H322 cell lines.  
 
Cells were transduced with shSC or shNF-YA viruses and collected 72 hrs after treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig.S3 Global Metabolic maps of genes deregulated after NF-YA inactivation in HCT116 
and H322 cells 
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Fig.S4 Global Metabolic maps of genes deregulated after NF-YA, NF-YB, NF-YC and NF-
Y (all subunits) inactivations in mouse embryonic stem cells. 
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Gene expression profiling a er NF-YC silencing in mES cells 
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Fig.S5 Global Metabolic maps of genes bound in their promoters by NF-YB according to 
ENCODE data in HeLa cells. 
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Fig.S6 Global Metabolic maps of genes bound in their promoters by NF-YA according to 
ENCODE data in K562 and GM12878 cells.  
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Fig.S7 Global Metabolic maps of genes bound in their promoters by NF-YB according to 
ENCODE data in K562 and GM12878 cells. 
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Fig.S8 Global Metabolic maps of genes bound in their promoters by NF-YA, NF-YB and 
NF-YC according to data published by Oldfield AJ et al.. 
 
NF-YA binding in mES cells 
NF-YB binding in mES cells 
NF-YC binding in mES cells 
Glycan Biosynthesis 
and Metabolism 
Lipid 
Metabolism 
Carbohydrate 
Metabolism 
Amino Acid 
Metabolism 
Energy 
Metabolism 
Nucleotide  
Metabolism Metabolism of Cofactors and Vitamins 
Biosynthesis of Other 
Secondary Metabolites 
Xenobiotics 
Biodegradation and 
Metabolism 
Metabolism of 
Other Amino Acid  
Metabolism of Terpenoids 
and Polyketides 
Glycan Biosynthesis 
and Metabolism 
Lipid 
Metabolism 
Carbohydrate 
Metabolism 
Amino Acid 
Metabolism 
Energy 
Metabolism 
Nucleotide  
Metabolism Metabolism of Cofactors and Vitamins 
Biosynthesis of Other 
Secondary Metabolites 
Xenobiotics 
Biodegradation and 
Metabolism 
Metabolism of 
Other Amino Acid  
Metabolism of Terpenoids 
and Polyketides 
Glycan Biosynthesis 
and Metabolism 
Lipid 
Metabolism 
Carbohydrate 
Metabolism 
Amino Acid 
Metabolism 
Energy 
Metabolism 
Nucleotide  
Metabolism Metabolism of Cofactors and Vitamins 
Biosynthesis of Other 
Secondary Metabolites 
Xenobiotics 
Biodegradation and 
Metabolism 
Metabolism of 
Other Amino Acid  
Metabolism of Terpenoids 
and Polyketides 
Genes with promoter bound by NF-Y 
 
Fig.S11 Inactivation of NF-YB in Hela cells using sh-NF-YB-2 and analysis of expression 
of targets genes. 
 
 
 
 
 
Western blot analysis of protein level of NF-YB in Hela cells inactivated of NF-YB using sh-
NF-YB-2. qRT-PCR evaluation of expression levels of NF-YB and selected genes after 
inactivation of NF-YB in Hela cells. The average -/+ SD of three biological replicates is 
represented (*p<0.05).  
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Fig.S12 Regulation of genes of TCA cycle.  
 
A) Expression levels of genes encoding TCA enzymes are shown after inactivation of NF-
Y in different cell lines, and the presence of NF-Y binding is indicated as in Fig. 3. B) qRT-
PCR validation of expression levels of selected genes after inactivation of NF-YB in Hela 
cells. The average -/+ SD of three biological replicates is represented (*p<0.05). C) 
Western blot analysis of protein levels of PDHA1 in Hela cells inactivated of NF-YA (Left 
panel) or NF-YB (Right panel). 
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FigS13 Activation of genes of purine and pyrimidine metabolisms by NF-Y. 
 
 
Genes of the purine and pyrimidine metabolisms are shown with the expression levels 
after inactivation of NF-Y, and the presence of in vivo NF-Y binding. 
 
 
 
 
PDK1 TCTCAGGACACCATCCGTTC
GGGCCATTGTGGGAATGAC
PDH1a GACTGTACGCCGAATGGAGT
CCGGTAGGCTGTGATGAGAT
PDHB AGGCATAGGGACATCAGCAC
GGCCACAGTTTGGAGTAGGA
ACLY CTGGGCGGTACAGTTTGGAG
GGACCAGAAGGGAGTGACCA
DLD CACACCCTGAAGTTGCTTGG
CACCATGCCATCTGTGTCAG
IDH2 ACCTGAGCCACCATGTCATC
CGCTGTACATGAGCACCAAG
OGDH GCTGAGCCCTTTCTCAGTGG
GGGGACTCTGGTAGGCAGTG
RPS20 GCGCCTCTTATCAAGTCAGC
CGGAAAAACACCCGTGGAG
ATP5B ACCTCAGCAACCTGGAATGG
GTGGGGTGCAAAAGATCCTG
ATP5I GGTCGCAGGGTCACTCACTT
GGCAGAAGAGGAGAGGAGGA
ATP5L CCTGCTGAGATCCCTAGAGCT
GCCCCGCTTGCCTATAATC
ATP6AP1 ATACACAGCGGCCCTCACAG
GGTCCTTGTACGCCACAGAG
CYC1 GTCACTGCGGGAAGGTCTCT
GATGGTCGTGCTCTGGCTCA
NDUFA3 CAGTGCTGGTCGTGTCCTT
TAGTTGTAGGGCGTGGCCTTG
NDUFA11 GCAGCCACCGAGGAAGTAGT
CGCTGCCTACAGAGTCACAC
HK1 CGGACCACGGTTGGTGTC
CTTGCCGCTGCCACTCTC
HK2 AGGAGAACAAAGGCGAGGAG
CGCACGGTCTTATGTAGACG
PFKM CTGGTGGATGGTGGAGATCA
CACCCCCAATGACACAGAGA
ALDOA TTGGGGGTGTCATCCTCTTC
GGGTGGTAGTCTCGCCATTT
GAPDH GCCTCAAGATCATCAGCAATGC
CCACGATACCAAAGTTGTCATGG
PKM2 isoform 1 GGCTGAAGGCAGTGATGTGG
GGCTTCCATGAGGTCTGTGG
PKM2 isoform 2 TACCAGCGACCCCACAGAAG
GGAAGATGCCACGGTACAGG
LDHA AGGCTGGGAGTTCACCCATT
CAACCACCTGCTTGTGAACC
PHGDH GCGTGTGGTGAACTGTGC
AGGTGGGGACAGCTGATG
PSAT1 AGCAGGAAGGTGTGCTGACT
GTAGGAGGCATCTGGGTTGA
PSPH GCTGCGTCTCATCAAAACCT
AGCTCAATATCCCAGCAACC
SHMT1 GCCCTTCCACCATCTGTG
GACGGAGCTGGGCTACAA
ADI1 TCC CTC ACA TCG AAG TAC CC
GGA ACT ACT CCT GGA TGG ACA
AMD1 AGC ACT CTG GCA ATC AAG AC
CAG ACC TCC TAT GAT GAC CTG A
GOT1 GCT TCT AGT CGT GCC CTG AG
CAC CCT CTC TAA CCC TGA GC
SRM GGC AGC AGA GGA CAC CAT
CAG GAT GCC TTC GAC GTG
The Fig. S2, S9 and S10 will be available on-line. 
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The evolutionary conserved domain of NF-YA harbors two Cell Penetrating Peptides. 
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ABSTRACT 
 
Cell Penetrating Peptides -CPPs- are short aminoacidic stretches that enable proteins to be 
internalized into cells. They are usually rich in basic residues, and often organized as alpha helices. 
NF-Y is a transcription factor trimer that binds to the widespread CCAAT box element. The NF-YA 
subunit possesses two α-helices rich in basic residues in the 56 aminoacids evolutionarily conserved 
part. Protein transfections with recombinant NF-YA showed efficient entry at nanomolar 
concentrations. Mutagenesis pinpointed two CPPs in the subunits interaction A1 and DNA-binding 
A2. The half-life of the transduced protein is shorter in transformed cells than in immortalized HaCaT 
and NIH3T3. In NIH3T3 cells, NF-YA affects transcription of CCAAT-dependent promoters 
inducing growth retardation, and an increase in the expression of pro-apoptotic genes. In conclusion, 
we describe novel CPPs empowering NF-YA with new and unexpected properties. 
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1 INTRODUCTION 
 
Cell Penetrating Peptides (CPPs) are short aminoacids stretches which possess the capacity to mediate 
the internalization of the proteins, also functioning as carriers of additional materials, including 
nucleic acids and drugs (Dietz et al., 2004; Mae et al., 2006). They were originally discovered within 
sequences of proteins with a transcriptional role, the Drosophila Antennapedia and HIV TAT (Derossi 
et al., 1994; Green et al., 1988,). The peptides were extensively characterized: when fused to proteins, 
they provide a useful mean to efficiently introduce them into cells. Such protein transduction systems 
appear to be efficient for a number of proteins, with a wealth of possible biotechnological and 
therapeutic implications being currently explored (Roeder et al., 2004; Araki et al., 2010). Two 
common structural features of CPPs are the abundance of Arginines and the presence of amphipathic 
α-helices (Futaki et al., 2001; Crombez et al., 2008; Eiríksdóttir et al., 2010). 
One of the proteins in which TAT fusions proved valuable was the NF-YA subunit of the trimeric 
transcription factor NF-Y: it was demonstrated that a functional GST-TAT-NF-YA could be 
efficiently introduced into nuclei of hematopoietic cells by protein transfection (Domashenko et al., 
2010). Short term exposures of this protein, in the 10-50 nanomolar range, significantly affected 
transcription of NF-Y target genes, without inducing overt cellular toxicity. Indeed, it was shown that 
treatment of pools of cells enriched in hematopoietic stem cells –HSCs- led to an expansion of the 
stem precursors pool ex vivo, with a subsequent increase in bone marrow engraftment in irradiated 
nude mice. The functionality of recombinant TAT-NF-YA further assessed in mouse ES cells (Dolfini 
et al., 2012), and embryonal carcinoma NT2 cells (Moijsin et al., 2015), thus confirming that this 
strategy is potentially exploitable.  
Functionally, NF-Y is a “pioneer” TF, responsible to set up a favorable chromatin environment for 
companion “activating” TFs to bind DNA and induce mRNA elongation by the RNA Pol II machinery 
(Kabe et al., 2005). Gene deletion of NF-YA leads to lack of development due to early embryo failure, 
and conditional KO experiments established multiple roles in proliferating cells -liver and HSCs-, 
and in post-mitotic cells, adipocytes and cortical neurons (Bhattacharya et al., 2003; Lu et al., 2015; 
Bungartz et al., 2012; Yamanaka et al., 2014).  
NF-YA is the limiting subunit of the NF-Y trimer, which comprises two Histone Fold Domain -HFD- 
subunits, NF-YB and NF-YC (Nardini et al., 2013). The structure of the trimer bound to the target 
CCAAT sequence illustrates the unique modalities of DNA recognition: it is based on several non 
sequence-specific contacts of HFD subunits with the phosphate backbone a-la H2A/H2B, and 
specific CCAAT-binding in the minor groove by conserved structures of NF-YA: an amphipathic α-
helix -A2- and the unique GxGGRF motif. The HFD interacting part of NF-YA is located in another 
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α-helix, A1. Overall, the conserved 56-aminoacids domain of NF-YA is extremely basic, and subject 
to post-translational modifications, including Lysines-mediated poly-ubiquitination and degradation, 
responsible for the relatively rapid turnover of the protein (Manni et al., 2008).  
The inspection of the NF-Y/CCAAT 3D structure, in particular of NF-YA, suggested us the presence 
of features of CPPs. We decided to verify this hypothesis. 
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2 Materials and Methods 
 
2.1 Protein production and purification. The wild type long  and short NF-YA in pEt3b, pEt3b-
NF-YB and pEt32-NF-YC plasmids were described (Li et al., 1992). The mutants YAl 31, 32, 33 and 
34 of NF-YA were constructed by PCR, using mismatched oligos; the fragments were inserted using 
KpnI-BamHI sites in the pEt3b/NF-YAl backbone. pEt3b/NF-YA23 and pEt3b/NF-YA29, described 
in Mantovani et al., 1994, were used to create mutants YAl 23-33, YAl 23-34, YAl 31-29 and YAl 
32-29. The sequences of the mutants were checked by DNA sequencing. 
NF-YA recombinant proteins were produced using Escherichia coli BL21(DE3): logarithmically 
growing cells were induced for 3 hours with 0.1 mM IPTG at 37°C. The cell pellets were lysed in 
300 mM NaCl, 20 mM Tris-HCl, pH 7.5, 0,1 mM DTT, 0,05% NP40 and protease inhibitors (Sigma), 
briefly sonicated and centrifuged (Li et al., 1992). The procedure was repetead twice. Inclusion bodies 
were solubilized in 8 M urea, 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 0.1 mM DTT, renatured by 
dialysis in urea-free buffer (150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 0,1 mM DTT, 10% glycerol), 
centrifuged and stored at -80°C. Each recombinant NF-YA described (wt and mutants) was prepared 
three times. LPS was removed from protein preparations using Triton X114, as described (Liu et al., 
1997). Proteins were analyzed by SDS-polyacrylamide gel electrophoresis and visualized by staining 
with Coomassie Brilliant Blue R-250 solution (0.25% Coomassie Brilliant Blue R-250, 50% ethanol, 
10% acetic acid) for 40 minutes. 
Recombinant NF-YB and NF-YC (37 kD isoform) were produced separately as described above, 
except that the lysis solution was 300 mM KCl, 20 mM Tris-HCl, pH 7.8, 0,1 mM EDTA pH 8, 
0,05% NP40, 5 mM β-mercaptoethanol, protease inhibitors. Inclusion bodies were solubilized in 100 
mM KCl, 20 mM Tris-HCl, pH 7.8, 5 mM β-mercaptoethanol, 6 M GnCl. NF-YB and NF-YC were 
mixed in equimolar amounts and renaturated by slow dialysis in 10 mM Tri-HCl pH8, 300 mM KCl, 
10% glicerol, 1 mM DTT and 3.5 M urea for 2 hours at room temperature and then in-urea free buffer 
(10 mM Tri-HCl pH8, 300 mM KCl, 10% glicerol, 1 mM DTT) and stored at -80°C. After 
renaturation, NF-YB/NF-YC were purified using His-select® Nickel Affinity Gel, exploiting the His-
Tag of NF-YC. The dimer was eluted in 250 mM imidazole pH 8, 10 mM Tri-HCl pH8, 300 mM 
KCl, 10% glicerol, 1 mM DTT, dialyzed over-night in the same buffer without Imidazole, and stored 
at -80°C. 
 
2.2 Electrophoretic mobility shift assay. The probe used was a 31 bp double-stranded 
oligonucleotide containing the Hsp70 promoter CCAAT-Box, 5’-labelled with Cy5: (5’-
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CTTCTGAGCCAATCACCGAGCTCGATGAGGC-3’ Sigma). The annealing reaction was 
performed with an equimolar concentration of the complementary oligonucleotide (20 μM) in a final 
volume of 40 μl of TE. The dose-response experiments were performed with different concentrations 
of NF-YA and at 20 nM and 60 nM of DNA and NF-YB/NF-YC, respectively. Protein was diluted 
in dilution buffer (400 mM NaCl, 10 mM Tris-HCl, pH 8, 10% glycerol, 0,1 mg/mL BSA, 2.5 mM 
DTT). For incubation, binding buffer 5X (250 mM KCl, 25 mM MgCl2, 60 mM Tris-HCl, pH 8, 2.5 
mM EDTA, 60% glycerol, 25 mM DTT, 1 mg/mL BSA) was added to proteins and to labeled DNA. 
Reactions were incubated at 30°C for 30 minutes, protected from light, and loaded on the gel (TBE 
0.25X, 4% acrylamide, 19:1 Bis ratio, 2.5% glycerol, 0.1% APS), in a dark room at 4°C; 
electrophoresis was carried out at constant 120 V for 3 hours. Detection was performed with the 
ChemiDocTM MP imaging system (Biorad). Each EMSA experiment was performed in triplicate. 
 
2.3 Cell cultures and NF-YA protein transduction. Human HaCaT keratinocytes, human colon 
carcinoma HCT116, human cervical carcinoma HeLa, human osteosarcoma U2OS, human 
fibrosarcoma HT1080 and NIH3T3 mouse fibroblasts were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% of fetal bovine serum (FBS), L-glutamine, 100 units/ml penicillin 
and 100 μg/ml streptomycin at 37°C in a humidified 5% CO2 atmosphere. 25 x 104 cells/well in 6 
well plates were washed with DMEM without serum before protein delivery. Exponentially growing 
cells, were washed with PBS, treated with the indicated amounts of recombinant NF-YA in serum-
free medium for 30 minutes at 37°C in 5% CO2. After 30’, cells were washed with serum-free medium 
and further incubated with recombinant NF-YA for further 30’. Finally, cells were washed with 
serum-free medium and cultured in complete DMEM, and collected at different time points. 
Transfections with wt and mutant NF-YA proteins were repeated 2-4-times. 
 
2.4 Cell extracts and Western Blot Analysis. Cells were washed with PBS, collected by scraping 
and lysed in ice-cold Buffer A (10 mM KCl, 10 mM Hepes, pH 7.8, 0.1 mM EDTA, 0.1 mM EGTA, 
protease inhibitors mixture (Sigma) by incubation on ice for 30 minutes. NP40 was added to the final 
concentration of 0.65%. Cells were vortexed and centrifuged at 13,000 rpm for 5 minutes.  Pelleted 
nuclei were resuspended in ice-cold Buffer C (1 M NaCl, 20 mM Hepes, pH 7.8, 1 mM EDTA, 1 
mM EGTA, 1 mM dithiothreitol, protease inhibitors). Protein concentration was determined by 
Bradford (Bio-Rad Protein Assay). 10 μg of nuclear extracts were loaded on 10% SDS-
polyacrylamide gel and analyzed by Western blot using the following primary antibodies: anti-NF-
YA (Santa Cruz Biotechnology), anti-Vinculin (Santa Cruz Biotechnology), anti-Lamin B (Sigma), 
anti-LPS (Hycult biotech). Protein-antibody detection was performed using peroxidase-conjugate 
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secondary antibodies and ECL reagents (GeneSpin). Visualization of images was obtained with the 
ChemiDocTM MP imaging system (Biorad) and for quantification of the data we used the ImageLab 
software (Biorad). 
 
2.5 RNA extraction and RT-PCR analysis. Total RNAs were extracted using Trizol reagent 
(Sigma) according to the manufacturer’s instructions. 1 μg of RNA was retrotranscribed with 
SuperScriptTM reverse transcriptase (Biorad) and random primers. cDNA was diluted 1:20 with water 
and analyzed in triplicate in q-RT-PCR analysis. To normalize the data we used the housekeeping 
ribosomal gene RPS15. A comparative 2-∆∆Ct was used to detect relative gene expression. q-PCR 
analysis was performed using the primers indicated in Supplementary Fig. 6  
 
2.6 Cell counts by trypan blue exclusion. 80 x 104 NIH3T3 cells were plated in triplicate for each 
treatment in 60 cm plates and collected by trypsinization at different times. The growth curves were 
obtained by counting cells in Bϋrker chamber, using the trypan blue exclusion method. Duplicate 
biological replicates, each with triplicate samples, with two different proteins preparations, were 
performed. 
 
3 RESULTS 
 
3.1 Recombinant NF-YA enters cells efficiently. 
We noticed that the evolutionarily conserved part of NF-YA contains two features of CPPs, the 
presence of α-helices -A1 and A2- and the abundance of Arg residues (Nardini et al., 2013). We 
decided to test whether recombinant NF-YA would enter cells in the absence of any fused CPP. We 
produced in E. coli the two recombinant NF-YA isoforms, “long” and “short” -NF-YAl and NF-YAs- 
(Li et al.,1992;  Mantovani et al., 1992): the proteins were found in inclusion bodies, with a high 
degree of purity, as checked by SDS-PAGE (Fig. S1A). The recombinant proteins were solubilized 
in 8M urea and renatured by slowly removing the denaturing agent, as described (Mantovani, 1992). 
To get rid of contaminating LPS-like material present in the bacterial preparations, we used the Triton 
X114 precipitation protocol (Liu et al., 1997): indeed, this procedure largely eliminated LPS from 
our preparations, as checked by Western blot analysis (Fig. S1B).  
The recombinant proteins were then quantified and used in protein transfections of human colon 
carcinoma HCT116 cells. We tried different transfections procedures and finally set up a simplified 
system by adding the proteins twice at 30’ intervals in serum-free medium. 
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Because NF-Y is localized exclusively in the nucleus (Frontini et al., 2004), where it exerts its DNA-
binding and transcriptional functions, we prepared and assayed nuclear extracts in all further 
experiments. Fig. 1A shows a dose-response of NF-YAs and NF-YAl in nuclear extracts of HCT116 
cells prepared  2 hours post-transfection, monitoring protein uptake into cells by Western blot with 
an anti-NF-YA antibody: NF-YAs and NF-YAl enter cells at low nanomolar concentrations, as it was 
previously shown for TAT-NF-YA. Remarkably, transfections yielded amounts of recombinant NF-
YAs and NF-YAl that are many-fold those of the endogenous NF-YAs. HCT116 cells mainly express 
the short isoform of NF-YA; note the superimposition of the transfected short isoform with the 
endogenous one (Fig. 1A). 
We next performed a kinetic analysis of NF-YAl transfected protein levels: Fig. 1B shows that NF-
YAl is observed at near maximum levels already after 30’ post transfection, and still high at 2 hours; 
by 6 hours, the protein is considerably decreased. 
The endogenous NF-YAs of HCT116, serves as internal control, in addition to the loading control 
LaminB. Interestingly, the short half-life of the overexpressed protein is very similar to the one 
previously calculated, including in overexpression experiments generated with DNA-mediated gene 
transfections (Manni et al., 2008). Thus, it appears that NF-YA is rapidly internalized into cells and 
degraded. 
 
3.2 Identification of NF-YA CPPs. 
The assays shown  below were used to identify the aminoacids responsible for internalization of NF-
YA. Positively charged aminoacids are present in the primary sequence of NF-YA exclusively in the 
evolutionarily conserved domain (AA 262-317), which contains 7 Lysines and 11 Arginines. 
Specifically, there are four stretches of 3 consecutive basic residues, which were mutagenized into 
Alanines (Fig. 2A, YAl 31-34): YAl 31 and YAl 33 affect residues in the A1 and A2 helices, YAl 32 
and YAl 34 involve residues of the linker between A1 and A2 and of the RXGGRF DNA-binding 
motif, respectively (Nardini et al., 2013). Subsequently, we prepared double mutants in which these 
mutations were coupled to previously described mutants YA23 and YA29, in the subunits-interaction 
and DNA-binding subdomains (Mantovani et al., 1994): thus we generated mutants YAl 29-31, YAl 
29-32, YAl 23-33, YAl 23-34. 
We produced these mutants in the NF-YAl backbone: Coomassie staining of SDS-PAGE of 
representative preparations are shown in Fig. S2. To verify their functionality, we initially 
characterized these mutants for DNA-binding in EMSAs on the high affinity CCAAT box oligo of 
the HSP70 promoter (Nardini et al., 2013): note that mutants in the A2 and GXGGRF motif are 
predicted to be deficient in DNA-binding assays. Dose-response of NF-YAl on a fixed amount of 
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recombinant NF-YB/NF-YC dimer generated a specific band, as expected; the linker-mutated YAl 
32 showed robust DNA-binding, while A1 mutated YAl 31 was decreased (Fig. 2B). On the other 
hand, YAl 33 and YAl 34, crippled in A2 and the GXGGRF motif, were completely negative, even 
at high protein concentrations (Fig. 2B). Similarly negative were the double mutants YAl 29-31, YAl 
29-32, YAl 23-33 and YAl 23-34 (Fig. 2C and Fig. 2D). These results were expected, but we felt 
important to verify whether this was due to the renaturation process. To do so, we exploited the 
capacity of the DNA-binding mutants to bind normally to the HFD dimer, and prevent DNA 
association of wt NF-YAl, therefore acting as Dominant Negatives (Mantovani et al., 1994). We 
performed EMSAs by incubating YAl 33 and YAl 34 with a wt NF-Y complex prior to addition of 
DNA: Fig. S2 shows that both mutants were able to decrease the binding of NF-Y, indeed indicating 
that they are functional in terms of subunits interaction. Therefore, the NF-YA mutants behaved in 
vitro as expected, based on previous extensive mutagenesis (Xing et al., 1993; Xing et al., 1994; 
Mantovani et al.,1994), and the analysis of the 3D structure of the NF-Y trimer in complex with DNA 
(Nardini et al., 2013). 
 
Thereafter, we assayed these mutants in the proteins transfection assays: kinetic analysis at 10nM 
concentrations performed in HCT116 cells monitored NF-YA accumulations by Western blots. Fig. 
3 shows that YA 23, YAl 31, YAl 32, YAl 33 and YAl 34 were present in nuclear extracts, but at 
decreased levels compared to the wt NF-YAl. YA 29 was somewhat lower. The double mutants YAl 
29-31 and YAl 29-32 showed levels of NF-YAl similar to the single YAl 31 and 32 mutants. In none 
of these mutants complete elimination of uptake was observed, suggesting the presence of more than 
one CPP. On the other hand, the entry of YAl 23-33 and YAl 23-34 into cells was essentially 
abolished. Quantifications of these experiments are shown in Fig. S3. These results indicate that there 
are indeed two separate CPPs in NF-YA, one in the A1, centered on the KRR sequence, and a second 
in the DNA-binding subdomain, encompassing the basic RHRHAMARKR stretch. 
 
3.3 Stability of transfected NF-YA in different cell lines. 
The experiments performed in the tumorigenic colon carcinoma HCT116 cell line were extended to 
other cell lines: HeLa (human epithelial cervical carcinoma) U2OS (human osteosarcoma), HT1080 
(human fibrosarcoma), HaCaT (human immortalized epithelial keratinocytes) and NIH3T3 (mouse 
immortalized fibroblasts). We employed the 10nM dose of recombinant NF-YAl over 24 hours (Fig. 
4): in all cell lines, the protein is efficiently internalized, with expression maximal, or near maximal 
at 30’ post-transfection. Thereafter, however, there were differences in the stability of the protein. In 
HeLa, the levels were substantially reduced already at 2 hours after transfection and no exogenous 
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protein detected at 6 hours: for this reason we did not proceeded with 24 hours time point. At the 
opposite, slower degradation rates were observed in NIH3T3, HaCaT and, to a lesser extent, in U2OS. 
In NIH3T3, in particular, appreciable amounts of transfected NF-YAl was still visible after 24 hours. 
Note that further assessment at 48 hours post-transfection yielded negative results (See below). 
HT1080 showed a behavior similar to U2OS. Quantifications of these results are shown in Fig. S4. 
In summary, we generalize the entry of recombinant NF-YA in cells, but we notice a different half-
life of transfected NF-YAl depending on the specific cell line used. 
 
3.4 Functionality of transfected NF-YA. 
Previous work with TAT-NF-YA fusions established that the recombinant fusion protein is functional 
upon transfection in cell lines and primary cells (Moijsin et al., 2015; Domashenko et al., 2010). To 
assess this aspect of wt NF-YA, we used the NIH3T3 system, because of the longer half-life of the 
protein, which could exert more lasting effects on cellular physiology. We also considered the 
possibility that the two NF-YA isoforms might have a different behavior: we included NF-YAs in 
these experiments, as well as the YAl 23-33 mutant incapable to enter cells, as a negative control. We 
used two doses of NF-YA, 10 and 100 nM. After transfections with the different recombinant 
proteins, exponentially growing NIH3T3 were monitored for cell growth at 24 and 48 time points: 
Fig. 5A shows that both NF-YAl and NF-YAs slowed cell growth, compared to cells mock-
transfected with an irrelevant protein (BSA), or treated with YAl 23-33. The difference is particularly 
relevant at 24 hours, more pronounced for NF-YAl, and observed with the two protein concentrations. 
Note that appreciable levels of transfected NF-YA proteins are visible after 24 hours, but not at 48 
hours (Fig. S5). 
NF-Y controls a number of growth promoting, as well as pro- and anti-apoptotic genes: the growth 
suppression by recombinant NF-Y could be due to alteration in the different pathways. To shed light 
on this, we controlled the expression levels of genes involved in cell-cycle progression and control 
of apoptosis by qRT-PCR. Fig. 6 shows that G1/S (Pcna) and G2/M (Ccnb1/2) CCAAT-dependent 
genes are down-regulated by NF-YAl and NF-YAs; note, that while CCAAT boxes are important for 
phase-specific regulation of these promoters, they also mediate repression under specific conditions 
(Manni et al., 2001; Gurtner et al., 2003). On the other hand, apoptosis genes are differentially 
regulated: the pro-apoptotic Bax and Apaf1 are up-regulated, the anti-apoptotic Bcl2 is repressed. 
CCAAT-mediated regulation is not generalized, since Topoisomerase IIa, another NF-Y target, is 
unaffected, as is Mll1, a CCAAT-less gene. We also checked E2f1, an important NF-Y target, whose 
overexpression activates pro-apoptotic genes, notably Apaf1 and Bax (Van Ginkel et al., 1997; 
Moroni et al., 2001; Giovanni et al., 2000; Kabe et al., 2005): indeed E2f1 is activated by NF-YAl 
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and NF-YAs. In conclusion, NF-YA protein transfections in NIH3T3 mimic the effects of DNA-
mediated NF-YAl overexpression, in terms of induction of pro-apoptotic genes, possibly co-mediated 
by up-regulation of E2f1.  
 
4 DISCUSSION 
 
CPPs were identified in several proteins, drawing considerable interest over the last two decades, not 
least for their far-reaching translational potential. NF-YA adds to the list of TFs entering cells without 
the requirement of cargos, via the presence of two distinct CPPs in the evolutionarily conserved 
region. 
 
Our work was motivated by (i) previous experiments with GST-TAT-NF-YA fusions, showing 
efficient entry of the proteins, and functional proficiency in transcriptional activation, including in 
primary HSCs, and (ii) inspection of the NF-Y/CCAAT 3D structure. We reasoned that CPPs could 
be present in A1 or in A2: the transfection experiments confirm this and the mutagenesis experiments 
indicate that either CPPs mediate substantial cellular uptake. The mutants behave as predicted in 
DNA-binding assays in vitro, a relevant point to verify since we used proteins renatured from 
inclusion bodies. In transfections, elimination of two separate stretches –A1 KRR- and A2 RRK-
HRH-RKR- is required to abolish the full cell penetrating capacity of NF-YA. The protein 
concentrations are similar to the ones used for TAT-NF-YA, in the nanomolar range: thus, 
considering that many proteins are internalized in the low μM range, the efficiency of NF-YA CPPs 
is remarkable, and 30 minutes incubation are sufficient to yield nuclear levels of NF-YA that are 
many-fold those of the endogenous proteins. 
Under normal conditions, endogenous NF-YA is exclusively localized in the nucleus: this is unlike 
NF-YC, which utilizes heterodimerization with the companion NF-YB as a mechanism to enter in 
the nucleus (Frontini et al., 2004; Kahle et al., 2005). NF-YA nuclear localization is mediated by β-
importin interactions. Interestingly, two separate signals are required for efficient nuclear localization 
of NF-YA, in human cells in vivo, and Xenopus cells in vitro (Kahle et al., 2005): one is the KRR 
stretch in the A1, the other involves residues in the A2 (RRK and RKR); note that NF-YA mutations 
in either A1 or A2 retain substantial nuclear localization, whereas mutations of both essentially 
abolished it. These are the stretches showing CPP activity in our study. Thus, both A1 and A2 peptides 
are required for cellular penetration and nuclear localization. It remains to be determined whether the 
newly identified CPPs behave so when independently transferred to unrelated proteins. 
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The efficient entry is matched by a short half-life of the protein, but the half-life of the transfected 
NF-YA was dissimilar in the cellular contexts we used. Transformed HeLa, HCT116, HT1080, U2OS 
retain NF-YA for shorter periods, with respect to non-transformed HaCaT or NIH3T3 cells. Whether 
this is due to transformation per se, rather than to the specific tissue-specific contexts, is a relevant 
point that could be addressed by assaying larger sets of primary and transformed cells. Nevertheless, 
the half-life of the transfected NF-YA appears to be remarkably similar to the endogenous one and 
the produced by DNA-mediated transfections (Manni et al., 2008), a further indication that the 
recombinant proteins behave similarly to internally produced NF-YA. On the other hand, the rapidity 
of NF-YA degradation poses problems in assessing its functionality. In general, compared to the HFD 
dimer, NF-YA turnover is more rapid, and subject to extensive control by degradation. The Lysines 
involved in poly-ubiquitination are all in the homology domain. The acetylation protects them from 
poly-ubiquitination, and indeed K to R mutations prolong NF-YA half-life (Manni et al., 2008). Some 
of these Lysines are within the stretches identified here as CPPs: as basis for future experiments, it is 
possible that, K to R mutants, will increase the nuclear permanence and activity of transfected NF-
YA. Whether they impair CPP activity remains to be seen. 
 
As for other TFs shown to behave similarly, the fascinating question is what might be the 
physiological role, if any, of the cell penetrating capacity of NF-YA. Obviously, the aminoacids 
stretches identified here are required for key functions of the protein, nuclear localization, HFD 
interactions and sequence-specific DNA-binding, sufficient to justify their remarkable evolutionary 
conservation. However, this does not rule out that NF-YA can use the CPPs for additional purposes. 
For other TFs, cellular entry is matched by active export, supporting the notion that they can be used 
as signaling molecules in local paracrine circuits (Prochiantz and Joliot, 2003). One possible such 
case for NF-YA behavior might take place in the biology of macrophages. Monocytes undergo 
differentiation to macrophages by activation of sets of genes, in which CCAAT boxes predominate 
(Marziali et al., 1999). Among these, the genes of the antigen presentation pathways, chiefly MHC 
Class II, rely on the well characterized  combination of NF-Y/RFX and CIITA for activation (Zhu et 
al.,2000). Circulating monocytes are devoid of NF-YA, which is upregulated upon terminal 
differentiation. An intriguing possibility is that NF-YA, released from the nuclei of cells infected by 
bacteria or viruses, might be taken up by circulating monocytes, form a complex with the pre-existing 
HFD subunits, leading to accelerated maturation of effector macrophages, and help triggering of the 
immune response. 
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The functionality of the transfected NF-YA, previously established with TAT fusions, is confirmed. 
The effect of transfections –inhibition of cellular growth- is at first sight surprising, since NF-Y, in 
general, is known to bind growth promoting genes, and, indeed, NF-YC was recently isolated as a 
driver oncogene (Tong et al., 2015). However, it was shown that DNA-mediated overexpression of 
NF-YA in mouse primary fibroblasts and NIH3T3 leads to induction of apoptosis, which is dependent 
on p53 and E2F1. Elimination of NF-YA by shRNA, differently for the inactivation of the HFD 
subunits, also leads to apoptosis (Benatti et al., 2011). Thus, there are specificities in NF-YA, whose 
levels are indeed highly constrained. In particular, NF-YA appears to play an ambiguous role in 
apoptosis, regulating both apoptotic –Bax, Apaf1, FasL, Bim- as well anti-apoptotic -Bcl2- genes 
(Hughes et al., 2011; Benatti et al., 2008). Furthermore, the p53-activated lncRNA PANDA, 
produced as an anti-sense transcript from the p21 locus, mediates anti-apoptotic signals by interacting 
directly with NF-YA (Hung et al., 2011; Subramanian et al., 2013). The effect on E2f1 transcription 
observed here is in line with previous reports (Gurtner et al., 2010), and with the frequent co-
occurrence of the two TFs in genomic locations and regulation of common sets of genes (Elkon et 
al., 2003; Linhart et al., 2005; Caretti et al., 2003; Dolfini et al., 2012). These phenomena can now 
be studied in detail with the reagents developed here. 
 
The presence of CPPs in NF-YA is a potentially relevant point for practical purposes, since TAT-NF-
YAs was employed to increase the stem cells pools in HSCs preparations used for bone marrow 
transplantation –BMT (Zhu et al., 2005). In theory, a TAT-less NF-YAs could be directly used for 
these experiments. BMT is the treatment of choice in many malignancies in which the bone marrow 
has been infiltrated, making patients prone to relapse when treated with conventional therapy. One of 
the caveats in using NF-YA in such experiments is that it could boost proliferation of the residual 
cancer stem cells, in addition to the normal HSCs. Currently, there are no data as to the function of 
NF-YA in cancer stem cells, but the differences in NF-YA stability observed here might hint at a 
lesser impact, or indeed growth suppression, on cancer cells. This is an encouraging observation to 
pursue experiments on primary cells in vitro, for potential clinical development.  
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6 FIGURE LEGENDS 
 
Figure 1. Transfections of recombinant NF-YA in HCT116.  
(A) Western blot of NF-YA in nuclear extracts of HCT 116 cells treated with increasing concentration 
-2 nM, 10 nM and 50 nM- of recombinant NF-YAs and NF-YAl. Cells were collected 2 hours after 
treatments. (B) Kinetic analysis of NF-YAl in HCT 116 cells. LaminB was used as loading control. 
 
Figure 2. Effect of Mutations in basic stretches of the NF-YA on CCAAT-binding. 
(A) The amino acid sequence of the evolutionarily conserved domain of NF-YA is shown. The 
sequence of the mutants employed in this study are underlined and highlighted in red. NF-YA amino 
acids involved in NF-YB and NF-YC interactions, in CCAAT binding are reported. (B, C, D) EMSAs 
of NF-Y with increasing amounts of NF-YA and a fixed amount of NF-YB/NF-YC dimer. NF-YAl 
and YAl mutants are in 0,1:1, 0.3:1, 1:1 with the NF-YB/NF-YC dimer. 
 
Figure 3. Entry of NF-YAl mutants in HCT 116 cells.  
Western blot analysis of NF-YA in HCT116 nuclear extracts treated with 10 nM of recombinant NF-
YAl and YAl mutants. Cells were collected at indicated time points after protein transfections. 10 μg 
of nuclear extracts were loaded on the gels; (-) control sample of untreated cells. The endogenous 
short form of NF-YA present in HCT116 –NF-YAs- and the transduced recombinant NF-YAl are 
indicated. LaminB was used as loading control. 
 
Figure 4. Stability of NF-YAl in different cell lines.  
Western blot analysis of NF-YA in nuclear extracts of different cell lines treated with 10 nM NF-YAl 
protein. Cells were collected at indicated time points after transfection; 10 μg of nuclear extracts were 
loaded. Kinetics in HeLa cells are from 0,5 to 6 hours; in U2OS, HT1080, HaCat and NIH3T3 cell 
lines from 0,5 to 24 hours; (-) control sample of untreated cells. 
 
Figure 5. Growth curve of NIH3T3 cells treated with NF-YA.  
NHI3T3 cells were treated with 10 nM (A) and 100 nM (B) of recombinant NF-YAl, NF-YAs and 
mutant YAl 23-33 in triplicate and collected 24 and 48 hours after treatments. Growth curve was 
determined by cell counts using the Trypan Blue exclusion method. 
 
 
70 
 
Figure 6. Effect of NF-YA transfection on expression of CCAAT-dependent genes. 
NIH3T3 cells were treated with 10 nM of recombinant NF-YAl, NF-YAs and NF-YAl 23-33: after 
24 hours, mRNA was extracted and analyzed by qRT-PCR. The transcripts of the indicated genes are 
shown. mRNA transcripts were normalized with housekeeping RSP15 expression levels (*p<0.1,  
**p<0.05). 
 
Supplementary 1. Removal of LPS from protein preparations. 
(A) SDS-page stained with Blue Coomassie of NF-YAs, NF-YAl and the indicated YAl mutants. 1 
μg of recombinant proteins, produced from E.coli inclusion bodies, are loaded; Bovine Serum 
Albumin (BSA) was used as reference. (B) Western blot analysis of NF-YAs, NF-YAl and the 
indicated YAl mutants using antibodies against NF-YA (Upper Panel) and LPS lipid A (Lower 
Panel), before (-) and after (+) treatment with Triton X114. 
Supplementary 2. Dominant negative effect of A2 mutants. 
EMSA of competition of the NF-Y trimer with increasing amounts of NF-YAl, YAl33, YAl34 and 
YA23 recombinant proteins. A constant concentration of NF-YAl at a 1:1 ratio with NF-YB/YC was 
mixed with growing concentrations of YAl mutants (NF-YA:YAl mutants ratio of 1:1, 1:3, 1:10). 
The labelled CCAAT box probe was used at a 20nM concentration. 
Supplementary 3. Efficiency of protein transfections with NF-YA mutants. 
Quantifications of Western blot analysis of transfections of NF-YAl and different mutants (See Fig. 
3). The data were obtained using Image Lab software (BioRad), normalized with LaminB and related 
to the amount of transfected NF-YAl –or mutant- present at the 0.5 hours time-point. 
 
Supplementary 4. Measurement of NF-YA stability in different cell lines. 
Quantifications of Western blot analysis of NF-YAl transfections in different cell lines (See Fig. 4). 
The data were obtained using Image Lab software (BioRad) and normalized with LaminB and related 
to the amount of transfected NF-YAl present at the 0.5 hours time-point. 
 
Supplementary 5. Expression of NF-YA in NIH3T3. 
Western blot analysis of NF-YA (Upper Panel) and NF-YB (Lower Panel) in nuclear extracts of 
NIH3T3 cells treated with 10 nM and 100 nM of NF-YAl, NF-YAs and YAl 23-33. Cells were 
collected 24 hours (A) an 48 hours (B). 15 μg of nuclear protein extracts were used.  
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Supplementary 6. Sequences of the primers used in this study are shown. 
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CCNB1 (F) 5’-CAGGAAGCAGGGAGTCTTCA-3’ 
(R) 5’-CATGCTGGACTACGACATGG-3’ 
 
CCNB2 
 
 (F) 5’-GGAAGCCAGGAGCAGAGC-3’ 
 (R) 5’-CCTGGTGGACTGGCTGGT-3’ 
PCNA (F) 5’-AGGAGACAGTGGAGTGGCTTTTG-3’ 
(R) 5’-GAGAGCTTGGCAATGGGAACA-3’ 
 
TOPO IIA (F) 5’-ATCCACGTAACTGCGGAATCCT-3’ 
(R) 5’-GATGGATAACATGGGGAGAGCTG-3’ 
 
E2F1 
 
(F) 5’-TCAAGCCGCTTACCAATCCC-3’ 
(R) 5’-CGGTGTCGTTGACCTGAACT-3’ 
 
APAF1 
 
 (F) 5’ –GATGGCCTGTGTGGATCTCT-3’ 
 (R) 5’- GAGGATGTGGAGGTGATCGT-3’ 
BAX1 (F) 5’-CCCCAGTTGAAGTTGCCATC-3’ 
(R) 5’-CACCAAGAAGCTGAGCGAGT-3’ 
 
BCL2  (F) 5’- TCCTCCATCCCTTCATCCTCC-3’ 
 (R) 5’- GGGGAGCAACATTCATCAGC-3’ 
MLL1  (F) 5’-TGACAATGTGCTTCTGCCCATC-3’ 
 (R) 5’-CGCTCCATCCAGACAGACAAG-3’ 
 
 
 
Supplementary 6 
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Report 
 
Preliminary analysis of recombinant NF-YA activity in mESCs and hints about 
the role of NF-Y in hiPSCs circuitry. 
1. INTRODUCTION 
 
Embryonic stem cells (ESCs) have the extraordinary feature to be indefinitely propagated in vitro in 
an undifferentiated state, retaining the ability to differentiate and generate all somatic adult tissues 
under the appropriate differentiation signals. Master transcription factors maintain stem cells identity 
by regulating the expression profiles of crucial genes that are then transmitted through cell divisions. 
Among these, SOX2, OCT4, and KLF4 are necessary in cell reprogramming to induced pluripotent 
stem cells (iPSCs) (Takahashi and Yamanaka 2006). 
The TFs SOX2, OCT4 and NANOG create a regulatory feedback circuitry maintaining pluripotency 
both in human and mouse ESCs (Young, 2011). These three master embryonic transcription factors 
not only regulate each other but also are crucial for the activation of other pluripotency factors and 
for the repression of differentiation pathways. 
Among the battery of TFs involved in stemness circuitry, the CCAAT binding complex, NF-Y, was 
identified and described as an essential component of the core pluripotency network (Oldfield et al., 
2014 ). NF-Y is composed by NF-YA, considered the limiting and regulatory subunit of the trimer, 
NF-YB and NF-YC subunits, containing a histone-fold domain (Romier et al., 2003). 
NF-Y plays a very important role in early mouse embryonic development. Briefly, as demonstrated 
by Bhattacharya, NF-YA heterozygous mice are alive and fertile while, NF-YA null mice, die at 8.5 
dpc (Bhattacharya et al., 2003). Different studies demonstrated the role of NF-Y as important 
regulator of key stem cells transcription factors: the first refers to the retroviral infection of NF-YA 
subunit in mouse hematopoietic stem cells (HSCs). In this study, Zhu demonstrated that HSCs, 
overexpressing NF-YA subunits, are able to repopulate the bone marrow of immunocompromized 
animals enhancing the expression of transcription of several HOX genes and the activation of Notch 
and Wnt signaling pathways. Therefore, NF-YA is a potent cellular regulator of HSC self-renowal. 
Similarly, Domashenko, using TAT-fusion NF-YA protein, obtained a better engraftment and 
repopulation of bone marrow derived HSC in mice ex vivo (Domashenko et al., 2012). Moreover, the 
treatment of mESCs with TAT-NF-YA protein maintains cells in a pluripotent state in absence of 
leukemia inhibitory factor (LIF) as demonstrated by the activation of CCAAT stemness genes 
(Dolfini et al., 2012).  
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Although a TAT-fusion protein was a successful strategy to deliver a functional NF-YA protein in 
the nucleus, we discovered that NF-YA is able to translocate into the cells in a TAT-independent 
manner. The characterization of NF-YA as protein owning cell penetrating peptide (CPP) properties, 
was achieved by mutational analysis of basic amino acids in its evolutionary conserved domain.  
NF-YA exists in two different isoforms, the long and the short, that differ for the presence of 28 
amino acids codified by exon 3 of the longer isoform, in the Q-rich trans-activation domain. The 
conserved C-terminal domain of the protein is composed by two alpha helices, A1 and A2, rich in 
basic amino acids (Nardini et al., 2013). We demonstrated that specific basic aminoacidic stretches, 
in the two helices, are important to confer to the protein the property of CPP (Chiaramonte et al., 
manuscript in preparation in this thesis). 
The identified NF-YA skills to penetrate cells, its proved stability and functionality in non-
transformed cells, prompted us to investigate the possibility to use recombinant NF-YA as tool to 
study its activity also in mESCs.  
In this report I will describe data obtained from mESCs treatments with recombinant NF-YA and I 
will show preliminary results about a new project concerning the study of NF-Y in human stem cells. 
 
2. MATHERIALS AND METHODS 
 
2.1 Generation of human induced pluripotent stem cells and embryo bodies formation. 
1 x 105 human dermal fibroblasts were electroporated with a combination of episomal plasmid vectors 
including SOX2, KLF4, c-MYC, OCT4, LIN28 and NANOG using Nucleofector® Kit (Amaxa) 
plated in 10 cm dish in culture medium (EMEM, 15% FBS, 1% NEAA, 2 mM L-glutammine). 
We trypsinized transfected cells on day 7 and reseeded them on feeder layer in  embryonic stem cells 
medium (DMEM F12, 20% knockout medium, 2mM L-glutammine, 100 units/ml penicillin and 100 
μg/ml streptomycin, 1% NEAA, 1% sodium pyruvate, 0.1 mM β-Mercaptoethanol, 20 ng/ml b-FGF) 
at 37°C in a humidified, 5% O2, 5% CO2 atmosphere.   
Cells were maintained in embryonic stem cells medium until that small cell colonies became visible. 
Cell colonies were mechanically picked and seed in a feeder free layer and amplified on matrigel 
coated plates in human stem cells medium (STEMGENT). 
Embryo bodies were formed by suspension culturing of hIPSCs in human Embryo Bodies Medium 
(DMEM F12, 20% Knock-out medium, 1% NEAA, 1mM L-glutamine, 100 units/ml penicillin and 
100 μg/ml streptomycin, 1 mM sodium pyruvate, 0.1 mM β) at 37°C in a humidified 5% CO2 
atmosphere  for 7 days. 
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2.2 Lentivirus production and cell infection. 
pLKO.1 non-target short hairpin RNA (shRNA) (SHC002),  
shRNA-NF-YA, targeting exon 6 (CCATCGTCTATCAACCAGTTA),  
shRNA-NF-YB targeting exon  5 (GCTATGTCTACTTTAGGCTTT), were designed by Sigma-
Aldrich. For lentivirus production, the shRNA vector plasmid (20 μg) and second-generation 
packaging plasmids (5 μg of pMD2-VSVG and 15 μg of pCMV_R8.91) were co-transfected into 
HEK293T cells. Lentiviral particles were collected from supernatant 36 hours after transfection, 
centrifuged at 1500 rpm to remove cell debris for 5’, 0.45 μm filtered and stored at -80°C. 
60% confluent hiPSCs were infected with two ml of collected virus in 6 multi well plates and 
harvested 72 hours for protein total extract and RNA extraction. 
The experiments were repeated twice. 
 
2.3 mESCs culture. 
Mouse ESCs were maintained in glasgow minimum essential medium (Sigma-Aldrich) supplemented 
with 10% ESC qualified fetal bovine serum (Gibco), 1 mM L-glutamine, 0.1 mM non-essential amino 
acids, 100 units/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate, 0.1 mM 2-
mercaptoethanol and 1,000 units/ml of recombinant leukemia inhibitory factor (LIF) (Gene Spin).  
 
2.4 Recombinant protein production and transduction. 
NF-YAl, NF-YAs and mutant YAl 23-33 were purified as previously described (Chiaramonte et al., 
manuscript in preparation in this thesis). 
Protein concentration was determined by the Bradford method (Bio-Rad Protein Assay).  
Cells were treated with the indicated amount of recombinant proteins. Cells were washed with PBS 
and recombinant proteins were added in DMEM without serum for 30’. The treatment was repeated 
twice. After the second treatment cells were grown in ES medium and kept at 37°C in 5% CO2  for 
24 hours. Recombinant proteins were added at 24 hours intervals for four days. 
Alkaline phosphatase assays were performed using a colorimetric system (SIGMA). 
The experiments were repeated twice. 
 
2.5 Western blot analysis. 
Western blot analyses of nuclear and total extract were performed according to the standard 
procedures using the primary antibodies and peroxidase-conjugated antibody. 
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Primary antibodies used: anti-NF-YA (Santa Cruz), anti-NF-YB (GeneSpin), anti-KLF4 (GeneSpin), 
anti-SOX2 (Santa Cruz), anti-OCT4 (Santa Cruz), anti-GAPDH (Santa Cruz), ananti-Lamin B (Santa 
Cruz), anti-Vinculin (Santa Cruz). Visualization of images was obtained with the ChemiDocTM MP 
imaging system (BioRad). 
 
2.6 RNA extraction and RT-PCR analysis.  
Total RNA was extracted using Trizol reagent (Sigma) according to the manufacturer’s instructions. 
1 μg of RNA was retrotranscribed with SuperScriptTM reverse transcriptase (BioRad) and random 
primers. cDNA was diluted 1:20 with water. cDNA was analyzed in triplicate by q-PCR analysis and 
a comparative 2-∆∆Ct was used to detect relative gene expression.  
 
3. MAIN RESULTS AND DISCUSSION 
 
3.1 Recombinant NF-YA protein transduction in mESCs. 
Before testing recombinant NF-YA transfection in mouse embryonic stem cells, we evaluated the 
ability of the protein to translocate and enter nuclei of different cell lines. For all the treated mouse 
and human cell types, we observed a rapid uptake and accumulation of NF-YA in the nuclei at very 
low concentrations. One of the restriction use of recombinant NF-YA is due to the half-life of the 
protein inside to the cells. For many of the transformed cell lines tested, the protein disappears few 
hours (4-6h) after transduction making hard to evaluate possible effects of its overexpression 
(Chiaramonte et al., manuscript in preparation in this thesis). Curiously, we observed that the trend 
was different for non-transformed HaCaT and NIH3T3 cells that retain a relatively abundant amount 
of protein in the nucleus until 24 hours from treatment.  
Therefore, we decided to investigate the stability of recombinant NF-YA also in mESCs. 
Figure 1 shows the kinetic performed in order both to evaluate the capability of recombinant NF-YA 
to translocate mESCs and to determine the half-life of the protein after translocation. 
As we alredy knew, by previous experiments, that recombinant NF-YAl and NF-YAs have the same 
behavior in terms of transduction efficiency and time of cell residence (half-life), this experiment was 
performed using the long isoform of NF-YA. Protein transduction experiments were performed 
providing recombinant NF-YAl to mESCs in DMEM medium without serum, one time, every 30 
minutes, for one hour. After treatments, DMEM was removed, cells were cultured in complete 
mESCs medium and collected at different time points. Western blot analysis shows that recombinant 
NF-YA translocates efficiently and rapidly at very low concentrations (20 nM) in the nuclei where it 
is can be detected until 24 hours from treatments. The kinetic carried out up to 48 hours, revealed that 
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the protein completely disappeared two days after treatments. Quantification of these results are 
shown in Fig 1B. 
 
 
3.2 Effects of recombinant NF-YA on mESCs. 
Once established that recombinant NF-YA enters mESCs nuclei efficiently and rapidly and that it is 
present until 24 hours from treatments, we went to evaluate its molecular activity. In particular, we 
verified whether it was able, similarly to TAT-NF-YAs, to maintain mESCs in an undifferentiated 
state in absence of LIF (Dolfini et al., 2012). To note, experiments of TAT-NF-YA protein 
transduction were performed only with the short isoform of NF-YA. 
In this work, we wanted to evaluate whether the transduction of short and the long isoform of NF-
YA showed different effects in terms of stemness maintaining. For this reason, mESCs were treated 
with recombinant NF-YAs, NF-YAl and with the mutant of NF-YA unable to penetrate cells -YAl 
23-33-. Every 24 hours, recombinant proteins were provided to mESCs as described above. After 
treatments, mESCs were grown in ESCs medium supplemented or not with LIF (Fig.2A, schematic 
representation of cell treatments). These treatments were conducted for 4 days and the first 
observations about the effects of NF-YA transduction were marked by cell morphology. 
LIF is necessary for ESCs growth and pluripotency state stability and it is known that mESCs, in 
healthy conditions, grow as nice small colonies. We observed that control and YAl 23-33 treated 
cells, cultured for 4 days in withdrawal of LIF, lost their typically growing aspect. Daily treatments 
with NF-YA, in particular with recombinant NF-YAs, in absence of LIF, instead, maintained cells 
with their classic morphology (Fig. 2B). 
Moreover, we performed alkaline phosphatase assay as a further indication: in presence of LIF, cells 
treated with NF-YAs, NF-YAl, YAl 23-33 and control cells were positive to alkaline phosphatase 
assay; in absence of LIF positivity was weaker for control and YAl 23-33 treated cells while it was 
maintained for cells treated with NF-YAl and much more for that treated with NF-YAs (Fig. 2C). 
These findings pushed us to check the expression levels of stem cell genes by qRT-PCR (Fig. 2D). 
What emerged from mRNA analysis is that all considered stemness genes maintain the same 
expression levels when cells are cultured in presence of LIF. The scenario changes when LIF is 
removed from culture medium. The expression of Nanog, Klf4 and Klf5 are maintained to high levels 
(near to normal expression) for cells treated with recombinant NF-YAs and NF-YAl while they are 
dramatically reduced for control and YAl 23-33 treated cells.  
The expression levels of Oct4 and Sall4 are similar for all the treatments performed in absence of LIF 
while we did not observe a reduced expression of Sox2. This could be explained with the major 
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stability of mRNA of these genes therefore, treatments for over several days, will be performed to 
evaluate this point. 
The Ccnb2 expression level, instead, is drastically affected in control and YAl 23-33 treated cells 
while the transfection of NF-YAl and in particular NF-YAs maintains high its expression. This is in 
agreement with what was observed: mESCs treated with NF-YAs grow faster compared to the others. 
 
These preliminary data show that: 
i) recombinant NF-YA penetrates mESCs efficiently and rapidly at low concentrations (20 nM) and 
it is detectable until to 24 hours from treatment; 
ii) when cells are cultured in absence of LIF, the short isoform of NF-YA seems to have a more 
pronounced effect, compared to the long one, on maintaining mESCs morphology and in promoting 
cell growth. However, we did not observe a relevant difference, between the two treatments, on the 
expression levels of analyzed stemness genes. In both cases, they are maintained to higher levels 
compared to the control cells. It is clear that other genes involved in pluripotency, as well as genes 
involved in differentiation, have to be analyzed. 
The activity of the protein, highlighted by the modulation of important stemness and CCAAT 
containing genes, makes recombinant NF-YA a very important tool to study its effects in different 
cell systems avoiding problems related to classic methods of gene delivery. Moreover, this system 
allows to have controlled protein expression levels and, in general, these results lay the groundwork 
to use recombinant NF-YA also in other stem cell systems, such as human stem cells. 
For this reason, in parallel to this study, we started to investigate NF-Y in human induced pluripotent 
stem cells. 
 
3.3 Generation and characterization of human induced pluripotent stem cells (hiPSCs). 
The clear involvement of NF-Y in mESCs circuitry and, in particular, the importance of NF-YA 
subunit to maintain their pluripotent state, pushed us to turn the attention on the role of NF-Y also in 
human stem cells. 
Considering the clear ethical problems for the use of human embryons and the difficulties to get 
human embryonic stem cells, human induced pluripotent stem cells were used as model to start this 
study. 
Human dermal fibroblasts were electroporated with a mix of episomal plasmid vectors containing the 
Yamanaka factors: SOX2, KLF4, OCT4, L-MYC, LIN28 and the shp53 that was demonstrated to 
increase the efficiency of hiPSCs generation (Keisuke Okita et al., 2011). 1 x 105 electroporated cells 
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were plated in 10 cm dish, trypsinized after 7 days and reseeded onto a feeder layer (Fig. 3A, 
schematic representation of hiPSCs generation). 
Cells were grown in ESC medium and colonies became visible two weeks after transfection; the 
single colonies were mechanically picked and seeded into a feeder free (matrigel coated) system. 
The majority of obtained colonies were expandable, had a classic morphology of human ESCs 
characterized by large nuclei and scanty cytoplasm, and were positives to alkaline phosphatase assay 
(Fig. 3B). 
qPCR analysis revealed that colonies obtained by reprogramming express the main stemness 
transcription factors: SOX2, OCT4, KLF4 and NANOG. The expression levels of stemness genes 
were normalized on GAPDH housekeeping gene (Fig. 3C). 
We further characterized the pluripotency of obtained colonies by testing their differentiation 
potential. Along the hiPSCs differentiation process, embryo bodies (EBs) formation is a routine 
founder step to direct cell differentiation toward a specific lineage. EBs are three-dimensional 
aggregates of hiPSCs that mimic the structure of human developing embryos able to differentiate to 
all the three primary germ lines.  
hiPSCs dissociated to single cells, were seeded into a ultra-low adherence petri dish in EBs medium; 
dissociated hiPSCs spontaneously aggregate to form spheroid bodies (Fig. 4A) further demonstrating 
that colonies obtained by reprogramming process are pluripotent stem cells able to start the 
differentiation process under appropriate stimuli.  
 
3.4 From hiPSCs to EBs: a switch from short to long isoform of NF-YA 
As mentioned before, NF-YA subunit exists in two different isoforms generated by an exon skipping 
event and different cell lines preferentially express one of them (Ceribelli et al., 2009). 
Western blot analysis in hiPSCs reveals that, similarly to mESCs, the short isoform of NF-YA is that 
expressed in hiPSCs (Fig. 4B); very interesting, we observed that after differentiation to EBs, NF-
YAl becomes the mainly expressed isoform (Fig. 4C). SOX2, OCT4 and KLF4 protein expression 
levels have been used to monitor the differentiation process. 
These data reflect what observed in mESCs: a shift from short to long isoform of NF-YA occurs when 
cells are committed to EBs (Dolfini et al., 2012) suggesting that the short isoform of NF-YA governs 
stemness circuitry while the long one drives the differentiation process. 
 
3.5 NF-Y subunits silencing affect the expression of important stemness genes 
In order to determine the role of NF-Y in regulation of hiPSCs stemness genes, NF-Y subunits (NF-
YA and NF-YB) were silenced using lentiviral delivery of shRNAs. A non-target shRNA (sh-CTR) 
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was used as control vector. HiPSCs were collected 72 hours after lentiviral infection and the 
expression levels of NF-YA and NF-YB subunits were analyzed by western blot and qRT-PCR 
analysis (Fig. 5). We observed that at 72 hours from infection NF-YA and NF-YB protein subunits 
were depleted (Fig. 5A, 5C). qRT-PCR analysis  highlight that after NF-YB silencing the expression 
levels of SOX2 are dramatically affected; a modest effect was observed for the expression of SOX3 
and KLF4 while, the expression levels of KLF5, NANOG and OCT4 remain unchanged; GAPDH 
and PCNA were used as positive controls as they are housekeeping genes target of NF-Y (Fig.5 D). 
Interestingly, we observed that the silencing of NF-YA strongly affected the expression of all 
stemness genes analyzed (Fig. 5B). 
Curiously, the expression level of NF-YA and in particular the long isoform of the subunit, increased 
after NF-YB silencing, et vice versa, as if there was a sort of compensation between the subunits, 
whose mechanism of regulation is still not well understood. 
We speculated that the emerged predominant effect of NF-YA subunit on the expression levels of 
stemness genes compared to NF-YB depletion could be due to the different gene silencing levels 
obtained for the two proteins. A second hypothesis is that the two proteins may also cover different 
roles other that NF-Y trimer activity. The latter is supported by experiments carried out in other cell 
lines: NF-YA and NF-YB depletion leads different effects on HCT116 cells. While NF-YA silencing 
affects the progression of S phase and induces DNA damages, NF-YB deletion induces a delay in 
G2/M phase progression (Benatti et al., 2011).  
 
4. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The results reported in the first part of the work, regarding recombinant NF-YA transduction in 
mESCs, provide clear evidences that the protein is functional in this cell system because, similarly to 
TAT-NFYA, it is able to maintain the pluripotency properties of mESCs when they are grown in 
absence of LIF. 
This effect may be considered as a reflection of a role of NF-YA in preventing cell exit from the stem 
pool within the culture. This result was observed to be typical of other TFs belonging to the core of 
embryonic stem cells circuitry: KLF4 and TCF3, another important TF for ESCs, show effects similar 
to NF-YA when overexpressed in mESCs (Tam et al., 2008; Zhang et al., 2010).  
The use of CPPs as carriers for the transport of molecular drug inside to the cells is a developing field 
for clinical trials; a functional recombinant NF-YA gives the advantage to use a protein as near as 
possible to the endogenous one and we cannot exclude to undertake studies for  future therapeutic 
and clinical applications. 
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Data obtained from hiPSCs highlighted a good parallelism among mESCs and hiPSCs regarding the 
expression of NF-YA isoform before and after differentiation. Moreover, we observed that after NF-
YA subunit depletion, hiPSCs lost their pluripotency properties as demonstrated by the drastic 
reduction of stemeness genes expression levels.  
In order to have a broader and complete view about NF-Y activity in human stem cells network, we 
want to proceed with gene expression profiles experiments of hiPSCs upon NF-YA and NF-YB 
depletion and with ChIP analysis in order to better understand the relationship between NF-Y and the 
other master stemness TFs.  
Apart from Yamanaka factors, other TFs have been identified to enhance reprogramming of 
differentiated cells into iPSCs, among these, SALL4 (Wong et al., 2008). SALL4, like NF-YA, exists 
in two different isoforms which relative abundance changes according to the pluripotent or 
differentiated state of the cells (Rao et al., 2010). Moreover, it shows effects similar to NF-YA when 
transfected in HSCs (Yang et al., 2011), it is involved in leukemogenesis and in other types of cancers 
(Gao et al., 2011). The similes between NF-YA and SALL4 suggest us that NF-YA may be 
investigated for its potential role also in reprogramming process.  
Finally, the use of recombinant NF-YA to overexpress NF-YA subunit and the induction of hiPSCs 
to differentiate toward a specific lineage will provide further indications about the role of NF-Y in 
stemness and differentiation processes.  
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7. FIGURE LEGENDS 
 
Figure 1. Transfection of recombinant NF-YA in mESCs. 
(A) Western blot of NF-YA in nuclear extracts of mESCs treated with 20 nM of recombinant NF-YA. 
Cells were collected at indicated time points after protein transfection; 10 μg of nuclear extracts 
were loaded. Lamin B was used as loading control. 
(B)  Quantification of western blot analysis of NF-YAl transfection in mESCs. The data were 
obtained using Image software (BioRad), normalized with Lamin B and related to the amount of 
transfected NF-YAl present at 0.5 hours time-point. 
 
Figure 2. Effects of recombinant NF-YA protein in mESCs in withdrawal of LIF. 
(A) Recombinant NF-YAs, NF-YAl and the mutant NF-YAl 23-33, were transfected in mESCs. The 
addition of recombinant proteins was performed daily, every 24 hours for four days at the final 
concentration of 20 nM and mESCs were grown in presence or absence of LIF. 
(B) Morphology of mESCs colonies treated with recombinant NF-YA proteins after four days of 
indicated treatments. 
(C) Alkaline phosphatase assay of mESCs after four days of indicated treatments. 
(D) qRT-PCR analysis of embryonic stem cells transcription factors from mESCs transfected with 
recombinant NF-YA in presence or absence of LIF. mRNA of ESCs transcription factors were 
analyzed four days after indicated daily treatments. mRNA transcripts were normalized with 
housekeeping RSP20 expression levels.  
 
Figure 3. Generation and characterization of human induced pluripotent stem cells (hiPSCs). 
(A)  Schematic representation of hiPSCs generation protocol. 
(B)  Phase contrast images of (1) human dermal fibroblasts before transfection with OKSM vectors,   
(2) hiPSCs clone originated by human fibroblasts reprogramming on a feeder layer, (3) iPSCs 
clone seeded on a feeder free layer, (4) alkaline phosphatase assay of hiPSCs at p4. 
(C)  qRT-PCR analysis for pluripotent cell markers were performed on total RNA extraction from 
colonies obtained by reprogramming of human fibroblasts. The expression levels of stemness 
genes are relative to GAPDH. mRNA from HaCaT cells was used as negative control for the 
expression of stemness genes. 
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Figure 4. NF-YA isoform in hiPSCs before and after differentiation. 
(A) Phase contrast images of hiPSCs colony grown on a feeder free layer and embryo body (EB) 
originated by induction of hiPSCs differentiation.  
(B) Western blot analysis of B panel compare hiPSCs with mouse embryonic stem cells (mESCs) 
for the expression of NF-YA subunits. NF-YB was used as internal loading control. 
Western blot analysis of the indicated proteins before and after 7 days of hiPSCs 
differentiation to EBs.  
For western blot analysis 20 μg of total protein extracts were loaded on the gel.  
 
Figure 5. Effects of NF-Y subunits depletion on the expression of stemness genes. 
(A)  and (C) Western blot analysis of  NF-YA and NF-YB subunits after 72 hours of shRNA    
lentiviral  infection of hiPSCs. 
(B)  and (D) mRNA levels of NF-YA and NF-YB subunits, stemness genes and housekeeping 
NF-Y target genes, were analyzed by qRT-PCR after inactivation of NF-YA (B panel) and 
NF-YB (D panel) depletion by shRNA lentiviral infection of hiPSCs. mRNA transcripts 
were normalized with housekeeping RSP20 expression levels. Error bars represent SD of 
qPCR replicates (six analyses). Experiments were performed twice both for NF-YA and 
NF-YB inactivation. 
 
Supplementary 1. Primers used in this study are shown. 
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Supplementary 1: primers used in this study 
 
Klf4 (F) 5’-AGAGAGTTCCTCACGCCAAC-3’ 
(R) 5’-GCGAGTCTGACATGGCTGT-3’ 
 
Klf5 (F) 5’-CAGGTGCACTTGTAGGGCTT-3’ 
(R) 5’-AGCGACGTATCCACTTCTGC-3’ 
 
Nanog (F) 5’-GCGGACTGTGTTCTCTCAGG-3’ 
(R) 5’-CCACCGCTTGCACTTCATCC-3’ 
 
Sox2 (F) 5’-GACCAGCTCGCAGACCTACA-3’ 
(R) 5’-CTGGAGTGGGAGGAAGAGGT-3’ 
 
Sall4 (F) 5’-GGCGCTCTCTTTCCCTCAG-3’ 
(R) 5’-GCGAACACACACGGGAGAG-3’ 
 
Oct4 (F) 5’-CAGCCAGACCACCSTCTGC-3’ 
(R) 5’-TGGTCTCCAGACTCCACCTC-3’ 
 
Ccnb2 (F) 5’-GGAAGCCAGGAGCAGAGC-3’ 
(R) 5’-CCTGGTGGACTGGCTGGT-3’ 
 
NF-YA (F) 5’-TCAATTCAGGAGGGATGGTC-3’ 
(R) 5’-GCCGAGACTCATGCAGGTAT-3’ 
 
NF-YB 
 
(F) 5’-AGGTGCCATCAAGAGAAACG-3’ 
(R) 5’-TGTTGTTGACCGTCTGTGGT-3’ 
 
SOX2 (F) 5’-ACCCTCCCCAGGTTTTCTCT-3’ 
(R) 5’-CACCCACAGCAAATGACAGC-3’ 
 
SOX3 (F) 5’-GGGGAGGGCTGAAAGTTTTG-3’ 
(R) 5’-ACACAGCGATTCCCAGCCTA-3’ 
 
KLF4 (F) 5’-ACCAGGCACTACCGTAAACACA-3’ 
(R) 5’-GGTCCGACCTGGAAAATGCT-3’ 
 
KLF5 (F) 5’-CTTCCACAACAGGCCACTTACTT-3’ 
(R) 5’-AGAAGCAATTGTAGCAGCATAGGA-3’ 
 
 
OCT4 (F) 5’-TCTCCAGGTTGCCTCTCACT-3’ 
(R) 5’-GCTTTGAGGCTCTGCAGCTT-3’ 
 
NANOG (F) 5’-CTGCGTCACACCATTGCT-3’ 
(R) 5’-ATACCTCAGCCTCCAGCAGA-3’ 
 
PCNA (F) 5’-GAGTCAAAGAGGCGGGGAGAC-3’ 
(R) 5’-CTTGCGGGGAAGACTTTAGGG-3’ 
 
GAPDH (F) 5’-GCCTCAAGATCATCAGCAATGC-3’ 
(R) 5’-CCACGATACCAAAGTTGTCATGG-3’ 
 
 
 
 
